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My	 study	 has	 revealed	 the	 structure	 of	 the	 complete	 75-component	 yeast	
Saccharomyces	cerevisiae	mitochondrial	ribosome	solved	to	3.3	Å	by	single	particle	
cryo-electron	microscopy	 (cryo-EM).	The	previously	unsolved	small	 subunit	of	 the	
mitoribosome	was	built	de	novo	to	include	34	proteins,	of	which	7	are	specific	to	the	
yeast	 mitochondrial	 ribosome	 and	 the	 15S	 ribosomal	 RNA.	 This	 mitochondrial	
ribosome	has	a	distinct	architecture	compared	to	other	mitochondrial	ribosome	and	
its	ancestral	bacterial	ribosome.		Elements	specific	to	the	yeast	mitoribosome	give	it	
a	 distinct	 shape	 and	 architecture	 to	 include	 a	 putatively	 active	 enzyme	 on	 the	
periphery.	 An	 expanded	 messenger	 RNA	 exit	 channel	 has	 also	 been	 found	
harbouring	 a	 platform	 suitable	 for	 translational	 activator	 binding.	 In	 general	 this	
structure	 has	 provided	 insight	 into	 translation	 specialisation	 amongst	 species	 and	
its	continued	evolution.			
	
Multiple	 states	 of	 actively	 translating	 human	 mitoribosome	 have	 been	 elucidated	
using	 single	 particle	 cryo-EM.	 The	 human	 mitoribosome	 structures,	 stalled	 by	
different	antibiotics,	have	been	seen	with	A/A	and	P/P	site	tRNAs	in	situ	as	well	as	
structures	with	an	unidentified	 factor	 in	 the	mitoribosomal	 factor	 site.	 In	addition	
the	human	mitochondrial	large	subunit	and	stalled	complete	mitoribosome	has	been	
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variety	of	 cellular	processes,	 including	synthesising	adenosine	 triphosphate	 (ATP),	
regulating	 cellular	 metabolism,	 apoptosis	 and	 aging.	 Mitochondria	 have	 double	
membranes	 consisting	 of	 an	 inner	 and	 outer	 membrane,	 separated	 by	 the	 inter-
membrane	 space.	 In	 addition,	 the	 inner	 membrane	 forms	 cristae	 folds,	 which	
protrude	 into	 the	 interior	matrix.	Within	 the	 inner	membrane	 reside	 five	 enzyme	
complexes	 of	 oxidative	 phosphorylation.	 	 These	 enzyme	 complexes,	 through	 the	
process	of	oxidative	phosphorylation	(OXPHOS),	are	responsible	for	generating	the	
energy	 unit	 ATP	 from	 the	 breakdown	 of	 carbohydrates	 and	 fatty	 acids.	 For	 this	
reason	mitochondria	are	often	called	the	‘powerhouses	of	cells’.	Mitochondria	are	a	
unique	 feature	 of	 eukaryotic	 cells.	 They	 are	 thought	 to	 have	 arisen	 from	 an	 α-
proteobacterium	 endosymbiont	 (1).	 This	 notion	 is	 supported	 by	 the	 fact	 that	




Mitochondria	 contain	 both	 mitochondrial	 DNA	 (mt-DNA)	 and	 the	 machinery	
necessary	 to	 express	 this	 genetic	 code,	 including	 mitochondrial	 ribosomes	
(mitoribosomes).	 However,	much	 of	 the	 genetic	material	within	mitochondria	 has	
been	 lost	 or	 transferred	 to	 the	 host	 during	 evolution,	 leaving	 a	 vestigial	 genome.	
Adaptations	to	the	cellular	environment	have	led	to	inactivation	of	redundant	genes	
and	 transfer	 of	 essential	 genes	 to	 the	 nucleus	 (2).	 In	 addition,	 the	 mitochondrial	
proteome	 has	 expanded,	 as	 a	 result	 of	 the	 mitochondrion	 being	 a	 beneficiary	 of	




transfer	 to	 mt-DNA	 is	 also	 known	 to	 occur,	 but	 the	 net	 result	 remains,	 of	
mitochondrial	genomes	being	a	fraction	of	the	size	compared	to	their	ancestral	free-
living	 α-proteobacterium	 (2).	 The	 extent	 of	 this	 reduction	 in	 genome	 size	 is	
organism-dependent,	 with	 very	 little	 correlation	 between	mt-DNA	 length	 and	 the	
number	of	genes	retained.	The	coding	capability	of	mt-DNA	is	an	average	of	40-50	
genes	 across	 eukaryotes.	At	 one	 extreme,	 jakobid	 flagellates	 have	 as	many	 as	 100	
genes	 (3).	 These	 genes	 are	 largely	 involved	 in	 the	 fundamental	 processes	 of	
oxidative	 phosphorylation,	 translation,	 transcription,	 ribonucleic	 acid	 (RNA)	
maturation	and	protein	import.	While	at	the	other	extreme,	Plasmodium	falciparum	
have	 only	 5	 genes	 (3).	 The	 likely	 advantages	 of	 nuclear	 centralisation	 of	 genetic	
material,	 include	 sex	 recombination	 and	 protection	 against	 oxidative	 stress	 in	 the	
mitochondrial	 microenvironment.	 However,	 in	 most	 aerobic	 eukaryotes,	
mitochondria	 retain	 a	 set	 of	 genes.	 In	 these	 cases,	 the	 transfer	 of	 genes	 to	 the	
nucleus	 is	 not	 random.	 Most	 aerobic	 eukaryotes	 have	 not	 lost	 all	 their	 genes	
involved	 in	 oxidative	 phosphorylation	 (4).	 The	 membrane	 proteins	 cytochrome	 b	
(Cytb)	 and	 cytochrome	 oxidase	 subunit	 1	 (Cox1)	 remain	 present,	 as	 do,	
mitoribosomal	RNA	 (mt-rRNA)	 genes.	 These	 features	 can	be	 explained	by	 the	 fact	
that	translocation	of	 large	molecules	such	as	mt-rRNA	into	the	mitochondria	could	
be	 problematic.	 In	 the	 case	 of	 Cytb	 and	 Cox1,	 these	 highly	 hydrophobic	 proteins	
were	 also	 thought	 to	 be	 difficult	 to	 transport	 across	 mitochondrial	 membranes.	
However,	recent	experiments	suggest	that	they	are	retained	in	the	mitochondria	to	
prevent	aberrant	 targeting	to	 the	endoplasmic	reticulum	if	nuclear	encoded	(5).	 In	
addition,	 protein	 synthesis	 within	 the	 mitochondria	 is	 thought	 to	 allow	 greater	
control	 over	 gene	 expression	 in	 response	 to	 the	 redox	 state	 of	 mitochondria	 (6).	
Eukaryotes	 have	 therefore,	 largely	 retained	 a	 separate	 translation	 system	 within	
mitochondria	 despite	 the	 considerable	 expense	 to	 the	 cell,	 at	 times	 for	 the	
production	of	 only	 a	 few	proteins.	An	exception	 is	 the	 aerobic	 eukaryotic	parasite	
Amoebophrya	ceratii	(A.	cerattii).	A	 recent	 study	has	 revealed	 that	no	mt-DNA	was	
found	in	A.	cerattii	(7).	Although	mitochondrial	genomes	have	been	previously	found	
to	be	 lost	 in	 anaerobes,	 this	 is	 the	 first	 time	an	aerobic	 species	has	been	 found	 to	
completely	 lose	 its	genome.	The	explanation,	however,	 is	similar	 for	both	cases.	 In	





cerattii	is	 in	 line	with	 loss	of	 certain	respiratory	complexes	and	energy	adaptation	
(7).		
	
In	 the	 vast	 majority	 of	 species,	 due	 to	 the	 reduced	 genome	 size,	 almost	 all	 the	
ribosomal	 proteins	 and	 the	 translation	 factors	 vital	 for	 this	 mitochondrial	
translation	 system	 have	 to	 be	 imported	 in	 from	 the	 cytoplasm.	 This	 feature	 is	 in	
addition	 to	 the	 components	 of	 the	machinery	 necessary	 for	mt-DNA	maintenance,	
replication,	 transcription,	 mt-mRNA	 processing	 and	 maturation. The	 yeast	
Saccharomyces	cerevisiae	(S.	cerevisiae)	 and	mammalian	mt-DNA	encode	 for	only	8	
and	 13	 proteins	 respectively,	 but	 there	 is	 a	 nearly	 five-fold	 difference	 in	 their	
genome	 sizes	 (85.8kb	 and	 16.5kb,	 respectively)	 (8,9).	 A	 representation	 of	 the	
genomes	 taken	 from	a	review	by	Ott	et	al	 is	 shown	 in	Figure	1	 (10).	An	estimated	
250-300	 nuclear	 encoded	 proteins	 are	 postulated	 to	 be	 necessary	 to	 maintain	







(10).	 (A)	 Human	 mitochondrial	 genome.	 (B)	 Saccharomyces	 cerevisiae	










shared	 the	 Nobel	 Prize	 in	 1974	 (14).	 The	 basic	 ribosome	 unit	 consists	 of	 a	 large	
subunit	(LSU)	and	a	small	subunit	(SSU).		In	the	70S	bacterial	ribosome	the	subunits	
are	designated	50S	 and	30S	 for	 the	LSU	and	SSU,	 respectively.	Ribosomes	 contain	
over	50	proteins,	in	complex	with	3	rRNA	molecules.	It	was	first	postulated	that	the	




(15).	 mRNA	 contains	 the	 protein	 sequence	 to	 be	 decoded	 by	 the	 ribosome	 for	
polypeptide	production.	 Shine	and	Dalgarno	 later	 identified	 this	 to	be	a	16S	 rRNA	
pyrimidine-rich	 tract	 at	 the	 3'-	 end	 (16,17).	 In	 E.	 coli,	 the	 ACCUCC	 nucleotide	
sequence	 at	 the	 3’-	 end	 base	 pairs	with	 complementary	mRNA	 to	 form	 the	 initial	
mRNA:30S	 complex	 (16).	 The	 sequence	on	 the	mRNA	 is	now	known	as	 the	 Shine-
Dalgarno	 sequence.	 Thus,	 the	 SSU	 is	 able	 to	 bind	 the	mRNA	 encoding,	 via	 triplet	
nucleotides	(codons),	the	sequence	of	amino	acids	of	a	polypeptide.		
	
Subsequent	 sequencing	 of	 rRNA	 allowed	 secondary	 structure	 modelling	 and	
subsequent	chemical	 footprinting	and	crosslinking	methods	to	study	specific	rRNA	
interactions	with	proteins	and	transfer	RNA	(tRNA)	(18-20).	Three	binding	sites	on	
each	 of	 the	 ribosomal	 subunits	 were	 found	 to	 exist	 (21).	 The	 ribosomal	 A-site	
(aminoacyl	 site)	 is	 responsible	 for	binding	 the	 incoming	 aminoacylated	 tRNA.	The	
ribosomal	 P–site	 (peptidyl	 site)	 harbours	 the	 tRNA	 that	 holds	 the	 nascent	
polypeptide.	The	ribosomal	E-site	 (exit	 site)	accepts	 the	deacylated	 tRNA	before	 it	
exits	 the	 ribosome.	 Details	 of	 the	 steps	 in	 the	 translation	 pathway	 have	 been	
mapped	out	 in	bacteria,	with	 the	help	of	pre-steady-state	kinetic	 experiments	 and	
single-molecule	 fluorescence	 resonance	 energy	 transfer	 experiments	 (22-25).	 The	
SSU	 was	 found	 to	 bind	 the	 anticodon	 stem	 of	 the	 tRNA	 that	 recognises	 the	
corresponding	codon	of	the	mRNA.	In	this	way	the	SSU	is	involved	in	decoding	and	






centre	 (PTC).	 Early	 protease	 and	 phenol	 extraction	 experiments,	 to	 remove	 the	
thermophilic	 eubacterium	 Thermus	 aquaticus	 50S	 ribosomal	 proteins,	 found	
retention	of	petidyl	 transferase	activity	pointing	 to	 the	catalytic	 role	of	 rRNA	 (26).	
Biochemical	studies	have	thus	paved	the	way	towards	an	in-depth	understanding	of	
ribosomal	translation.	However,	it	would	be	structural	biology	that	would	provide	a	
more	 detailed	 picture	 of	 the	 components	 of	 the	 ribosome	 and	 with	 this	 further	
mechanistic	understanding	of	translation.		
	
Early	work	 towards	 understanding	 the	 structure	 of	 the	 complete	 ribosome	 in	 situ	
used	room	temperature	electron	microscopy	(EM).	This	was	followed	by	early	cryo-
electron	 microscopy	 (cryo-EM),	 which	 allowed	 low	 resolution	 visualisation	 of	
ribosomes	 in	complex	with	tRNA	and	translational	 factors,	although	 it	would	be	x-
ray	 crystallography	 that	 first	 provided	 atomic	 level	 detail.	 In	 2000,	 Ban	 et	 al	
published,	at	2.4	Å,	the	first	high	resolution	structure	of	the	LSU	from	the	archaean	
Haloarcula	marismortuii	 (27).	This	 was	 followed	 by	 a	 3.1	 Å	 reconstruction	 of	 the	
bacterium	 Deinococcus	 radioduarans	 LSU	 by	 Harms	 et	 al	 (28).	 In	 2000,	 the	
Ramakrishnan	 and	 Yonath	 groups,	 respectively,	 reported	 the	 structure	 of	 the	 SSU	
from	 the	bacterium	Thermus	thermophilus	 to	3.0	Å	and	3.3	Å	 (29,30).	These	 initial	
structures	 were	 significant	 breakthroughs	 and	 were	 followed	 by	 further	 crystal	
structures	 of	 actively	 translating	 ribosomes,	 that	 have	 greatly	 improved	 our	
understanding	of	the	precise	mechanisms	of	protein	synthesis	(31).	
	
Protein	 translation	 by	 ribosomes	 is	 a	 highly	 regulated	 process,	 directed	 by	 the	
sequence	 of	 mRNA	 codons.	 Translation	 occurs	 in	 distinct	 phases;	 initiation,	
elongation,	termination	and	ribosome	recycling	(31).	These	phases	are	regulated	by	











move	 the	 tRNAs	and	mRNA	 in	 their	 triplet	 codon	units	 through	 the	 ribosome	 into	






It	 has	 been	 known	 since	 the	 late	 1950s	 that	 radiolabelled	 amino	 acids	 can	 be	
incorporated	 into	nascent	polypeptides,	 in	 isolated	 rat	 liver	mitochondria	 (32).	By	
the	 1960s,	 ribosome-like	 particles	 were	 visualised	 by	 negative-stain	 electron	
microscopy	within	 the	mitochondrial	matrix	 (33).	 By	 1967,	 it	 became	 possible	 to	
purify	mitoribosomes	 from	 yeast	 and	 human	 cells	 (34-38).	 These	 advances	 led	 to	
more	comprehensive	negative-stain	EM	studies	of	mitoribosomes	(39-41).	However,	
progress	 in	 high	 resolution	 visualisation	 of	 mitoribosomes	 was	 hampered	 by	 the	
limitations	 of	 room	 temperature	 EM	 technology,	 and	 the	 difficulty	 in	 crystallising	
mitoribosomes	 for	 X-ray	 crystallography.	With	 the	 emergence	 of	 cryo-EM,	 several	
low	resolution	structures	of	the	mitoribosome	from	a	variety	of	species	were	solved	
(42-45).	Improved	purification	methods	and	technological	advances	in	cryo-EM	have	
together	 provided	 high	 resolution	 cryo-EM	 structures	 of	 the	 mammalian	
mitoribosome,	 and	 large	 subunit	 of	 the	 yeast	 S.	 cerevisiae	 (46-51).	 From	 these	
structures	 there	 is	 evidence	 of	 species-specific	 specialisation	 amongst	
mitoribosomes.	 Species-specific	 pressures	 on	 the	 mitoribosome	 have	 resulted	 in	
mitoribosomes	 from	 different	 species	 exhibiting	 individuality,	 whilst	 retaining	
largely	conserved	functional	sites	comparing	with	other	ribosomes.	The	differences	
may	 be	 a	 reflection	 of	 genomic	 translational	 requirements	 and	 also	 manifest	 in	
unique	 translational	 factors,	 mt-tRNAs	 and	 regulation.	 Progress	 in	 our	
understanding	 of	 these	 peculiarities	 is	 still	 in	 its	 infancy	 and	 is	 obstructed	 by	 the	








Figure	 2	 –	 Large	 subunit	 of	 the	 yeast	mitochondrial	 ribosome	 adapted	 from	
Amunts	A,	Brown	A,	Bai	XC,	 et	 al.	 Structure	of	 the	 yeast	mitochondrial	 large	
ribosomal	 subunit.	 From	 Science.	 2014;343(6178):1485–1489/	 Reprinted	
with	 permission	 from	 AAAS	 (46).	 The	 54S	 is	 shown	 in	 two	 views	 with	 the	




human	mitoribosome	 is	 considerably	 smaller,	 with	 a	 sedimentation	 coefficient	 of	
55S,	 and	comprises	a	39S	mt-LSU	and	a	28S	mt-SSU.	 In	 the	yeast	54S	mt-LSU,	 the	
protein	 and	 mt-rRNA	 components	 have	 expanded	 considerably	 relative	 to	 the	
bacterial	 ribosome	 (46).	 The	 structure	 of	 its	 large	 subunit	 (determined	 at	 a	
resolution	of	3.2	Å)	revealed	that	the	additional	elements	are	largely	mitochondrial-
specific	surface	protein	elements	that	alter	the	overall	shape	of	the	mt-LSU	(Figure	
2)	 (46).	 In	 addition	 the	exit	 tunnel	has	been	 remodelled	 to	 follow	a	different	path	
with	 a	 wider	 exit	 site.	 This	 adaptation	 is	 perhaps	 to	 facilitate	 co-translational	
assembly	and	insertion	of	polypeptides	into	the	mitochondrial	inner	membrane.	The	
structure	of	the	complete	human	and	bovine	mitoribosomes	have	also	been	solved	
to	 a	 resolution	of	 3.5	Å	 and	3.8	Å,	 respectively	 (Figure	3)	 (48,50).	 Similarly	 to	 the	






ribosome	 by	 comparison	 consists	 of	 2/3rds	 rRNA.	 Although	 the	 exit	 tunnel	 in	 the	
human	 mitoribosome	 follows	 a	 similar	 path	 to	 the	 bacterial	 tunnel,	 it	 has	 been	






Figure	 3	 –	 Taken	 from	 Amunts	 A,	 Brown	 A,	 Toots	 J,	 Scheres	 SHW,	
Ramakrishnan	 V.	 Ribosome.	 The	 structure	 of	 the	 human	 mitochondrial	
ribosome.	 From	 Science.	 2015;348(6230):95–98/	 Reprinted	with	 permission	
from	 AAAS	 (48).	 Overview	 of	 the	 human	 mitoribosome.	 The	 areas	 with	
bacterial	 conservation	 are	 coloured	 in	 blue.	 	 The	 extensions	 of	 homologous	




In	 order	 to	 understand	 differences	 in	 translation	 in	 the	 mitochondrion,	 it	 is	
important	to	understand	the	differences	in	gene	expression.	The	circular	human	mt-
DNA	genome	encodes	only	37	genes,	divided	 into	13	proteins,	22	mt-tRNAs	and	2	







the	circular	mt-DNA	(52).	The	heavy	and	 light	strands	reflect	 the	mass	of	 the	DNA	
strands	 due	 to	 differing	 proportions	 of	 heavier	 nucleotides.	 Transcription	 is	
catalysed	 by	 the	mitochondrial	 RNA	polymerase	mt-RNAP	 (53).	 Additional	 factors	
required	 are;	 mitochondrial	 transcription	 factor	 A	 (TFAM),	 mitochondrial	
transcription	 factor	B2	(TFB2M)	and	mitochondrial	 transcription	elongation	 factor	
(TEFM)	 (53).	 Following	 RNA	 transcription,	 processing	 at	 the	 5’	 by	 mitochondrial	
endonuclease	 RNase	 P	 and	 at	 the	 3’	 by	 ELAC2,	 liberates	 the	 RNA	 into	 individual	
components	of	mt-tRNAs	and	polycistronic	RNA	units	(54,55).	Where	mt-mRNA	and	
mt-rRNA	are	not	 flanked	by	mt-tRNA,	 the	 factors	FASTK,	 FASTKD4,	 FASTKD5	and	
GRSF1	have	been	 implicated	 in	RNA	processing	 (11).	Mt-mRNA,	mt-rRNA	and	mt-
tRNA	 all	 undergo	 post-transcriptional	 modifications	 including	 3’	 polyadenylation	
(poly(A)tail)	 by	 mitochondrial	 poly(A)	 polymerase	 (mt-PAP)	 (56).	 Post	
transcriptional	modifications	 of	mt-tRNA	 include	nucleotide	modifications	 and	 the	
addition	of	a	3’	CCA	for	aminoacylation	of	cognate	amino	acids	(57).	
	
Although	 the	 majority	 of	 mt-mRNAs	 lack	 5’	 untranslated	 regions	 (UTRs),	 some	
human	mt-mRNAs	do	contain	very	short	5’	UTRs	(52).	This	is	in	contrast	to	human	
cytosolic	 mRNA	 that	 can	 harbour	 long	 5’	 UTRs	 with	 an	 average	 length	 of	 210	
nucleotides	(58).	This	long	5’	UTR,	upstream	of	the	initiation	codon,	is	instrumental	
for	 translation	 regulation	 of	 cytosolic	 mRNAs.	 The	 lack	 or	 shortened	 5’	 UTRs	 in	
human	mt-mRNAs	presents	questions	on	the	mechanism	of	initiation	of	translation	
in	 these	 circumstances.	 In	 human	mitochondria	 there	 are	 8	 transcripts	without	 5’	




and	 ATPase6	 start	 codons	 are	 embedded	 in	 the	middle	 of	mt-mRNA.	 There	 are	 4	
transcripts	that	contain	3’	UTRs,	with	3	of	these	being	within	the	anti-sense	of	other	








amounts	 (59).	 The	 S.	 cerevisiae	mitochondrial	 genome	 encodes	 35	 genes	 which	
represent	 8	 proteins,	 24	 mt-tRNAs,	 2	 mt-rRNAs	 (21S	 and	 15S)	 and	 the	 9S	 RNA	
subunit	of	RNase	P	(12).	The	8	proteins	 include	the	ribosomal	SSU	protein	(VAR1),	
cytochrome	 oxidase	 subunits	 I,	 II	 and	 III	 (COX1,	COX2,	COX3),	 apocytochrome	 b	
(COB)	 and	 three	 ATP	 synthase	 subunits	 (ATP6,	APT8,	ATP9).	Transcription	 is	 less	
complex	in	yeast	mitochondria	as	it	requires	only	two	components;	a	mitochondrial	
polymerase	(Rpo41)	and	the	transcription	factor	mt-TFB	(Mtf1)	(60).	However,	RNA	
processing	 is	 a	much	more	 complicated	 affair.	 Individual	 transcripts	must	 first	 be	
liberated,	with	subsequent	non-coding	introns	within	transcripts	requiring	removal	
by	 a	 process	 called	 splicing	 (61).	 As	 in	 human	mitochondria,	 yeast	 mt-tRNAs	 are	
liberated	 from	their	position	at	 the	end	of	 transcripts	by	the	action	of	RNaseP	and	
RNase	Z	(62).	Pet127	in	addition	is	important	for	5’	end	trimming	of	transcripts	(63).	
Following	 these	 processing	 steps,	 mt-tRNA,	 mt-rRNA	 and	 mt-mRNA	 to	 include	
monocistronic	 and	 one	 discistronic	 transcript	 encoding	 ATP8	 and	 ATP6,	 are	
released	 from	 the	 original	 continuous	 RNA	 stretches	 (64).	 In	 contrast	 to	 humans,	
yeast	 mt-mRNAs	 contain	 long	 5’	 and	 3’	 UTRs	 more	 akin	 to	 canonical	 cytosolic	





requires	 that	 the	messages	 for	 transcriptional	 regulators	are	encrypted	within	 the	




Translation	 initiation	 is	 a	 highly	 coordinated	 process	 and	 in	 bacteria	 is	 largely	
regulated	by	 three	 SSU	binding	 factors,	 initiation	 factor	 1	 (IF1),	 initiation	 factor	 2	
(IF2)	and	initiation	factor	3	(IF3)	(66).	IF1	binds	the	30S	A-site	and	anchors	IF2	and	





codon	positioning.	 The	GTPase	 IF2	 recruits	 formylmethionyl-tRNA	 (fMet-tRNAfMet)	




The	 situation	 in	 mitochondria	 has	 differences	 from	 the	 bacteria.	 IF1	 is	 absent	 in	
mitochondria,	 whereas	 the	 GTPase	 mitochondrial	 IF2	 (mt-IF2)	 is	 universally	
present.	IF3,	previously	thought	not	to	exist	in	S.	cerevisiae,	has	now	been	identified	
as	 Aim23p	 (67).	 However	 deletion	 of	 Aim23	 in	 S.	 cerevisiae	 does	 not	 affect	
mitochondrial	 translation	 indiscriminately,	 but	 instead	 causes	 an	 imbalance	 in	




which	 have	 roles	 in	 initiator	 mt-tRNA	 binding	 to	 the	 28S	 mt-SSU	 and	 anti-








initiator	mt-tRNA,	mt-IF2	also	performs	 functions	 that	 are	usually	 associated	with	




especially	 important	 for	 leaderless	 mRNAs	 (71).	 Furthermore,	 the	 C-terminal	
domain	of	the	large	subunit	protein	bL12m	has	been	found	to	interact	with	mt-IF2	





which	contains	multiple	pentatricopeptide	repeats	 that	aid	 the	 threading	of	mRNA	
through	the	entrance	channel	(48,50).		
	





but	 location	 of	 translation.	 Unlike	 their	 bacterial	 ancestors,	 mitochondrial	 mRNA	
does	not	initiate	using	a	Shine-Dalgarno	sequence.	This	mechanism	is	lost	not	just	in	





Unique	mt-mRNA	motifs	 or	 sequences	 that	might	 aid	 this	 process	 remain	 largely	
elusive	in	the	mammalian	system.	An	exception,	however,	is	TACO1,	which	has	been	
identified	 as	 a	 translational	 activator	 of	 the	 COX1	 transcript	 (74).	 Although	 yeast	
mitochondrial	translational	activators	are	by	far	the	best	studied,	since	human	mt-
mRNAs	 on	 the	 whole	 do	 not	 contain	 long	 5’	 UTRs,	 alternative	 mechanisms	 must	
therefore	 exist	 (52).	 Specific,	 but	not	universal,	 features	 of	 translational	 activators	
include	their	ability	to	interact	with;	5’	UTRs,	proteins	of	the	small	and	large	subunit,	
the	 inner	 membrane	 surface	 and,	 either	 directly	 or	 indirectly,	 with	 the	 nascent	
polypeptide	chain	(65).	In	this	way	they	are	able	to	direct	expression	of	their	target	
mt-mRNA	to	their	site	of	usage	at	the	inner	membrane.		The	amount	translated	can	
thus	 be	 coordinated	 with	 nuclear	 encoded	 products	 through	 a	 negative	 feedback	
mechanism,	 ensuring	 stoichiometric	 protein	 production	 of	 macromolecular	
complexes	 (65).	 Translational	 activators	 promote	 translation,	 but	 once	 the	
polypeptide	 is	 synthesised,	 the	 same	 activator	 binds	 the	 polypeptide	 product	 and	
therefore	 is	not	able	 to	promote	another	 round	of	 translation	elsewhere	until	 it	 is	
released,	 when	 the	 translated	 polypeptide	 is	 translocated	 to	 the	 inner	membrane	












decoded	 by	 aminoacylated	 tRNAs	 to	 add	 amino	 acid	 residues	 to	 the	 growing	
polypeptide	chain.	In	humans	and	S.	cerevisiae,	there	are	22	and	24	mitochondrially-
encoded	 amino	 acid	 specific	 tRNAs,	 respectively.	 These	mt-tRNAs	 possess	 diverse	
structures	and	non-canonical	truncated	species	are	also	present	in	metazoans	(78).	
Adaptations	 are	 apparent	 in	 both	mt-tRNA	 and	mitoribosomal	 subunit	 interfaces.	
Simplified	 decoding	 mechanisms,	 termed	 wobbling	 and	 superwobbling	 allow	 for	
less	than	the	32	tRNA	species	normally	required	by	Crick’s	wobble	hypothesis	(79).	
In	 Crick’s	 wobble	 hypothesis,	 tRNAs	 with	 a	 modified	 uridine	 (U)	 in	 the	 wobble	
position	of	their	anticodon	compensate	for	the	reduced	number	of	tRNAs	by	pairing	
with	 any	 of	 the	 four	 bases	 at	 the	 third	 position	 of	 the	 codon	 (80).	 Unmodified	
uridines	in	the	wobble	position	base	pairing	is	called	‘superwobbling’	(80).	
	
Elongation	 on	 mitoribosomes	 is	 similar	 to	 the	 bacteria.	 A	 ternary	 complex,	
comprising	 the	 mitochondrial	 elongation	 factor	 (mt-EF-Tu),	 GTP	 and	 an	
aminoacylated	mt-tRNA,	 enters	 the	 ribosomal	A-site,	with	 the	mt-tRNA	 initially	 in	
the	A/T	conformation	(81).	Following	anticodon:codon	recognition	between	the	mt-
tRNA	and	mt-mRNA	respectively,	GTP	 is	hydrolysed	 to	 release	GDP:mt-EF-Tu.	The	
mt-tRNA	then	fully	accommodates	into	the	A-site	to	permit	peptide	bond	formation	
between	the	incoming	amino	acid	and	the	last	amino	acid	in	the	nascent	chain	at	the	
peptidyl	 transferase	 centre	 of	 the	 mt-LSU.	 Through	 an	 interaction	 with	 another	
GTPase	 elongation	 factor	 (mt-EF-G1),	 the	 A-site	 mt-tRNA,	 which	 now	 bears	 the	







during	 recycling	when	acting	with	 ribosome	 recycling	 factor(31).	 In	mitochondria,	
however,	these	two	functions	are	fulfilled	by	mt-EF-G1	and	mt-EF-G2	(81).	The	yeast	
and	mammalian	mitoribosome	 structures	 of	 the	mt-LSU	 confirm	 that	 the	 peptidyl	
transferase	 centre,	 entirely	 formed	 of	mt-rRNA,	 is	 highly	 conserved	 and	 therefore	





Class	 I	 factors;	 release	 factor	1	 (RF1)	and	2	 (RF2),	harbour	specific	motifs	 (SPF	or	




RF3,	which	 promotes	 a	 conformational	 change	 that	 favours	 dissociation	 of	 RF1/2	
and	subsequent	dissociation	of	RF3	upon	GTP	hydrolysis	(31).		
	
While	 the	 canonical	 codons	UAA	and	UAG	serve	as	 stop	 codons	 in	 the	human	and	
yeast	 mitochondria,	 UGA	 instead	 codes	 for	 a	 tryptophan	 (9,52).	 In	 human	
mitochondria,	the	stop	codon	is	recognised	by	a	single	mitochondrial	release	factor	





RF2	 homologue	 in	 mitochondria	 is	 understandable	 as	 it	 is	 unnecessary	 owing	 to	
UGA	not	 encoding	 a	 stop	 codon.	 In	 the	 early	1980s,	 it	was	 thought	 that	 in	human	
mitochondrial	translation,	AGA	and	AGG	also	represented	stop	codons	in	the	ORFs	of	
proteins;	 CO1	 and	ND6	 (13).	 However,	 it	 has	 now	been	 shown	 that	 the	AGA/AGG	
was	in	fact	instrumental	in	creating	a	-1	frameshift	in	conjunction	with	downstream	
3’	UTR	sequences	that	form	a	secondary	structure	(84).	This	secondary	structure	has	








Following	 termination,	 a	 deacylated	 mt-tRNA	 in	 the	 P/E	 state,	 and	 mt-mRNA,	
remains	associated	with	the	ribosome	in	the	post	termination	complex	(PoTC).	Two	
ribosomal	 recycling	 factors	 mt-RRF1	 and	 mt-EF-G2	 then	 bind	 and	 promote	 the	
dissociation	of	the	subunits	and	other	bound	components	to	be	recycled	for	further	




Aberrant	 translation	 within	 the	 mitochondria	 is	 known	 to	 be	 associated	 with	
perturbations	of	human	health.	This	is	not	surprising	as	the	products	of	translation	
are	 all	 components	 of	 the	 electron	 transport	 chain,	 involved	 in	 oxidative	
phosphorylation.	 Mitochondrial	 electron	 transport	 chain	 deficiencies	 are	 a	 major	
cause	 of	 metabolic	 and	 neurological	 disorders.	 However,	 there	 is	 considerable	
heterogeneity	 in	 both	 the	 clinical	 picture	 and	 the	 pathogenesis	 of	 the	 various	
disorders	 (89,90).	 This	 heterogeneity	 is	 in	 part	 a	 reflection	 of	 different	mutations,	
but	also	the	burden	of	different	populations	of	mt-DNA	(wild	type	and	mutant)	that	
are	 present	 in	 individual	 cells,	 a	 phenomenon	 called	 heteroplasmy	 (89).	 During	





translated.	 Therefore,	 any	 defect	 affecting	 the	mitochondria’s	 ability	 to	 produce	 a	
functional	product	can	be	 involved	 in	 the	pathogenesis	of	electron	 transport	chain	
diseases.	Mutations	involving	mt-DNA	protein	encoding	regions	that	cause	diseases	
include	isolated	myopathy	and	Leber’s	hereditary	optic	neuropathy	(89).	Examples	
of	 mitochondrial	 diseases	 related	 to	 defective	 translation	 of	 the	 thirteen	 mt-DNA	




encephalomyopathy	 with	 lactic	 acidosis	 and	 stroke-like	 episodes,	 resultant	 of	 an	
A3243G	mutation	 in	 the	 tRNA	 Leu(UUR)	(MTTL1)	 gene	 (91).	 Aminoglycoside-induced	
deafness	 is	 associated	 with	 mitoribosomal	 RNA	 mutations	 such	 as	 the	 A1555G	
mutation	 in	 the	 12S	 rRNA	 gene,	 although	 the	 mutation	 itself	 appears	 to	 be	
insufficient	 to	 produce	 a	 clinical	 phenotype	 without	 additional	 factors,	 as	
demonstrated	 by	 the	 variability	 in	 clinical	 penetrance	 (92).	 The	 first	 discovered	
nuclear	 gene	 mutation,	 PUS1	 encodes	 a	 mt-tRNA	 modification	 enzyme,	
pseudouridine	 synthase,	 responsible	 for	 converting	 uridine	 into	 pseudouridine	
within	mt-tRNA	(93).	Mutations	in	this	gene	appear	to	affect	stability	of	the	mt-tRNA	
secondary	and	 tertiary	 structure	and	 the	associated	 clinical	 syndrome	observed	 is	
mitochondrial	 myopathy,	 lactic	 acidosis	 and	 sideroblastic	 anaemia	 (MLASA)	 (93).	
Additional	mutations	affecting	mitochondrial	translation	are	found	in	mitoribosomal	
proteins,	 aminoacyl-tRNA	 synthases,	 elongation	 factors,	 translational	 activators,	
translation	 terminators	 and	 proteins	 regulating	 mt-mRNA	 stability	 (94).	
Additionally,	 any	 defects	 in	 the	 pathway	 that	 mediates	 transport	 and	 import	 of	
nuclear-encoded	 mitochondrial	 proteins	 associated	 with	 translation	 can	 be	
pathogenic.	 These	 can	 include;	 mutations	 in	 either	 the	 mitochondrial	 localisation	
signal	 itself,	 chaperones	 that	 assist	 in	 the	 pathway,	 the	 import	 machinery	 or	
deficiencies	in	the	assembly	and	processing	of	the	clients.	
	
On	 the	 non-pathogenic	 side,	 there	 has	 been	 considerable	 interest	 in	 the	
mitochondria	 as	 a	 possible	 chemotherapeutic	 target.	 This	 is	 based	 on	 the	
identification	of	tumour	vulnerabilities	not	necessarily	related	to	particular	somatic	
mutations.	 As	 the	 apparent	 genetic	 heterogeneity	 of	 tumours	 increases	 with	 the	
presence	of	clonal	subtypes	with	differing	genetic	landscapes	emerging	within	single	
tumours,	 targeting	 global	 tumour	 vulnerabilities	 in	 association	with	more	 specific	
gene	targets	continues	to	be	an	attractive	strategy.	The	mitochondrion,	an	 integral	
part	 of	 cellular	 metabolism,	 is	 beginning	 to	 be	 considered	 as	 one	 of	 these	 global	
targets	(95).	 	Alterations	to	metabolism	have	 long	been	considered	a	tumourigenic	
hallmark	(96).	The	originally	described	Warburg	effect	is	the	idea	that	tumours	use	
increased	 aerobic	 glycolysis	 and	 are	 shifted	 away	 from	 ATP	 generation	 through	
oxidative	 phosphorylation,	 even	 under	 normal	 oxygen	 concentrations	 (96).	 	 ATP	




comparatively	 inefficient	 in	 generation	 of	 ATP	 per	 unit	 of	 glucose	 consumed.	
However,	 it	 is	apparent	that	this	model	 is	 too	simplistic	and	that	tumours	must	be	
metabolically	 adapted	 to	 provide	 the	 crucial	 requirements	 of	 not	 only	 increased	
energy	production	but	generation	of	sufficient	macromolecules	and	maintenance	of	
redox	 balance	 (96).	 	 Additionally,	 it	 is	 known	 that	many	 key	 oncogenic	 signalling	
pathways	 result	 in	 an	 adaptation	 of	 tumour	 cell	 metabolism,	 to	 allow	 increased	
growth	and	survival.	Anti-cancer	drugs	acting	on	mitochondria	have	recently	been	
classified	 according	 to	 their	 targets	within	 the	mitochondria,	which	 include	 drugs	
targeting	 hexokinase	 on	 the	 outer	 mitochondrial	 membrane,	 components	 of	 the	
electron	 transport	 chain	 and	 mt-DNA	 (95).	 	 Of	 interest	 to	 us	 is	 the	 possibility	 of	
chemotherapeutics	affecting	the	translational	function	of	mitochondria.	Tigecycline	
has	recently	been	reported	as	an	effective	 inhibitor	of	mitochondrial	 translation	 in	
acute	 myeloid	 leukaemia	 (AML),	 and	 selectively	 killed	 leukaemic	 stem	 and	
progenitor	 cells	 preferentially	 to	 normal	 cells	 (97).	 Furthermore,	 small	 interfering	
RNA-mediated	knockdown	of	mt-EF-Tu	in	leukaemic	cells	produced	a	similar	effect.	
The	AML	cells	were	found	to	have	increased	numbers	of	mitochondria,	coupled	with	
increased	mt-DNA	copies	 and	an	 increased	oxygen	 consumption	 rate	 compared	 to	
normal	 cells	 (97).	 Tigecycline	 is	 an	 FDA-approved	 antimicrobial	 and	 is	 currently	









may	 be	 unique	 (47,49).	 In	 the	 structure	 of	 the	 human	 mitoribosome	 there	 was	
density	 for	 an	 endogenous	 polypeptide	 interacting	with	 the	 hydrophobic	 lining	 of	
the	 tunnel	 (47).	 It	 is	 hypothesised	 that	 helices	 of	mitochondrial	 OXPHOS	 proteins	
may	start	 forming	within	 the	exit	 tunnel,	 the	hydrophobicity	of	 the	 tunnel	slowing	




hydrophobic	 environment	 of	 the	 mitochondrial	 membrane.	 The	 exit	 is	 also	
remodelled	 compared	 to	 the	 bacteria	 with	 a	 more	 proteinacious	 character	 and	
consists	 of	 a	 conserved	 ring	 of	 polypeptides;	 uL23m	 (Mrpl22),	 uL29m	 (Mrpl47),	
uL22m	 (Mrpl22),	 uL24m	 (Mrpl24)	 and	 the	 mitochondrial	 specific	 protein	 mL45	
(47,49).	 	 Interestingly,	 in	 the	 initiating	 mitoribosome,	 the	 polypeptide	 tunnel	 has	
been	found	to	be	occupied	by	an	N-terminal	portion	of	mL45,	which	later	becomes	
exposed	 in	 the	 elongating	 mitoribosome,	 further	 supporting	 the	 role	 of	 mL45	 in	
targeting	the	mitoribosome	to	the	inner	mitochondrial	membrane	(71).	In	the	yeast	
54S	mt-LSU,	 the	 canonical	 polypeptide	 tunnel	 of	 the	 bacterial	 50S	 is	 blocked	by	 a	









translocation	 of	 proteins	 across	 membranes	 is	 widespread	 in	 biology.	 In	 the	
bacterial	 and	 eukaryotic	 system,	 co-translational	 protein	 translocation	 is	 a	
conserved	process	involving	the	SecY	and	Sec61	complexes,	respectively,	along	with	
their	regulatory	partners	(101).	The	Sec61	complex,	a	conserved	protein	conducting	
channel,	 is	 found	 on	 the	 membrane	 of	 the	 endoplasmic	 reticulum.	 It	 facilitates	
transport	 of	 proteins	 emerging	 from	 membrane	 bound	 ribosomes	 across	 the	
membrane	 or	 laterally	 into	 the	 lipid	 bilayer.	 The	 structure	 of	 the	 mammalian	








Figure	 4	 –	 Taken	 from	 Englmeier,	 Robert	 et	 al.	 “Structure	 of	 the	 Human	
Mitochondrial	 Ribosome	 Studied	 In	 Situ	 by	 Cryoelectron	 Tomography.”	
Structure	 25	 10	 (2017):	 1574-1581.e2	 (100).	 Top	 left	 is	 a	 tomographic	 slice	
showing	 a	 cluster	 of	 mitoribosome.	 Scale	 bar,	 50nM.	 The	 coloured	 images	




In	 the	 mitochondria	 the	 cytochrome	 oxidase	 assembly	 (OXA)	 translocase,	 OXA1L	
and	OXA1,	in	the	human	and	yeast,	respectively,	is	a	translocase	bound	to	the	inner	
mitochondrial	membrane.	Mitoribosomes	of	both	human	and	yeast	origin	are	bound	
to	 the	 inner	mitochondrial	membrane	via	a	 few	postulated	proteins,	of	which	OXA	
has	been	found	to	be	consistently	identified	(99,103-105).	OXA	is	thought	to	mediate	
the	 co-translational	 insertion	 of	 mitochondrially	 encoded	 membrane	 proteins	
through	an	attachment	 to	 the	mitoribosome.	 In	addition,	 it	also	plays	a	 role	 in	 the	
insertion	 of	 nuclear	 encoded	 proteins	 that	 have	 been	 imported	 into	 the	
mitochondrial	matrix.	This	process	of	import	of	proteins	through	the	translocase	of	
the	 outer	 membrane	 (TOM)	 and	 translocase	 of	 the	 inner	 membrane	 (TIM)	
machinery	 into	 the	mitochondrial	matrix	 and	 export	 into	 the	 inner	mitochondrial	
membrane	 through	 OXA	 has	 been	 termed	 ‘conservative	 sorting’	 (106).	 OXA	 is	 a	
member	 of	 the	 highly	 conserved	 OXA/YidC/Alb3	 protein	 family	 in	 eukaryotes,	
prokaryotes	 and	 plant	 chloroplasts,	 respectively,	 involved	 in	 membrane	 protein	
insertion	 (107).	 In	 general,	 OXA	 contains	 five	 hydrophobic	 transmembrane	




mitochondrial	 membrane	 (108).	 The	 N-terminus	 sits	 within	 the	 inter-membrane	
space	and	 the	 long	C-terminal	 tail	 in	 the	mitochondrial	matrix.	 It	has	also	recently	
been	 found	 to	 be	 part	 of	 an	 even	 bigger	 ‘OXA1	 superfamily’,	 consisting	 of	 the	
additional	 endoplasmic	 reticulum	 proteins	 Get1,	 EMC3	 and	 TMCO1	 that	 also	
facilitate	 biogenesis	 of	 membrane	 proteins	 (109).	 Thus	 OXA’s	 role	 in	 both	 co-
translational	insertion	of	mitoribosome	produced	proteins	and	conservative	sorting	
of	nuclear	encoded	proteins	from	the	mitochondrial	matrix	to	the	inner	membrane	
establishes	 its	role	 in	global	 inner	mitochondrial	membrane	protein	assembly.	The	
use	 of	 OXA	 by	 two	 translational	 systems	 also	 highlights	 the	 mitochondrion	 as	 a	








proteins	 are	nuclear-encoded	and	are	 translated	by	 cytosolic	 ribosomes	 (110),	 (ii)	
proteins	 destined	 for	 the	 mitochondria	 often	 possess	 a	 recognisable	 localisation	
motif,	(iii)	mitochondrial	targeting	typically	occurs	post-translationally,	but	can	also	
occur	 during	 translation,	 (iv)	most	 proteins	 use	 the	 classical	 protein	 import	 route	
that	 requires	 a	 cleavable	 mitochondrial	 localisation	 “pre-sequence”	 (110),	 (v)	
proximity-specific	 ribosome	profiling	 studies	 in	yeast	have	 shown	 that	most	 inner	
membrane	proteins	 are	 targeted	 to	 the	mitochondria	 co-translationally	 (111),	 and	
finally,	(v)	recent	low-resolution	cryo-electron	tomographic	studies	have	shown	that	
cytosolic	ribosomes	actively	synthesising	mitochondrial	proteins	associate	with	the	
mitochondrial	 membrane	 surface	 (112).	 Interestingly,	 ribosomes	 bearing	 nascent	
chains	 have	 been	 shown	 to	 bind	 in	 the	 proximity	 of	 the	 TOM	 complex	 (112).	 The	
TOM	complex	recognises	the	nascent	chain	pre-sequence	to	facilitate	translocation.	
In	the	canonical	pathway	the	preprotein	is	transferred	to	the	TIM23	complex	and	is	







The	need	 for	 tight	 regulation	of	mitochondrial	 import	 becomes	 even	more	 critical	
when	concerning	the	production	of	proteins	from	two	different	translation	systems	
that	 need	 to	 come	 together	 and	 be	 assembled,	 for	 example	 as	 an	 oxidative	
phosphorylation	 component.	Monitoring	 of	 global	mitochondrial	 and	nuclear	 gene	
expression	 in	 S.	 cerevisiae	 shows	 that	 mitochondrial	 translation	 is	 controlled	 by	
cytosolic	translation	in	a	unidirectional	manner	allowing	orchestration	of	assembly	
of	the	macromolecular	complexes	of	oxidative	phosphorylation	(114).	There	is	also	
evidence	 of	 translational	 adaptation	 to	 global	 changes	 in	 cellular	 state	 in	 both	
cytosolic	 and	mitochondrial	 compartments,	 allowing	 the	 focus	of	 translation	 to	be	
where	 it	 is	needed	at	 times	of	 stress	 (114).	 	Overall,	 this	 synchronisation	between	
cytosolic	 and	 mitochondrial	 translation	 is	 likely	 to	 increase	 the	 efficiency	 of	
oxidative	phosphorylation,	reducing	the	production	of	unnecessary	and	potentially	
harmful	 subunits	 if	 stoichiometry	 is	 not	 retained.	 The	 exact	 role	 of	 translational	
activators	 in	 this	 synchronised	 response	 remains	 to	 be	 elucidated.	 Indeed,	 it	 has	
been	shown	that	human	mitoribosomes	translating	COX1	mRNA	have	been	found	to	








The	development	of	 techniques	 in	 structural	biology	have	been	essential	 in	 aiding	
our	 understanding	 of	 the	 architecture	 of	 macromolecular	 complexes	 and	 have	
complemented	 the	 quest	 in	 understanding	 biological	 and	 molecular	 function.	
Historically,	the	most	widely	used	technique	for	obtaining	atomic	models	was	X-ray	









and	 later	 computationally	 combined	 to	 obtain	 a	 3D	model	 of	 the	 structure	 to	 be	
determined.	In	1995,	Henderson	hypothesised	that	with	macromolecules	of	100	kDa	
and	 above,	we	 could	 in	 theory	 reach	 atomic	 resolution	 using	 electron	microscopy	
with	~	10,000	averaged	together	particles	(117).	Whilst	atomic	resolution	has	long	




Minimisation	 of	 radiation	 damage	 has	 been	 obtained	 through	maintenance	 of	 low	
temperatures	and	techniques	to	minimise	the	exposure	of	the	biological	specimen	to	
electrons	(116).	Early	experiments	into	the	preparation	of	frozen	hydrated	samples,	
followed	 by	 the	 development	 of	 rapid	 vitrification	 of	 biological	 samples	 in	 liquid	
ethane	or	 propane	 in	 the	1980s,	 identified	 techniques	 to	 preserve	high	 resolution	










a	 sharp	 increase	 in	 the	 number	 of	 high	 resolution	 structures	 solved	 by	 cryo-EM	
since	2012	which	has	not	been	limited	to	macromolecular	structures	but	have	also	
included	 small	 protein	 structures	 as	 well	 as	 membrane	 proteins.	 Direct	 electron	
detectors,	detecting	electrons	without	having	to	first	convert	them	into	photons,	as	
in	the	charge	coupled	device	(CCD)	cameras,	have	the	advantage	of	fast	readouts	and	
limited	 noise,	 resulting	 in	 higher	 contrast	 images.	 Automated	 data	 acquisition	
packages	 such	 as	 EPU	 (from	 FEI)	 work	 in	 line	 with	 direct	 electron	 detectors,	
allowing	automated	collection	of	images	as	multi	frame	movies	in	‘movie	mode’	from	
pre-selected	 areas.	 The	 collection	 of	 cryo-EM	 data	 in	 ‘movie	mode’	where	 several	
images	are	 recorded	 successively,	 allows	 for	 tracking	of	 the	beam	 induced	motion	
that	 can	 be	 corrected	 for	 to	 retain	 higher	 resolution	 information	 (120).	Maximum	
likelihood	 based	 image	 analysis	 programmes	 such	 as	 RELION	 (REgularized	
LIkelihood	OptimizatioN),	have	overcome	challenges	in	image	processing,	including	
dealing	 with	 the	 inherent	 background	 noise	 of	 the	 raw	 images	 and	 the	 need	 to	
identify	 the	 relative	 orientations	 of	 the	 selected	 particles	 (121-123).	 Features	
include;	 automated	particle	 selection,	 pre-processing	 of	 the	 raw	 images	 to	 correct	
for	 the	 microscope	 contrast	 transfer	 function	 and	 2D	 class	 averaging	 to	 group	




maps	 and	 models.	 Model	 building	 molecular-graphics	 software	 packages	 such	 as	




Thus,	 the	 combined	 advances	 in	 cryo-electron	 microscopy	 over	 the	 last	 40	 years	
have	revolutionised	the	world	of	structural	biology.	Examples	of	the	first	wave	of	the	
single	 particle	 cryo-EM	 ‘resolution	 revolution’	 structures	 include	 the	 2013	






field	 that	 continues	 to	 grow	 with	 exciting	 developments	 in	 grid	 preparation	
methods,	data	collection,	for	example	phase-plate	technology	allowing	in-focus	data	
acquisition,	 and	 data	 processing	 such	 as	 on	 the	 fly	motion	 correction	 for	 improve	







just	 begun	 to	 emerge.	 The	 Ramakrishnan	 and	 Ban	 lab	 had	 both	 elucidated	 the	





resolution	near-atomic	mitoribosome	 structures	 but	 previous	work	had	 existed	 of	
lower	 resolution	 cryo-EM	structures	 (42-45,130).	 I	was	 interested	 in	exploring	 the	
mitoribosome	 field	 in	2	particular	 aspects;	1)	 the	basic	 structure	of	mitochondrial	
ribosomes	 and	 2)	 the	 co-translational	 insertion	 of	 mitochondrially	 translated	
proteins.	
	











The	 mechanism	 of	 mitoribosome	 co-translational	 insertion	 of	 inner	 membrane	
proteins	 is	 one	 of	 the	 next	 interesting	 questions	 to	 be	 answered	 in	mitochondrial	
translation.	Because	of	the	high	proportion	of	mitoribosomes	attached	to	the	inner	
mitochondrial	 membrane	 this	 is	 thought	 to	 be	 a	 key	 aspect	 of	 mitochondrial	
translation	(99,100).	The	OXA	translocon	mediates	this	co-translational	insertion	of	






proteins	 by	 trapping	 an	 actively	 translating	 complex	 of	 the	mitoribosome	with	 its	
translocon	 OXA.	 In	 particular,	 I	 focussed	 on	 the	 human	 system	 for	 its	 pathogenic	
relevance.	 As	 a	 clinician	 I	 am	 interested	 in	 the	 way	 perturbations	 to	 basic	
mitochondrial	 translation	 cause	 human	 disease.	 Thus,	 studying	 the	 normal	








The	 large	 subunit	 of	 the	 yeast	mitoribosome	 had	 previously	 been	 solved	 to	 near-
atomic	resolution	by	cryo-EM,	but	as	yet	there	was	no	structure	of	the	mt-SSU	and	
hence	no	 structure	of	 the	 full	 yeast	mitoribosome	 (46).	 The	yeast	S.	cerevisiae	 has	
long	been	used	as	a	 tool	and	model	system	to	understand	genetic	and	biochemical	
activities	 of	 mitochondria,	 largely	 aided	 by	 our	 ability	 to	 manipulate	 its	 mt-DNA	
(133).	 Thus,	 it	 has	 also	 been	 a	 model	 to	 study	 mitochondrial	 disease	 (134).	
Mitochondrial	 ribosomes	 have	 been	 shown	 to	 differ	 in	 both	 structure	 and	
constituents	when	compared	not	only	with	 their	bacterial	 and	cytosolic	 ribosomal	
counterparts,	 but	 also	 between	 different	 eukaryotic	 species.	 The	 mitoribosome	
within	 the	 yeast	 mitochondrion	 is	 an	 important	 and	 integral	 macromolecule,	
responsible	 for	 translating	7	essential	proteins	of	oxidative	phosphorylation	and	1	
protein	integral	to	the	mt-SSU.	The	fundamental	protein	and	RNA	components	of	the	
yeast	 mitoribosome	 have	 been	 well	 characterised	 biochemically,	 but	 the	 relative	
positions	of	proteins	were	not	well	elucidated	and	best	ascertained	through	a	high	
resolution	 structure	 of	 the	 whole	 mitoribosome.	 In	 addition,	 high	 resolution	
structural	 information	 of	 the	 whole	 mitoribosome	 may	 shed	 light	 on	 particular	
functional	 aspects	 of	 proteins,	mt-rRNA	and	mitoribosomal	 active	 sites,	 as	well	 as	
evolutionary	 information	 particularly	 from	 mapping	 homologous	 regions	 of	
proteins/rRNA.		
	
To	 gain	more	 understanding	 of	 the	 constituents	 of	 the	whole	 yeast	mitoribosome	
and	 the	 spatial	 relationship	 of	 the	 components,	 in	 order	 to	 try	 and	 answer	 some	
more	mechanistic	questions	of	the	translation	cycle	such	as	mt-mRNA,	mt-tRNA	and	
factor	 binding	 sites,	we	have	determined	 and	published	 the	 complete	 structure	 of	
the	whole	yeast	mitochondrial	ribosome	by	single	particle	cryo-electron	microscopy	
























Processing	 was	 performed	 using	 RELION,	 apart	 from	 particle	 picking	 which	 was	
done	using	EMAN2	(121,136).	After	particle	picking,	extraction	and	subsequent	2D	
classification	 a	 total	 of	 341,270	 particles	 was	 retained.	 2D	 classes	 with	 different	


















from	 the	 complete	 dataset	 as	 judged	 by	 the	 Fourier-shell-correlation	 (FCS)	 0.143	
criterion.	After	mt-SSU	masked	3D	 refinement,	 3	 classes	were	 identified	 following	
3D	classification	without	alignments.	The	most	abundant	classes,	class	I	and	II,	were	
further	 3D	 classified	 without	 alignments	 and	 overall	 3	 monosome	 classes	 were	
identified	 (class	 A,	 B	 and	 C),	 which	 displayed	 distinctive	 conformational	
heterogeneity	and	resolved	to	3.3	Å,	3.7	Å	and	4.6	Å,	respectively	(Figure	7).	Due	to	
the	flexible	movement	of	the	small	and	large	subunits	relative	to	each	other	it	was	
necessary	 to	 further	 improve	 the	 quality	 of	 the	 maps	 of	 individual	 parts	 of	 the	
ribosome	to	aid	de	novo	building	by	applying	specific	soft	masks	during	subsequent	
refinements,	 in	 combination	 with	 further	 3D	 classification.	 To	 improve	 the	
resolution	of	the	mt-SSU	we	went	back	to	the	initial	3D	classification,	pooled	these	





the	 mt-LSU	 we	 combined	 the	 final	 three	 monosome	 classes	 and	 performed	 3D	
refinement	with	a	mt-LSU	mask.	Overall,	 the	 local	 resolution	 improved	after	 these	






















It	 is	 evident	 from	 the	maps	 of	 the	monosomes	 and	 the	masked	maps	 coloured	by	
resolution,	 that	 the	 cores	 of	 the	maps	 are	 of	 higher	 resolution	 compared	with	 the	
peripheries	 (Figure	 9).	 This	 is	 due	 to	 relative	 flexibility	 of	 the	 peripheral	
components	to	include	flexible	helical	segments	of	mt-rRNA.	As	expected	the	overall	
resolution	of	the	most	abundant	class,	class	A,	was	better	than	the	other	monosome	
classes.	 Local	 resolution	was	 further	 improved	 in	 the	masked	map	 refinements	 of	
individual	 sections	 of	 the	mitoribosome	 (as	 described	 above),	 compared	with	 the	
whole	 monosome	 class	 refinement	 due	 to	 reduction	 of	 the	 obligate	 movement	
between	the	 larger	segments	of	 the	mitoribosome.	 In	particular	 the	 improvements	
of	the	mt-LSU	maps	were	crucial	for	map	interpretation	and	de	novo	model	building	
of	previously	unbuilt	areas	(Figure	10).	A	comparison	of	the	FSC	curves	between	the	
old	 (EMD-2566)	 and	 the	 new	 mt-LSU	 map	 showed	 that,	 although	 the	 overall	













the	 mt-SSU	 and	 fitting	 and	 further	 modelling	 of	 the	 mt-LSU	 was	 done	 in	 the	
Crystallographic	Object-Oriented	Toolkit	(Coot)	software	(125).	Known	structures	of	
the	 human	 mitoribosome	 (PDB	 3J9M)	 and	 bacteria	 Escherichia	 coli	 (E.	 coli;	 PDB	
5IQR)	ribosomal	proteins	were	docked	into	homologous	regions	using	a	trace	of	the	











the	 mt-SSU	 mt-rRNA	 (137).	 The	 modelling	 was	 done	 using	 the	 higher	 resolution	
maps	 of	 the	mt-SSU	 head	 and	 body,	 and	 the	mt-LSU.	 These	 individually	modelled	
sections	 were	 then	 fitted	 into	 the	 3	 monosome	 maps,	 to	 obtain	 a	 model	 of	 the	
complete	mitoribosome.	The	FSC	curves	of	 the	 fit	of	 the	refined	model	 to	 the	 final	
map	for	each	of	 the	3	classes	of	 the	monosome	are	shown	in	Figure	11.	 In	the	mt-
LSU,	in	areas	that	previously	were	unable	to	be	confidently	built	into,	we	were	now	









Figure	 11	 –	 FSC	 curves	 representing	 the	 fit	 of	 the	 refined	model	 to	 the	 final	
map	(black	line)	for	each	of	the	three	yeast	mitoribosome	conformations.	The	
dashed	line	indicates	the	resolution	at	FSC=0.5.	Denoted	by	blue	and	red	lines	














	 Class	A	 Class	B	 Class	C	
Data	Collection	 	 	 	
	 Particles	 141,795	 24,632	 55,448	
	 Pixel	size	(Å)	 1.34	 1.34	 1.34	
	 Defocus	mean	(µm)	 2.4	 2.5	 2.6	
	 Defocus	range	(-µm)	 1.3–4.8	 1.3–4.8	 1.3–4.8	
	 Voltage	(kV)	 300	 300	 300	
	 Electron	dose	(e·	Å−2)	 23.5	 23.5	 23.5	
Model	composition	 	 	 	
	 Non-hydrogen	atoms	 201,475	 201,475	 201,475	
	 Protein	residues	 13,711	 13,711	 13,711	




Refinement	 	 	 	




	 Average	B	factor	(Å2)	 74.9	 87.0	 111.0	
	 FSCaverage	CRef	(Å)	 0.80	 0.77	 0.72	
Rms	deviations	 	 	 	
	 Bond	lengths	(Å)	 0.005	 0.005	 0.005	
	 Bond	angles	(°)	 1.03	 1.02	 1.02	
Validation	(proteins)	 	 	 	















	 Poor	rotamers	(%)	 6.0	 6.0	 6.0	
Ramachandran	plot	 	 	 	
	 Favored	(%)	 94.3	 94.4	 94.3	
	 Outliers	(%)	 0.4	 0.4	 0.4	
Validation	(RNA)	 	 	 	















by	 cryo-electron	microscopy	 (Figure	 13)	 (135).	 The	 small	 subunit	 head	 has	 been	
determined	to	a	resolution	of	3.5	Å,	the	body	to	3.3	Å	and	the	large	subunit	to	3.2	Å.	






bacterial	 homologues	 (Figure	 13,	 Table	 2).	 In	 fact,	 only	 the	 bacterial	 SSU	 protein	
bS20	was	found	to	be	absent.	Additionally	the	yeast	mt-SSU	was	not	found	to	have	
homologues	to	the	human	mitoribosomal	proteins	mS22,	mS25,	mS27,	mS31,	mS34	
and	 mS39.	 	 14	 of	 the	 mt-SSU	 proteins	 have	 been	 found	 to	 be	 unique	 to	
mitoribosomes	 and	 of	 these,	 7	 are	 yeast	 mitochondrial	 specific.	 These	 have	 been	
renamed	 in	 accordance	 with	 the	 new	 classification	 for	 the	 naming	 of	 ribosomal	
proteins	(138).		
	
We	 were	 unable	 to	 locate	 2	 proteins	 previously	 reported	 in	 the	 literature	 to	 be	
constituents	 of	 the	 yeast	mitoribosome	RSM22	 and	 YMS2	 (131,132).	 It	 is	 possible	
that	 these	 proteins	 are	 located	 in	 the	 periphery	where	 unaccounted	 alpha	 helices	








and	 the	mt-rRNA	expansion	segments	 largely	occupy	 the	peripheral	 surface	of	 the	




mitoribosomes.	 Two	 new	 proteinacious	 protuberances	 dominate	 the	 periphery	 of	
the	mt-SSU	body.	mS38	(Cox24)	not	previously	identified	as	a	yeast	mitoribosomal	
protein	was	assigned	by	directly	interpreting	the	density	and	obtaining	a	sequence	
that	 was	 cross	 referenced	 against	 protein	 databases	 (Figure	 15).	 Although	 not	
known	 previously	 to	 be	 a	 mitoribosomal	 protein,	 it	 had	 been	 reported	 in	 the	









Protein	 constituents	 of	 the	 yeast	 mt-SSU	 (135).	 The	 figures	 represent	 the	











bS1m	 MRP51	 Q02950	 AA	 1-344	 39,445	 2-109,	 195-233,	
244-299,	
Extensively	 remodelled	 when	 compared	 to	
bacterial	and	human	mitochondrial	homologs.		
uS2m	 MRP4	 P32902	 BB	 26-394	 44,162	 128-393	 	
uS3m	 VAR1	 P02381	 CC	 1-398	 47,123	 30-68,	78-158,	166-
280,	295-398	
Yeast	mitochondrial	genome	encoded.		
uS4m	 NAM9	 P27929	 DD	 35-486	 56,356	 2-80,	 88-192,	 384-
486	
	
uS5m	 MRPS5	 P33759	 EE	 14-307	 34,883	 14-113,	119-306	 	
bS6m	 MRP17	 P28778	 FF	 1-131	 15,021	 1-125	 	
uS7m	 RSM7	 P47150	 GG	 27-247	 27,816	 87-247	 	
uS8m	 MRPS8	 Q03799	 HH	 1-155	 17,471	 2-155	 	
uS9m	 MRPS9	 P38120	 II	 11-278	 31,925	 35-71,	81-134,	144-
278	
	
uS10m	 RSM10	 Q03201	 JJ	 15-203	 23,424	 17-201	 	
uS11m	 MRPS18	 P42847	 KK	 60-217	 24,563	 70-99,	106-217	 	
uS12m	 MRPS12	 P53732	 LL	 21-153	 16,917	 29-152	 	
uS13m	 SWS2	 P53937	 MM	 1-143	 16,089	 2-121	 	
uS14m	 MRP2	 P10663	 NN	 1-115	 13,538	 1-115	 	
uS15m	 MRPS28	 P21771	 OO	 34-286	 33,057	 34-112,	128-286	 	
bS16m	 MRPS16	 Q02608	 PP	 1-121	 13,639	 2-106,	110-120	 	




bS18m	 RSM18	 P40033	 RR	 1-138	 15,835	 40-72,	81-138	 	
uS19m	 RSM19	 P53733	 SS	 1-91	 10,275	 9-88	 	











mS23	 RSM25	 P40496	 UU	 1-264	 30,513	 1-233	 	
mS26	 PET123	 P17558	 VV	 1-318	 35,998	 2-234	 	
mS29	 RSM23	 Q001163	 WW	 15-450	 50,867	 50-450	 	
mS33	 RSM27	 P53305	 XX	 1-110	 12,393	 1-96	 	
mS35	 RSM24	 Q03976	 YY	 31-319	 37,393	 47-119,	124-319	 	
mS37	 MRP10	 O75012	 ZZ	 2-95	 10,691	 5-70,	75-95	 Certain	 human	 homologous	 domains	 but	
different	spatial	orientation	adopted.	
mS38	 COX24	 P32344	 11	 1-111	 12,772	 78-111	 Not	 previously	 identified	 as	 a	 mitoribosomal	
protein	 in	 yeast.	 Shown	 to	 be	 involved	 in	
processing	COX1	transcripts	(138).	
	
mS41	 FYV4P	 P38783	 22	 28-130	 15,292	 30-128	 Sterile	alpha	motif	domain	
mS42	 RSM26	 P47141	 33	 1-266	 30,224	 8-100,	112-262	 Forms	a	heterodimer	with	mS43.	Homologous	to	
Fe/Mn	superoxide	dismutases.	




mS44	 MRP13	 P12686	 55	 38-339	 38,988	 42-78,	115-136	 	
mS45	 MRPS35	 P53292	 66	 27-345	 39,575	 27-276,	291-345	 	
mS46	 RSM28	 Q03430	 77	 1-359	 41,216	 197-361	 Occupies	 a	 similar	 position	 to	 human	 mS31	
however	 structural	 similarities	 appears	
resultant	 of	 environmental	 constraints	 rather	
than	shared	ancestry.	

















mt-LSU	 	 mt-SSU	 	 Translational	
Activators	
	 Others	
uL1m	 uL30m	 	 bS1m	 	 Aep1	 	 Ach1	 Lpd1	
uL2m	 bL31m	 	 uS2m	 	 Aep2	 	 Aco1	 Lsc2	
uL3m	 bL32m	 	 uS3m	 	 Atp25	 	 Ald4	 Lsp1	
uL4m	 bL33m	 	 uS4m	 	 Cbp1	 	 Atp1	 Mdh1	
uL5m	 bL34m	 	 uS5m	 	 Cbs2	 	 Atp16	 Mic10	
uL6m	 bL36m	 	 bS6m	 	 Mam33	 	 Atp2	 Mir1	
bL9m	 mL38	 	 uS7m	 	 Ssc1	 	 Atp3	 Mss116	
uL10m	 mL40	 	 uS8m	 	 		 	 Atp4	 Ndi1	
uL11m	 mL41	 	 uS9m	 	 	 	 Atp5	 Om45	
bL12m	 mL43	 	 uS10m	 	 	 	 Atp6	 Pda1	
uL13m	 mL44	 	 uS11m	 	 		 	 Atp7	 Pdb1	
uL14m	 mL46	 	 uS13m	 	 		 	 Cat2	 Pdx1	
uL15m	 mL49	 	 uS14m	 	 		 	 Cit1	 Pet9	
uL16m	 mL50	 	 uS15m	 	 		 	 Cor1	 Phb1	
uL17m	 mL53	 	 bS16m	 	 		 	 Cox2	 Phb2	
bL19m	 mL54	 	 uS17m	 	 		 	 Cox5	 Por1	
bL21m	 mL57	 	 bS18m	 	 		 	 Fum1	 Pth4	
uL22m	 mL58	 	 bS21m	 	 		 	 Ggc1	 Qcr2	
uL23m	 mL59	 	 mS23m	 	 		 	 Gut2	 Qcr7	
uL24m	 mL60	 	 mS26	 	 		 	 Hsp60	 Rip1	
bL27m	 mL61	 	 mS29	 	 		 	 Idh2	 Sdh1	
bL28m	 MHR1	 	 mS33	 	 		 	 Ilv5	 Sdh2	
uL29m	 	 	 mS35	 	 		 	 Kgd1	 Stb1	
	 	 	 	 mS37	 	 		 	 Kgd2	 Suv3	
	 	 	 mS41	 	 		 	 Krt14	 Tim9	
	 	 	 mS42	 	 		 	 Lat1	 	
	 	 	 mS43	 	 		 	 	 	
	 	 	 mS44	 	 		 	 	 	
	 	 	 mS45	 	 		 	 	 	
	 	 	 mS46	 	 		 	 	 	
	 	 	 mS47	 	 		 	 	 	





Figure	 15	 –	mS38	 (Cox24)	 (135).	Model	 of	 S38	 (Cox24)	 fitted	 to	 the	 density.	




Of	 the	 mt-SSU	 proteins	 modelled,	 the	 ones	 found	 to	 be	 homologous	 with	 the	
bacterial	 ribosome	 include	 bS1m	 (Mrp51),	 uS2m	 (Mrp4),	 uS3m	 (Var1),	 uS4m	
(Nam9),	 uS5m	 (Mrps5),	 bS6m	 (Mrp17),	 uS7m	 (Rsm7),	 uS8m	 (Mrps8),	 uS9m	




reaching	 considerable	 length	 (Figure	 17).	 The	 extensions	 however	 do	 not	




The	 proteins	 that	 have	 homologues	 in	 both	 the	 human	 and	 yeast	 mitochondrial	




mS44	 (Mrp13),	 mS45	 (Mrps35),	 mS46	 (Rsm28)	 and	 mS47	 (Ehd3).	 Overall,	 the	
addition	 of	 the	 mitochondrial-specific	 elements	 results	 in	 a	 more	 proteinacious	
mitoribosome	 with	 a	 conserved	 core	 of	 bacterial	 proteinacious	 elements	 and	
surrounding	mitochondrially	unique	elements	(Figure	16).	Figure	16	shows	the	mt-
SSU	 proteins	 with	 the	 areas	 homologous	 to	 bacteria	 in	 blue	 occupying	 the	 inner	
layer.	 The	 red	 sections	 represent	 the	 areas	 homologous	 to	 human	 only	 and	 not	
bacteria.	 These	 sections	 largely	 occupy	 the	 peripheral	 layer.	 To	 an	 even	 greater	
proportion,	 the	 outer	 layer	 is	 occupied	 by	 yeast	 specific	 elements	 (represented	 in	
yellow).	Figure	18	(A)	shows	the	proteins	of	the	mt-SSU	represented	by	the	presence	
of	homologues.	The	core	represents	proteins	that	have	bacterial	homologues	in	blue.	
The	 mitochondrial	 specific	 proteins	 (red)	 and	 the	 new	 yeast	 specific	 proteins	
(yellow)	 are	 present	 at	 the	 periphery,	 including	 two	 protuberances	 giving	 the	



















to	 accurately	 model	 two	 of	 the	 expansion	 segments,	 h16-ES	 and	 h17-ES,	 which	
occupy	 the	 periphery	 due	 to	 insufficient	 density.	 It	 was	 however	 possible	 to	
	 47	
recognise	 that	 they	 formed	 helical	 domains.	 Overall,	 these	 new	 extension	 and	
proteins	 serve	 to	 give	 the	 yeast	 and	 human	 mitoribosome	 and	 the	 bacterial	
ribosome	 their	 unique	 shapes	 (Figure	 20).	 Human	 and	 yeast	 protein	 extension	
disparity	supports	elongation	of	 these	proteins	after	divergence	 from	the	common	
bacterial	 ancestor	 rather	 than	 contraction	 of	 their	 bacterial	 homologues.	 Bacterial	





Figure	 16	 –	 Protein	 elements	 of	 the	mt-SSU	 coloured	 by	 conservation	 (135).	
The	 blue	 coloured	 regions	 are	 elements	 conserved	 with	 the	 bacterial	
ribosome.	The	red	coloured	regions	are	elements	conserved	with	the	human	
mitochondrial	 ribosome	 but	 not	 the	 bacterial	 ribosome.	 Yeast	 specific	













Figure	 18	 –	 Interactions	 between	 proteins	 of	 the	 yeast	 mt-SSU.	 (A)	 Yeast	
mitoribosomal	 proteins	 with	 bacterial	 ribosome	 homologues	 are	 shown	 in	
blue.	 Yeast	 mitoribosomal	 proteins	 with	 human	mitoribosomal	 homologues	
are	 shown	 in	 red.	 Yeast	 specific	 proteins	 are	 shown	 in	 yellow.	 The	 figure	
represents	the	PyMOL	surface	representations	of	the	model.	(B)	The	protein-
protein	network	of	 the	mt-SSU.	The	size	of	 the	nodes	represents	 the	relative	
molecular	masses	of	the	proteins,	and	the	thickness	of	the	edge	represents	the	
extent	 of	 the	 interface	 between	 the	 interacting	 proteins.	 Interactions	 also	
occurring	 in	bacterial	and	human	mitoribosomes	are	shown	in	blue	and	red,	
respectively.	 Yeast	 mitoribosome	 specific	 interactions	 are	 shown	 in	 grey.	




Figure	 19	 –	 Secondary	 structure	 diagram	 of	 the	 yeast	mt-SSU	 15S	 rRNA.	 (A)	
The	15S	mt-rRNA	coloured	by	the	different	domains	and	labelled	according	to	
the	 E.	 coli	 counterparts	 when	 appropriate.	 The	 yeast	 mitoribosome	 specific	
expansions	are	highlighted	in	red.	The	nucleotides	that	could	not	be	modelled	
are	 shown	 with	 no	 background	 colouring.	 Unmodelled	 areas	 specific	 to	 the	
yeast	 mitoribosome	 are	 denoted	 in	 red	 lettering.	 (B)	 Secondary	 structure	




Figure	 20	 -	 Comparison	 between	 the	 yeast	 mitoribosome,	 human	
mitoribosome	and	E.	coli	ribosome.	Mt-rRNA	is	coloured	in	grey.	Homologous	




The	 subunits	 of	 the	mitoribosome	 are	 connected	 through	 a	 series	 of	 intersubunit	
bridges,	which	serve	to	regulate	the	relative	movements	of	the	subunits	(Figure	21).	






Figure	21	–	 Intersubunit	Bridges	 (135).	 (1)	The	 intersubunit	 interface	of	 the	
mt-SSU	and	mt-LSU	are	shown.	Residues	involved	in	intersubunit	contacts	are	
coloured	 and	 labelled	 with	 the	 respective	 bridge	 names.	 Residues	 coloured	
blue	 represent	 bridges	 also	 present	 in	 the	 bacterial	 ribosome.	 Residues	
coloured	red	represent	bridges	present	in	the	yeast	and	human	mitoribosome.	
Residues	 coloured	 yellow	 represent	 yeast	 specific	 bridges.	 Yeast	 specific	
residues	that	are	found	only	in	class	B	are	coloured	in	teal.	b	=	body,	h	=	head	






The	 increased	 number	 of	 intersubunit	 bridges	 in	 the	 yeast	 mitoribosome	 (as	
	 53	
compared	to	the	bacterial	ribosome)	may	 limit	 the	 intersubunit	movement.	This	 is	
reflected	in	the	relatively	subtle	movement	between	the	three	monosome	classes	we	
observed	(Figure	7).	In	the	mammalian	mitoribosome	a	remodelled	helix	44	has	led	
to	 comparatively	 fewer	 intersubunit	 contacts	 (48,50).	 In	 our	models	we	were	 not	
able	 to	 observe	 the	 previously	 seen	 ‘racheted	 and	 ‘rolled’	 states	 of	 the	 human	
mitoribosome	 or	 the	 hyper-rotated	 state	 for	 the	 yeast	 mitoribosome	 captured	
previously	by	cryo-electron	tomography	(48,99).		
	
In	 Class	B,	 further	 yeast	mitoribosome	 specific	 bridges	were	 observed	 (Figure	21,	
Table	5).	This	is	mediated	by	an	8°	rotation	of	the	head	bringing	it	into	contact	with	
the	 central	 protuberance	 of	 the	 mt-LSU	 (Figure	 21,	 Figure	 23).	 This	 also	 has	 the	





association	 is	 in	 some	 way	 linked	 to	 subunit	 association.	 However,	 in	 the	 yeast,	
mS29	 is	 involved	 in	 an	 alternative	 subunit	 bridge	 contacting	 a	 mt-LSU	 mt-rRNA	











Figure	 22	 –	 Conserved	 Bridges	 (135).	 Molecular	 details	 of	 the	 intersubunit	
bridges	 of	 the	 yeast	 mitoribosome	 that	 are	 conserved	 with	 the	 bacterial	










































mB10R	 are	 only	 present	 in	 class	 B.	 The	 8° 	 rotation	 of	 the	 mt-SSU	 creates	












































human	 mitoribosome	 have	 a	 red	 background	 (135).	 Bridges	 only	 found	 in	














Figure	 25	 –	 Position	 of	 mS29	 in	 the	 yeast	 and	 human	 mitoribosome.	 (A)	
Position	of	mS29	shown	in	purple	in	the	yeast	mitoribosome	class	A.	Close	up	
of	 the	 boxed	 section.	 (B)	 mS29	 contacts	 H82-ES4	 of	 the	mt-LSU	mt-rRNA	 in	
class	B	 (bridge	mB7)	 in	 the	yeast	mitoribosome	due	 to	an	8° 	 rotation	of	 the	










ribosome	 constitute,	mS42,	mS43	 and	mS47.	mS42	 and	mS43	 (RSM26	 and	MRP1	
respectively)	 are	 both	 homologues	 of	 the	 iron/manganese	 binding	 superoxide	
dismutase,	however	the	catalytic	metal	binding	cores	of	each	of	these	proteins	have	
diverged	 in	sequence	rendering	a	 likely	 inactive	hydrophobic	environment	(Figure	
26(A)(B)).	 	 They	 appear	 in	 the	model	 as	 a	 hetero-dimer	protuberance	 adjacent	 to	
proteins	that	surround	the	mt-mRNA	exit	tunnel.		
	
mS47	 (EHD3)	 forms	 the	 other	 protuberance	 and	 is	 a	 3-hydroxyisobutyryl-CoA	
hydrolase,	a	member	of	 the	enoyl-CoA	hydratase/isomerase	 family.	 	There	 is	good	
fitting	homology	with	human	3-hydroxyisobutyryl-CoA	hydrolase	(PDB	3BPT),	with	
an	 overlap	 of	 240	 residues	 (35%	 identity)	 to	 include	 the	 active	 site,	which	 shows	
apparent	conservation	(Figure	26(A)(C))	(144).	β-hydroxyisobutyryl-CoA	hydrolase	
is	a	human	mitochondrial	protein,	(albeit	not	part	of	the	human	mitoribosome)	that	




capable	 of	 accommodating	 its	 substrate,	 and	 retains	 a	 coordinating	 glutamate	 at	
position	172	(146).	 	Active	site	residues	are	either	preserved	or	show	conservative	
mutations.	 	 We	 hypothesise	 that	 maintenance	 of	 such	 an	 environment	 suggests	
selective	pressure.	This	would	be	consistent	with	the	ability	of	EHD3,	as	part	of	the	
mitochondrial	 ribosome,	 to	 be	 an	 active	 enzyme	 and	 have	 potential	 functions	
beyond	being	an	integral	structural	component.	As	it	occupies	a	peripheral	location	
on	the	mitoribosome,	it	is	likely	that	its	role	in	translation	is	non-essential	which	is	
consistent	with	viable	null	mutants.	 Its	 co-localisation	with	 the	mitoribosome	may	
act	as	a	link	between	translation	and	the	catabolic	state	of	the	mitochondrion	(144).		
	
uS3m	or	Var1,	 the	yeast	mitoribosomal	homolog	of	uS3	 is	 the	only	soluble	protein	
encoded	 by	mt-DNA	 (147,148).	 Curiously,	 in	 contrast	 to	 nuclear	 encoded	 uS3m	 in	
other	species,	mitochondrially	encoded	yeast	uS3m	has	a	~30%	asparagine	content	
(Figure	26(D)).	The	asparagines	are	largely	represented	on	the	solvent	surface	of	the	
protein	and	 is	most	 likely	a	consequence	of	 the	mt-DNA	having	~83%	AT	content.	
	 61	









Figure	 26	 –	 Features	 of	 the	 yeast	 mt-SSU.	 (A)	 Structure	 of	 the	 mt-SSU	 with	
uS3m,	 mS42,	 mS43,	 and	 mS47	 coloured.	 This	 figure	 represents	 the	 PyMOL	
surface	representation	of	the	model.		(B)	mS42	and	mS43	form	a	heterodimer	
that	 structurally	 resembles	 the	 yeast	 mitochondrial	 superoxide	 dismutase	
dimer	(PDB	3LSU).	The	image	is	related	to	(A)	by	a	90° 	rotation	around	the	y-
axis.	(C)	mS47,	catalytic	residues	conserved	with	human	β-hydroxyisobutyryl-
CoA	 hydrolase	 (PDB	 3BPT).	 The	 image	 is	 related	 to	 (A)	 by	 an	 approximate	
180°rotation	 around	 the	 x-axis.	 (D)	 uS3m	 has	multiple	 asparagine	 residues	






in	 bacteria	 has	 been	 shown	 to	 enter	 between	 the	 head	 and	 shoulder	 of	 the	 SSU	
through	an	entry	site	surrounded	by	uS3,	uS4	and	uS5.	The	proteins	uS3	and	uS4	are	




In	 the	 yeast	model,	 the	mt-mRNA	entrance	has	been	 found	 to	have	 the	 conserved	
elements	 of	 uS3m	 (Var1),	 uS4m	 (Nam9)	 and	 uS5m	 (Mrps5).	 Additionally,	 the	
mitochondrial	 specific	protein	mS35	(Rsm24)	and	 the	yeast	mitochondrial	 specific	
protein	 mS45	 (Mrps35)	 contribute	 to	 the	 architecture	 of	 the	 outer	 mt-mRNA	
entrance,	 but	 the	 large	 scale	 remodelling	 observed	 in	 the	 human	mitoribosome	 is	
not	 seen	 (48).	 At	 the	 mitoribosomal	 A-site,	 mt-mRNA	 threads	 through	 the	 major	
groove	 made	 up	 of	 the	 upper	 part	 of	 helix	 44.	 The	 decoding	 centre	 here,	 which	
mediates	the	interaction	of	the	mt-mRNA	and	A-site	mt-tRNA,	is	made	up	of	the	15S	
nucleotides	 G644,	 A1584	 and	 A1585	 (G530,	 A1492,	 and	 A1493	 in	 bacteria	
respectively)	and	a	loop	of	uS12m	(Mrps12).		The	mechanism	of	decoding	appears	to	
be	preserved	when	compared	with	other	 ribosomes.	The	cryo-EM	structure	of	 the	
mammalian	 55S	 mitoribosome	 with	 all	 3	 mt-tRNAs	 (A-,	 P-,	 and	 E-	 site)	 sites	
occupied	confirms	the	conservation	of	the	decoding	centre,	comparable	to	the	here	
reported	 yeast	 mitoribosome	 structure	 (50).	 However,	 the	 yeast	 mitoribosome	
appears	 to	be	devoid	of	a	P-site	 finger	extending	 from	the	central	protuberance	 to	





the	early	and	intermediate	parts	of	 the	mt-mRNA	channel.	 In	bacteria	the	3’	 tail	of	
the	 16S	 rRNA	 contains	 an	 anti	 Shine-Dalgarno	 sequence	 that	 base	 pairs	 with	 the	
Shine-Dalgarno	 sequence	 of	 the	 5’UTR	 of	mRNA,	 facilitating	 start	 codon	 selection	
during	 initiation	 of	 translation.	 Yeast	 mitochondrial	 transcripts	 do	 not	 contain	 a	
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Shine-Dalgarno	 sequence	 and	 the	 3’	 tail	 of	 the	 16S	 mt-rRNA	 is	 additionally	
embedded	 within	 the	 mt-SSU	 and	 not	 accessible	 to	 the	 mt-mRNA.	 Clearly	 an	
alternative	 mechanism	 of	 translation	 initiation	 is	 needed.	 From	 our	 structure	 we	
observed	a	wide	V-shaped	canyon	at	the	mt-mRNA	exit	channel	(Figure	27).	On	one	
side	 of	 the	 canyon	 lies	 the	 heterodimer	 protuberance	 composed	 of	 mS42-mS43	
(Rsm26-Mrp1).	 The	 other	 side	 is	 flanked	 by	 a	 series	 of	 mitoribosomal	 protein	
extensions	 to	 include	 bS6m	 (Mrp17),	 uS15m	 (Mrps28),	 uS17m	 (Mrps17),	 bS18m	
(Rsm18),	 and	 bS21m	 (Mrp21).	 Ribosome	 profiling	 data	 has	 shown	 that	 the	 yeast	
mitoribosome	protects	longer	stretches	of	mt-mRNA	during	translation	compare	to	
cytosolic	 ribosomes	 (~38	 nucleotides	 compared	 to	 28	 nucleotides)	 (114).	 This	
would	 be	 consistent	 with	 the	 mt-mRNA	 occupying	 the	 space	 created	 by	 the	 V-
shaped	 canyon.	 In	~60%	of	 our	particles	 additional	 density	was	 visible	 above	 the	
mt-mRNA	exit	canyon	(Figure	27).	We	employed	focussed	classification	with	signal	
subtraction	methods	for	the	unknown	density	but	were	not	able	to	resolve	it	further	
(Figure	 29).	 A	 similarly	 placed	 density	 has	 previously	 been	 observed	 by	 cryo-
electron	 tomography	using	subtomogram	averaging	of	 in	situ	 yeast	mitoribosomes	
(99).	 In	 our	model	 the	 density	 contacts	 both	walls	 of	 the	V-shaped	mt-mRNA	 exit	
canyon.	bS1m	(Mrp51),	bS6m	(Mrps17)	and	mS43	are	contacted	on	one	side	while	
on	 the	 other	 side	 uS15m	 (Mrps28),	 uS17m	 (Mrps17)	 and	 mS26	 (Pet123)	 are	
contacted.	 Evidence	 that	 the	 canyon	 is	 involved	 in	 translation	 initiation	 includes	
bS1m	being	shown	to	interact	with	the	5’	UTRs	of	yeast	mt-mRNAs,	thereby	showing	
similarity	 to	 bS1	 in	 the	 bacterial	 system	where	 this	 function	 is	 better	 understood	
(153,154).	 Pet122	 is	 a	 known	 translational	 activator	 for	 cytochrome	 c	 oxidase	
subunit	 III	 and	 has	 been	 shown	 to	 functionally	 interact	 with	 the	 following	
components	of	the	canyon,	bS6m	(Mrp17),	mS26	(Pet123)	and	mS43	(Mrp1)	(155-
157).	 In	 the	 yeast	 mitochondrial	 translation	 system,	 translational	 activators	 are	
thought	 to	 be	 the	 factor	 unifying	 the	 5’	 UTRs	 of	 mitochondrial	 transcripts,	 the	
mitoribosome	 and	 the	 inner	 mitochondrial	 membrane,	 and	 are	 found	 to	 be	
transcript	specific	(10,65).	An	absence	of	the	Shine-Dalgarno	sequence	in	yeast	mt-
mRNA	 transcripts	 necessitates	 an	 alternative	method	 of	 aligning	 and	 priming	 the	
mt-mRNA	 for	 translation	 and	 defining	 the	 start	 codon.	 However,	 translational	
activators	 are	 also	 thought	 to	 have	 functions	 that	 extend	 to	 establishing	 tailored	
translational	micro-environments.	We	hypothesise	 that	 the	 large	V-shaped	 canyon	
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that	 form	 the	 mt-mRNA	 exit	 canyon.	 (C)	 The	 canyon	 walls	 coloured	 by	
conservation.	 Yellow	=	 yeast	mitochondrial	 specific.	 Red	 =	 human	 and	 yeast	








exit	 channel	 (135).	 Multiple	 rounds	 of	 focussed	 classification	 with	 signal	






Mitochondria,	 amongst	 their	 other	 cellular	 functions,	 universally	 carry	 out	 the	
function	of	 aerobic	 respiration	 in	 eukaryotic	 cells.	 Their	 presence	 is	 a	 hallmark	of	
eukaryotic	 cells	 and	 they	 are	 descended	 from	 a	 common	 bacterial	 endosymbiont	




entire	 translation	 system	 must	 exist	 and	 be	 adapted	 to	 serve	 its	 purpose.	 The	
translation	system	itself	in	the	mitochondrion	has	been	found	to	have	considerable	
species-specific	 specialisation.	 This	 is	 likely	 a	 response	 to	 different	 evolutionary	
pressures	and	a	reflection	of	their	different	intra-cellular	environments.		
	
Translation	 specialisation	 has	 extended	 to	 the	 composition	 and	 structures	 of	
mitoribosomes.	High	resolution	cryo-EM	structures	of	mitoribosomes	have	begun	to	
emerge	 since	2014	and	have	 further	posed	questions	as	 to	 the	evolutionary	 cause	
and	 functional	 effects	 of	 mitoribosomes	 being	 so	 varied	 (46,48-50,158).	 From	 the	
structures	 of	mitoribosomes	 from	 different	 species,	 they	 appear	 to	 have	 diverged	
from	 their	 ancestral	 bacterial	 ribosome,	 and	 additionally	 there	 are	 divergences	
between	 mitoribosomes	 from	 different	 species	 (Figure	 20)	 (48,50,135).	 The	
variation	 in	 ribosomal	RNA:protein	 ratio	 is	between	2:1	 in	bacterial	 ribosomes,	 to	
1:3	and	even	1:6	in	mitoribosomes,	sometimes	with	comparable	molecular	weights	
between	 the	 ribosomes.	 This	 is	 also	 in	 stark	 contrast	 to	 the	 chloroplast	 organelle	
whose	 ribosome	 more	 closely	 resembles	 the	 bacterial	 ribosome	 with	 good	
conservation	 between	 rRNA	 and	 ribosomal	 proteins;	 only	 6	 plastid	 specific	
ribosomal	proteins	are	observed	(159-161).	
	
In	 general,	 it	 has	been	observed	 that	mitoribosomes	have	acquired	novel	proteins	
and	 protein	 extensions	 compared	 to	 bacterial	 ribosomes,	 and	 their	 mt-rRNA	 has	
undergone	some	remodelling	at	the	peripheries	to	include	shortening	in	mammalian	
mt-rRNA	 and	 areas	 of	 expansion	 in	 yeast	mt-rRNA	 (48,50,135).	 It	 is	 hypothesised	
that	mitoribosomes	 have	 evolved	with	 an	 initial	 constructive	 phase	 in	 eukaryotic	
evolution	of	protein	accumulation,	 followed	by	a	reductive	phase	during	metazoan	
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in	metazoan	 evolution	 (45).	 Interestingly,	 it	 is	 thought	 that	 the	 5	macromolecular	




55S	 ribosome.	 Its	mt-rRNA	has	 gone	 through	 a	 reductive	 phase	 having	~	 half	 the	









areas	 of	 expansions	 leave	 an	 overall	 mt-rRNA	 size	 comparable	 to	 the	 bacterial	
ribosome	 (Figure	 19).	 However,	 due	 to	 the	 increase	 in	 protein	 mass	 it	 has	
comparatively increased in molecular weight by ~30% (46).	
	
It	is	unclear	whether	acquisition	of	these	novel	mitoribosomal	proteins	was	part	of	‘	
non	adaptive’	 evolution	 implying	 that	 they	have	become	part	of	 the	mitoribosome	
and	subsequently	have	evolved	to	fulfill	a	function,	or	whether	they	are	a	necessary	
evolutionary	 adaptation	 to	 fulfill	 this	 function,	 ‘adaptive’	 evolution	 (45).	 The	







numbers	 (162). In	 metazoan	 bilaterians,	 in	 particular,	 the	 mitochondrial	 genome	






to	 other	 mitochondrial	 proteins	 with	 alternative	 functions.	 An	 example	 of	 this	 is	
mS47	 (EHD3)	 a	 putatively	 active	 enzyme	 found	 at	 the	 peripheral	 location	 of	 the	
mitoribosome	whose	positioning	may	not	be	 crucial	 to	mitoribosome	 function	but	
may	serve	a	co-localisation	purpose	(Figure	26).	Thus,	addition	of	these	proteins	to	





the	 structure	 of	 the	 mitoribosome	 has	 allowed	 the	 retention	 of	 this	 function	 to	
produce	 a	 soluble	 product,	 which	 is	 lost	 in	 other	 mitoribosomes.	 Similarly,	 the	
remodelled	V-shaped	canyon	on	the	yeast	mt-SSU	hypothesised	to	serve	the	purpose	
of	 a	 binding	 platform	 for	 translational	 activators,	 is	 a	 mechanism	 that	 is	 not	
employed	 in	 the	 bacterial	 or	 human	mitochondrial	 translation	 system	 (Figure	 27,	
Figure	 28).	 Hence,	 this	 large	mt-mRNA	 exit	 canyon	 is	 absent	 in	 the	 bacterial	 and	
human	mitochondrial	ribosome.		
	




differences	 and	 similarities	 between	 mitoribosomes.	 Our	 yeast	 mitoribosome	
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on	 other	 ribosome.	 Further	 structural	 and	 biochemical	 studies	 are	 needed	 to	
elucidate	the	translational	cycle	in	mitoribosomes	together	with	its	co-translational	
insertion	 of	 emerging	 polypeptides	 into	 the	 inner	 mitochondrial	 membrane.	 The	













resuspended	 in	 pre-warmed	 (30°C)	DTT	buffer	 (100	mM	Tris-HCl	 pH	9.3,	 10	mM	
DTT)	and	left	for	30	min	in	a	30°C	incubator	to	shake.	This	was	followed	by	further	
pelleting	 by	 centrifugation	 at	 3,500	 x	g	 for	 10	minutes	 at	 room	 temperature.	 The	
pellet	 was	 resuspended	 in	 Zymolyase	 buffer	 (20	 mM	 K2HPO4-HCl	 pH	 7.4,	 1.2	 M	





4,000	 x	 g.	 The	 pellet	 was	 then	 resuspended	 in	 homogenisation	 buffer	 (20	 mM	
Hepes-KOH	pH	7.45,	0.6	M	sorbitol,	1	mM	EDTA)	and	the	pellet	homogenised	using	a	
glass	Dounce	homogeniser	for	15	stroked.	The	cell	debris	and	nuclei	was	separated	
from	 the	 mitochondrial	 fraction	 by	 centrifugation	 at	 2000	 x	 g	 for	 20	 min.	 The	
supernatant	 was	 collected	 and	 centrifugation	 for	 20	 minutes	 at	 4500	 x	 g.	 The	
collected	 supernatant	 was	 then	 centrifuged	 at	 13,000	 x	 g	 for	 25	 minutes.	 This	











MgOAc,	 1.7%	 Triton	 X-100,	 2	 mM	 DTT)	 with	 added	 0.0075%	 Cardiolipin	 and	
100ug/ml	 chloramphenicol	 was	 added	 to	 sucrose	 gradient	 purified	 mitochondria	
and	 incubated	 for	 10	 minutes	 on	 ice.	 	 Centrifugation	 at	 30,000	 x	 g	 for	 20	 min	
pelleted	out	the	membrane	fraction.		The	supernatant	was	loaded	onto	a	1	M	sucrose	
cushion	 in	 buffer:	 20	 mM	 Hepes-	 KOH	 pH	 7.5,	 100	 mM	 KCl,	 20	 mM	MgOAc,	 1%	
Triton	 X-100,	 2	 mM	 DTT,	 0.0075%cardiolipin,	 0.05%	 β-DDM	 and	 50µg/ml	
chloramphenicol.	The	sucrose	cushion	was	centrifuged	 for	4	hours	at	231,550	x	g.	
The	pellet	was	resuspended	in	the	same	buffer	as	above	(without	Triton	X-100)	and	
loaded	 on	 15%-30%	 sucrose	 gradient	 and	 run	 for	 16	 hours	 at	 80,000	 x	 g.		
Mitoribosome	fractions	were	collected.	The	sucrose	was	exchanged	with	the	above	
buffer	 (without	 triton	but	with	 added	0.001%	cardiolipin)	using	 a	15	ml	Vivaspin	









ethane	 and	 subsequently	 stored	 in	 liquid	 nitrogen.	 The	 grids	 were	 subsequently	
loaded	onto	an	FEI	Titan	Krios	300kV	electron	microscope	 for	data	collection.	The	
images	 were	 collected	 in	 linear	 mode	 using	 FEI’s	 automated	 single	 particle	
acquisition	software	(EPU).	The	images	were	recorded	on	a	back-thinned	FEI	Falcon	
II	 detector	 at	 a	 magnification	 of	 104,478	 (pixel	 size	 1.34	 Å).	 For	 each	 1	 second	











468,858	 particles	were	 extracted	 from	 2525	micrographs.	 127,588	 particles	were	
discarded	 after	 2D	 classification	 leaving	 a	 total	 of	 341,270	 particles.	 Initial	
refinement	 of	 the	 data	 set	 obtained	 a	 resolution	 of	 3.3	 Å.	 Particle	 polishing	 in	
RELION	was	subsequently	used	to	correct	beam-induced	particle	motion	(121).	The	
resolutions	quoted	were	estimated	during	post-processing	using	 the	Fourier-shell-
correlation	 (FSC)	 0.143	 criterion	 (166).	We	 subsequently	 performed	 a	 refinement	
with	 a	 mt-SSU	 mask	 followed	 by	 3D	 classifications	 without	 alignments.	 Further	
refinement	of	selected	classes	with	soft	masks	applied	over	the	mt-SSU	head,	mt-SSU	
body	and	mt-LSU	was	 followed	with	subsequent	3D	classification.	The	masks	used	
were	 generated	 using	 RELION	 applying	 a	 soft	 edge.	 Prior	 to	 visualisation	 of	 the	
density	 maps,	 the	 modulation	 transfer	 function	 of	 the	 Falcon	 II	 detector	 was	
corrected	and	the	maps	sharpened	by	application	of	a	negative	B-factor,	estimated	
using	automated	procedures	(166).	The	best	monosome	class	(class	A)	resolved	to	
3.3	Å.	However,	due	 to	regions	of	 this	map	being	of	 insufficient	 local	 resolution	 to	
model	build	de	novo	we	did	further	masked	refinements	with	masks	created	for	the	
mt-SSU	head	and	body	and	the	mt-LSU.	The	mt-SSU	body	elucidation	went	through	
an	 additional	 round	 of	 3D	 classification.	 	 The	 final	 resolution	 of	 the	mt-SSU	 head	
reached	3.5	Å,	 the	mt	 –SSU	body	3.3	Å	 and	 the	mt-LSU	3.2	Å	 (Figure	 8).	 Figure	 9	
highlights	the	improved	resolution	of	these	areas.	 	Additionally,	multiple	rounds	of	




Model	 building	 was	 done	 in	 Coot	 using	 the	 generated	 masked	 maps	 which	 had	
improved	 local	 resolution	 (125).	 In	 regions	 of	 poor	 density	 Chimera	 was	 used	 to	
generate	Gaussian-filtered	maps	 to	 aid	model	 building	 (167).	 The	 structure	 of	 the	
human	mitoribosome	(PDB	3J9M)	and	the	E.	coli	ribosome	(PDB	5IQR)	were	used	as	
aids	 to	building	homologous	proteins	(48,137).	This	was	done	by	 first	 fitting	 these	
models	 into	 the	 yeast	 mt-SSU	 map	 using	 the	 Chimera	 ‘fit	 in	 map’	 function	





the	 sequence	and	numbering	modified	 to	 relate	 to	 the	yeast	mitoribosome.	To	aid	
this,	the	sequences	from	the	two	different	species	were	aligned	using	ClustalOmega	
(168).	 Real	 space	 refinement	 in	 Coot	 was	 used	 to	 fit	 the	 new	 yeast	model	 to	 the	
density,	 and	 extensions	 and	 insertions	 were	 built	 de	 novo	 (125).	 Torsion,	 planar-
peptide,	trans-peptide	and	Ramachandran	restraints	were	all	applied	during	model	
building	 (trans-peptide	 restraints	 removed	 to	model	 clear	cis-proline	 residues).	 In	
addition	during	real-space	refinement	of	α-helices	helical	restraints	were	applied.		
	
Poly(alanine)	models	 were	 built	 into	 unknown	 sections	 of	 the	map	 and	 searched	








mt-rRNA	 (137).	 Secondary	 structure	 diagrams	 were	 used	 in	 conjunction	 with	
sequence	 alignment	 information	 using	 ClustalOmega	 to	 rigid	 body	 fit	 conserved	
section	 of	 the	 16S	 rRNA	 to	 our	 map,	 with	 subsequent	 sequence	 mutation,	 re-
numbering	 and	 de	 novo	 building	 (168,173).	 Each	 individual	 nucleotide	 was	
examined	 and	 fitted	 to	 the	 density	 using	 real-space	 refinement	 in	 Coot	 (125).	Mt-














using	 ProSMART	 (174).	 LIBG	was	 used	 to	 obtain	mt-rRNA	 basepair,	 stacking	 and	




were	 then	 combined	 and	 further	 refined	 against	 each	 of	 the	 3	 mitoribosome	
monosome	classes.	To	maintain	the	stereochemistry	obtained	from	the	refinements	
with	higher	resolution	maps,	tighter	restraints	were	applied	to	refinements	against	
lower	 resolution	 maps.	 The	 subsequent	 fit	 of	 the	 model	 to	 the	 map	 density	 was	
quantified.	 The	 post-refinement	 model	 statistics	 obtained	 using	 REFMAC	 and	
Molprobity	 as	 shown	 in	 Table	 1	 on	 page	 37	 (176).	 Cross-validation	 against	





Figures	 were	 generated	 using	 PyMOL	 (‘The	 PyMOL	 Molecular	 Graphics	 System’,	






weighs	 from	 UniProt	 were	 used	 to	 represent	 the	 nodal	 size,	 and	 protein–protein	









3 Co-translational	 insertion	 of	 mitochondrial	 membrane	
proteins	
3.1 Scientific	Aims	
As	 all	 of	 the	 proteins	 translated	 by	 the	 human	 mitoribosome	 are	 membrane	
proteins,	 understanding	 the	 mechanism	 of	 co-translational	 membrane	 protein	
insertion	is	central	to	understanding	mitoribosome	translation.	In	mitochondria,	the	
oxidase	assembly	 (OXA)	 translocase	plays	a	 central	 role	 in	membrane	 insertion	of	
mitoribosome	 translated	 products	 (181).	 OXA	 shows	 conservation	 with	 the	
prokaryotic	protein	insertase	YidC,	and	is	thought	to	retain	functional	similarity	as	




act	 as	 a	 dimer	 (184).	 Cryo-electron	 tomography	 data	 has	 placed	 human	
mitoribosomes	 on	 the	 inner	 mitochondrial	 membrane	 but	 has	 lacked	 the	
appropriate	 resolution	 to	determine	 the	 structure	of	 the	OXA1L	 translocase	 (100).		
To	this	end,	the	aim	was	to	trap	the	human	mitoribosome	in	an	actively	translating	
state,	capturing	the	ribosomal	nascent	chain	as	it	traverses	through	the	exit	tunnel	
binding	 to	 its	 membrane	 bound	 translocase	 OXA1L	 (Figure	 30).	 The	 structural	
elucidation	 of	 the	 interaction	 sites	 of	 OXA1L	 with	 the	 nascent	 chain,	 and	 the	




present	 in	 the	 inner	 membranes	 of	 bacteria	 (YidC),	 chloroplasts	 (Alb3),	 yeast	
mitochondrial	 (OXA1)	 and	 mammalian	 mitochondria	 (OXA1L)	 (183,185-187).	 All	
members	of	this	family	contain	a	core	hydrophobic	domain	of	five	transmembrane	












mt-LSU	 of	 the	 mitoribosome	 are	 coloured	 in	 yellow	 and	 light	 cyan	
respectively.	 The	 ribosomal	 exit	 tunnel	 is	 depicted	 in	 blue.	 Mitoribosomes	







important	 in	 the	 assembly	 of	 oxidative	 phosphorylation	 components	 such	 as	
complex	IV	and	the	ATP	synthase	complex	(185,188).	Initially,	the	yeast	Oxa1p,	was	
found	 to	 be	 important	 in	 the	 export	 of	 the	 N-	 and	 C-termini	 of	 Cox2p,	 a	







the	mitochondrially	 encoded	 complex	 IV	 components,	 Cox1p	and	Cox3p	whose	N-
termini	are	retained	 in	 the	matrix	(191).	This	 interaction	was	 found	 to	be	prior	 to	





Oxa1p	 to	 ribosomes,	 in	 addition	 to	 improving	membrane	 protein	 insertion,	 had	 a	
role	in	the	coordinated	assembly	of	complex	IV	which	consists	of	both	mitochondria	
and	nuclear	encoded	proteins	(192).	Another	important	role	of	Oxa1p	was	found	in	
the	 assembly	 of	 the	 mitochondrially	 encoded	 components,	 Atp6	 and	 -9,	 of	 the	
F(1)F(o)-ATP	synthase	complex	 (193).	Oxa1p	 is	 thought	 to	 interact	with	Atp9	 in	a	
post-translational	 manner	 not	 dependent	 on	 the	 Oxa1p	 C-terminus,	 and	 be	
important	 in	 the	 assembly	 of	 the	 Atp9-F(1)-subcomplex	with	 Atp6	 (193).	 Thus,	 it	
appears	that	OXA1	is	not	only	important	for	co-translational	insertion	of	membrane	







led	 to	work	on	 the	attachment	of	OXA	 to	 the	mitoribosome.	The	C-terminal	 tail	 of	
Oxa1p	 resides	 in	 the	 mitochondrial	 matrix.	 Yeast	 Cox2,	 a	 product	 of	 the	
mitoribosome,	 was	 found	 to	 be	 inefficiently	 integrated	 into	 the	 mitochondrial	
membrane	following	deletion	of	the	C-terminal	end	of	Oxa1p	(103).	The	C-terminal	
domain	 was	 found	 to	 be	 a	 ~100	 amino	 acid	 element	 with	 the	 ability	 to	 bind	
mitoribosomes	(103-105).	Oxa1p	has	been	found	to	crosslink	to	uL23m	a	protein	of	
the	 yeast	mitoribosome	 exit	 tunnel	 (104).	 Studies	 in	 human	 found	 the	 C-terminal	









in	 the	 human	 and	 yeast	 systems.	 In	 the	 human	 mitoribosome,	 cryo-electron	




yeast,	 the	 inner	 membrane	 contacts	 of	 the	 mitoribosome	 are	 mediated	 by	 the	
expansion	 segment	 96	 ES-1	 and	 the	Mba1,	 an	 adapter	 protein	 that	 is	 not	 a	 main	
constituent	of	the	yeast	mitoribosome	(99).	It	is	thought	that	mL45	and	Mba1	have	
evolved	to	provide	similar	functions.	Figure	31	shows	a	graphical	representation	of	
the	 likely	membrane	 attachment	 (195).	 Thus,	 although	 information	 is	 available	 on	




Figure	 31	 –	 Adapted	 from	 High-resolution	 structures	 of	 mitochondrial	










strategy	 was	 to	 purify	 human	 mitoribosomes	 with	 the	 use	 of	 detergents	 and	
phospholipids	to	simulate	an	environment	 in	which	OXA1L	would	be	stably	bound	
to	 the	mitoribosome.	To	ensure	the	binding	of	OXA1L	 in	a	physiologically	relevant	
state,	we	 aimed	 to	 trap,	 by	 using	 antibiotics,	 an	 actively	 translating	mitoribosome	
with	 its	 polypeptide	 chain	 attached.	 We	 hypothesised	 that	 the	 presence	 of	 a	
polypeptide	 chain	 may	 help	 to	 increase	 the	 stability	 of	 the	 interaction	 of	 the	
mitoribosome	with	its	translocase	OXA1L,	as	well	as	being	of	biological	interest.	In	




According	 to	 the	 endosymbiont	 hypothesis	 of	 mitochondrial	 origin,	 mitochondria	
were	derived	 from	their	prokaryotic	ancestor,	and	thus	 the	basic	mechanisms	of	a	
variety	of	mitochondrial	activities	are	conserved	with	prokaryotes.	Included	in	this	
conservation	 are	 many	 of	 the	 catalytic	 site	 targets	 between	 bacterial	 and	
mitochondrial	 ribosomes.	 This	 results	 in	 a	 number	 of	 bacterially	 targeted	
antimicrobials	 also	 affecting	 human	 mitoribosomes,	 inducing	 toxicity	 (196).	 Our	
strategy	was	to	harness	the	ability	of	antibacterial	agents	to	bind	the	mitoribosome	
to	 affect	 translation	 in	 the	 mitochondria.	 Assumptions	 were	 made	 that	 the	
antibiotics	would	affect	mitoribosomes	 in	a	 similar	 conformation.	However,	 as	yet	
no	antimicrobials	have	been	visualised	structurally	on	the	mitoribosome.		
	
Examples	 of	 antibiotic	 classes	 known	 to	 bind	 the	 mitoribosome	 include	
oxazolidinone,	 amphenicols,	 aminoglycosides	 and	 tetracyclines.	 The	 oxazolidinone	











inhibit	 the	PTC	and	overlapping	with	 the	 tRNA	A-site	binding	on	 the	50S	 subunit.	













preventing	 binding	 of	 the	 anticodon	 step-loop	 of	 an	 A-site	 tRNA	 binding	 during	
elongation	(200).	Tigecycline	 is	a	 tetracycline	derivative	 that	has	 increased	affinity	




resistance	 (201).	 TetM	 works	 by	 binding	 ribosomes	 stalled	 by	 tetracyclines	 and	
displacing	 the	 drug.	 	 Tigecycline	 has	 been	 found	 to	 be	 useful	 in	 inhibiting	
mitochondrial	 translation	 in	acute	myeloid	 leukaemia	 (AML)	cell	 lines.	Tigecycline	
has	the	ability	to	selectively	kill	 leukaemic	stem	cells	and	clinical	 trials	 in	AML	are	
currently	underway	(97,98).	Additionally	 there	 is	evidence	 that	other	cancer	 types	
may	also	be	targets	to	include	MYC	driven	lymphomas	(202).		
	







(204).	Viomycin	has	been	 found	 in	 crystal	 and	EM	structures	 to	bind	 the	bacterial	
ribosomal	interface	between	helix	44	(h44)	of	the	SSU	and	Helix	69	(H69)	of	the	LSU	
(205-207).	 It	 is	 thought	 to	 compete	with	 EF-G	 for	 binding	 to	 the	 pre-translocated	
ribosome	and	maintain	 it	 in	 this	 state,	but	 it	has	also	been	 found	 to	stabilise	EF-G	
binding	in	the	pre-translocation	state (203,207).  
	
Thus,	 a	 variety	 of	 antibacterials	 are	 thought	 to	 effect	 mitoribosomes	 at	 different	
stages	of	 the	 translation	cycle.	We	aimed	 to	use	 this	 side	effect	 to	 stall	 the	human	
mitoribosome.	In	the	initial	purifications,	the	antibiotics	chloramphenicol,	viomycin	
and	 tigecycline	 were	 selected	 bases	 on	 their	 different	 mechanisms	 of	 action	 as	
described	 above.	 In	 addition,	 non-hydrolysable	GTP	analogues	were	 also	 added	 in	
some	instances	to	aid	mitoribosome	stalling	by	trapping	GTPases.	
	
Once	 an	 effective	 stalling	mechanism	 is	 ascertained	 the	 subsequent	 steps	were	 to	
create	an	environment	in	solution	in	which	the	membrane	protein	OXA1L	remained	
intact	 and	 bound	 to	 the	 mitoribosome.	 A	 biological	 membrane	 is	 a	 hydrophobic	
barrier	 between	 two	 aqueous	 compartments	 such	 as	 intermembrane	 space	 (IMS)	
and	mitochondrial	matrix.	 To	 create	 a	membrane-like	 environment	 of	 OXA1L,	we	
aimed	 to	 use	 different	 detergents	 and	 phospholipids.	 	 Detergents	 are	 amphiphilic	
compounds	 that	 typically	 have	 a	 polar	 hydrophilic	 head	 and	 a	 non-polar	




surfaces	 of	 membrane	 proteins.	 The	 polar	 hydrophilic	 regions	 are	 orientated	
towards	 the	 polar	 solute,	 forming	 stable	 micelles	 with	 hydrophobic	 cores.	 The	
concentration	 of	 detergent	 at	 which	 micelles	 start	 to	 form	 is	 called	 the	 critical	
micelle	 concentration	 (CMC).	 In	 general,	 detergents	 with	 low	 CMC	 values	 form	
micelles	 more	 easily	 and	 stably.	 Higher	 CMC	 values	 are	 associated	 with	 weaker	
binding,	 with	 these	 detergents	 being	 easier	 to	 remove	 by	 dialysis.	 The	 most	




detergents	 that	 are	 characterised	 by	 uncharged	 hydrophilic	 head	 groups	 (209).	
Examples	 of	 these	 detergents	 include	maltosides,	 glucosides	 and	 polyoxyethylene	
glycols.	These	detergents	work	in	a	mild	non-denaturing	fashion	to	disrupt	protein-
lipid	 and	 lipid-lipid	 interactions,	 while	 preserving	 protein-protein	 interactions	
(209).	 In	 this	 way,	 detergents	 are	 able	 to	 disrupt	 the	 bilayer	 of	 phospholipid	
molecules	 in	biological	membranes.	The	general	 architecture	of	 a	 lipid	bilayer	has	
the	 polar	 hydrophilic	 phosphoester	 head	 groups	 pointing	 outwards	with	 the	 lipid	
acyl	tails	pointing	towards	each	other	creating	a	hydrophobic	centre.	Mitochondrial	
membranes	 are	 composed	 of	 an	 inner	 and	 outer	 membrane	 with	 varying	 lipid	
compositions.	 The	 inner	 membrane	 has	 been	 found	 to	 contain	 low	 levels	 of	
triglycerides	 and	 high	 levels	 of	 cardiolipin	 (CL)	 (210).	 Cardiolipin	 is	 an	
evolutionarily	 conserved	 dimeric	 phospholipid	 that	 is	 specifically	 found	 in	 this	
organelle	 (211).	 CL	 is	 found	 almost	 exclusively	 in	 mitochondrial	 membrane	 and	
constitutes	 approximately	 15%	 of	 total	 mitochondrial	 phospholipids	 (212).	 In	
contrast,	 the	 outer	 membrane	 had	 higher	 levels	 of	 lipids	 to	 include	
phosphatidylcholine	 (PC),	 phosphatidylinositol	 (PI),	 plasmologen	 and	 triglyceride	














cardiolipin	 (TOCL)	 and	 chloramphenicol.	 Mitochondria	 were	 lysed	 with	 1.5%	 β-
DDM	 containing	 lysis	 buffer.	 Additionally	 this	 lysis	 buffer	 contained	 0.15mg/ml	





Figure	 32	 –	 Purification	 1.	 15-30%	 sucrose	 gradient	 fractions.	 Peak	 1	 was	
composed	 of	 fractions	 16-20	 and	 peak	 2	 composed	 of	 fractions	 21-26	 as	
circled.		
	
Once	 the	 mitochondria	 were	 lysed,	 the	 mitoribosomes	 were	 crudely	 pelleted	
through	 a	 sucrose	 cushion	 and	 fractionated	 after	 ultracentrifugation	 on	 a	 15-30%	
sucrose	 gradient	 (Figure	 32).	 From	 the	 sucrose	 gradient	 fractionation,	 there	were	
two	 visible	 A260	 peaks,	 peak	 1	 and	 2.	 These	 were	 thought	 to	 represent	









cytosolic	 ribosomes.	 Thus,	 mitoribosomes	 have	 a	 typical	 A260/A280	 of	 >1.6.	 The	
A260/A280	was	 found	to	be	an	average	of	1.85	 for	 fractions	16-20	(peak1)	and	1.86	
for	fractions	21-26	(peak	2)	that	were	pooled	together.	These	two	pooled	fractions	





the	 tandem	 mass	 spectrometry	 showed	 an	 abundance	 of	 mitoribosomal	 proteins	
and	in	addition	OXA1L	was	present	in	both	the	samples.	However,	there	were	also	
mitochondrial	proteins	not	known	to	be	related	to	mitochondrial	translation	found	
in	 the	 sample,	 probably	 a	 result	 of	 the	mitoribosome	 purification	 being	 imperfect	
with	 contaminations.	 Mass	 spectrometry	 was	 therefore	 used	 as	 a	 tool	 to	 confirm	
that	OXA1L	was	present	 in	 the	 sample	 but	 could	not	 confirm	 that	OXA1L	was	 co-




of	 both	 samples	 (peak	 1	 and	 2)	 were	 tested	 for	 migration	 on	 a	 10-15%	 sucrose	
gradient	 by	 centrifugation	 and	 collected	 as	 11	 equal	 fractions	 (Figure	 33).	 The	
collected	 fractions	 were	 subjected	 to	 western	 blotting	 with	 primary	 antibodies	
against	 the	mt-SSU	protein	mS27	 (MRPS27)	and	OXA1L.	Peak	1	 showed	signal	 for	
the	mitoribosomal	protein	mS27	in	fractions	3,	4	and	faintly	 in	5,	whilst	 the	signal	




mixture	 of	 subunits	 it	 seems	 that	 fraction	 3	 could	 represent	 isolated	 mt-SSU,	 in	
which	case	it	is	expected	that	OXA1L	would	not	be	present.	OXA1L	being	present	in	













mt-LSU	 	 mt-SSU	 	 Translationally	
Related	proteins	
	 Others	
uL1m	 bL32m	 	 bS1m	 	 MALSU1	 	 DLAT	 HSPD1	
uL2m	 bL33m	 	 uS2m	 	 OXA1L	 	 PDHB	 CELA1	
uL3m	 bL35m	 	 uS3m	 	 TUFM(mtEF-Tu)	 	 PDHA1	 POLRMT	
bL12m	 mL41	 	 uS10m	 	 		 	 PDHX	 CAD	
uL13m	 mL42	 	 uS11m	 	 	 	 GTPBP10	 PRDX3	
uL14m	 mL43	 	 uS12m	 	 		 	 NDUFAB1	 XRCC5	
uL15m	 mL44	 	 uS14m	 	 		 	 TFAM	 TFB1M	
uL16m	 mL45	 	 uS15m	 	 	 	 DLST	 CHCHD1	
bL17m	 mL46	 	 bS16m	 	 	 	 PHB2	 GLUD1	
uL18m	 mL48	 	 uS17m	 	 	 	 DBT	 POLG	
bL19m	 mL49	 	 bS18m	 	 	 	 SSBP1	 HIST1H1C	
bL20m	 mL50	 	 bS21m	 	 	 	 MRM3	 FTH1	
bL21m	 mL51	 	 mS22	 	 	 	 DLD	 HSPA9	
uL22m	 mL52	 	 mS23	 	 	 	 PHB	 ATAD3A	
uL23m	 mL53	 	 mS25	 	 	 	 NOA1	 HK1	
uL24m	 mL54	 	 mS26	 	 	 	 HSPD1	 HMGA2	
bL27m	 mL55	 	 mS27	 	 	 	 CELA1	 TTN	
bL28m	 mL62	 	 mS29	 	 	 	 POLRMT	 ABCC8	
uL29m	 mL66	 	 mS31	 	 		 	 DDX28	 LAMC1	
uL30m	 mL65	 	 mS33	 	 		 	 AURKAIP1	 MCAT	
	 	 	 mS34	 	 		 	 ERLIN2	 YBX1	
	 	 	 mS35	
mS39	
mS40	















Figure	 33	 –	 Purification	 1	 -	 western	 blotting	 results.	 Pooled	 fractions	 16-20	
(peak	1)	and	21-26	(peak	2)	were	run	on	a	10-50%	sucrose	gradient	and	11	
equal	fractions	collected.	Red	bands	represent	anti-mS27	signal.	Green	bands	





















This	 sample	was	 processed	 according	 to	 the	 scheme	 in	 Figure	 35.	 The	 processing	
was	 done	 with	 2.5X	 downscaled	 extracted	 particles	 to	 optimise	 the	 efficiency	 of	
processing.	 The	 initial	 first	 downscaled	 3D	 refinement	 reached	 nyquist	 at	 5.3	 Å	


















Unmasked	 3D	 classification	 without	 alignments	 resulted	 in	 two	 predominant	




and	 P-site	 mt-tRNA	 with	 weak	 E	 site	 mt-tRNA	 density.	 It	 also	 had	 density	 for	 a	













Furthermore,	 for	 each	 of	 these	 classes,	 focussed	 classification	 with	 signal	
subtraction	(FCwSS)	on	the	A-site	and	the	polypeptide	exit	site	was	performed.	For	
the	 A-site	 FCwSS,	 the	 aim	 was	 to	 identify	 classes	 of	 actively	 translating	
mitoribosomes	 that	might	 reveal	 density	 at	 the	 exit	 site.	 The	polypeptide	 exit	 site	
mask	 FCwSS	 aimed	 to	 use	 the	 bigger	 pool	 of	 particles	 to	 try	 and	 extract	
mitoribosomes	 that	 may	 have	 a	 translocon	 attached,	 but	 may	 not	 necessarily	 be	
actively	translating.	Both	of	these	strategies	on	the	two	above	classes	did	not	yield	
any	 density	 for	 the	 translocon	 OXA1L.	 	 Nor	 were	 there	 any	 classes	 with	 new	











One	 concern	 was	 that	 the	 initial	 mask	 used	 for	 the	 exit	 tunnel	 FCwSS	 was	 too	
restrictive.	Therefore	FCwSS	was	re-performed	encompassing	 the	polypeptide	exit	
site,	the	polypeptide	tunnel	and	the	P-site	mt-tRNA	in	one	continuous	mask	on	the	
1st	 3D	 refinement.	 However,	 the	 results	 did	 not	 reveal	 any	 extra	 density	 for	 the	
translocon.		
	
Thus,	what	we	were	 able	 to	 conclude	 from	 this	 preparation	was	 that	 under	 these	
conditions,	we	were	able	to	extract	actively	translating	mitoribosomes	with	a	with	
P-	and	A-	site	mt-tRNAs	and	a	polypeptide	chain.	It	is	hypothesised	that	the	nascent	
chain	 presence	 may	 strengthen	 the	 interaction	 between	 the	 mitoribosome	 and	
translocon.	However,	despite	having	a	density	for	a	nascent	chain	we	were	not	able	





While	 the	method	discussed	above,	 yielded	actively	 translating	mitoribosomes,	no	
OXA1L	 could	 be	 identified.	 Thus,	 an	 alternative	 strategy	 to	 stall	 the	 actively	
translating	complex	with	bound	OXAL1	was	employed	in	the	hope	that	with	a	more	
stable	stall	OXA1L	might	have	more	chance	of	being	bound.	Since	OXA1L	did	appear	
to	 co-migrate	 with	 monosomes	 according	 to	 our	 western	 blotting	 analysis	 for	
purification	1	(Figure	33),	we	decided	to	try	using	glutaraldehyde	as	a	crosslinker	in	
this	next	purification	in	the	final	step	before	grid	making	for	cryo-EM.	The	aim	was	
for	 OXA1L	 to	 be	 covalently	 crosslinked	 to	 the	 mitoribosome	 with	 the	 hope	 of	
strengthening	 its	 interaction.	 In	addition	 to	using	a	 crosslinker,	we	also	added	 the	
non-hydrolysable	 GTP	 analogue	 GDPNP	 (5'-Guanylyl	 imidodiphosphate).	 The	 aim	
was	 to	 trap	 GTPase	 translation	 factors	 such	 as	 mt-EF-Tu	 and	 mt-EG-G1	 on	 the	









peak	resulted	 in	a	 final	A260	of	8.7	and	8	respectively.	Furthermore,	aliquots	of	 the	





Figure	 38	 -	 Purification	 2.	 15-30%	 sucrose	 gradient	 fractions.	 Peak	 1	

















fractions.	 There	 was	 also	 increased	 signal	 in	 fraction	 25	 corresponding	 to	 the	
monosome	 fraction.	 As	 the	 signal	 for	 OXA1L	 was	 strongest	 in	 the	 fractions	
constituting	 peak	 1,	 the	 pooled	 fractions	 of	 peak	 1,	 we	 decided	 to	 analyse	 this	
further	by	single	particle	cryo-electron	microcopy	data	collection.	We	were	curious	
to	 see	 if	OXA1L	was	able	 to	be	 trapped	on	 the	 large	mitoribosomal	 subunit	 alone.	
Mt-LSU	 bound	 OXA1L	 would	 deliver	 valuable	 information	 to	 supplement	 any	













processed	 after	 2.5X	 downscaling.	 After	 2D	 classification	 there	 were	 243,893	
particles	remaining.	The	initial	3D	refinement	went	to	nyqvist	at	5.3	Å	and	revealed	
a	 map	 of	 the	 large	 subunit	 (Figure	 41).	 However,	 it	 was	 evident	 that	 it	 was	 a	
variation	 of	 the	 mt-LSU,	 usually	 associated	 with	 the	 monosome,	 as	 there	 was	 an	





3D	 classification	without	 alignment	 of	 the	 initial	 3D	 refinement	 yielded	 3	 distinct	
classes.	 Class	 2	 consisted	 of	 the	 monosome	 but	 there	 were	 only	 3,520	 particles	
present	 at	 a	 resolution	 of	 18	 Å.	 Class	 4	 (54,278	 particles)	 and	 class	 5	 (29,362)	
resolved	to	5.3	Å	and	7.5	Å	respectively.	Both	class	4	and	5	represented	the	mt-LSU	
with	the	extra	density	with	subtle	differences	in	the	subunit	interface.	All	maps	were	
examined	 for	 the	 presence	 of	 a	 nascent	 chain	 and	 OXA1L	 translocon	 at	 the	
polypeptide	exit	channel	but	neither	of	these	was	observed.	
	
Though	 the	 presence	 of	 a	 nascent	 chain	 was	 unlikely	 from	 the	 onset	 due	 to	 the	
absence	of	a	P-site	mt-tRNA	in	any	of	the	map,	it	remains	possible	that	OXA1L	could	
be	 associated	 to	 the	 mt-LSU	 in	 the	 absence	 of	 a	 nascent	 chain	 (although	 we	



















Modelled	 structures	 corresponding	 to	 the	 class	 4	 and	 5	maps	 of	 the	mt-LSU	 have	
recently	been	published	(214).	In	this	paper	the	structures	were	identified	as	2	late	
stage	assembly	intermediates	of	the	mt-LSU	and	have	been	determined	to	~3.0	Å.	In	
general,	 mitoribosome	 assembly	 is	 a	 finely	 tuned	 process	 involving	 proteins	 and	
rRNA	encoded	by	2	different	genomes,	nuclear	and	mitochondrial	respectively	(90).	
Known	 assembly	 factors	 with	 bacterial	 homologues	 are	 thought	 to	 mediate	 this	
effort	with	the	help	of	at	present	unknown	axillary	factors	(90).	It	is	thought	that	in	





In	 the	 published	 structure	 they	 identified	 the	 same	 additional	 density	 adjacent	 to	
uL14m	 that	 we	 observed,	 in	 their	 2	 classes.	 Their	 2	 classes	 composed	 of	 one	
showing	the	 interfacial	region	adopting	a	 fully	 folded	mt-rRNA	at	3.1	Å	resolution,	







suggests	 that	 recruitment	of	bL36m	and	 folding	of	 the	peptidyl	 transferase	 centre	
occurs	late	in	mt-LSU	biogenesis.		
	
The	 extra	 density	 adjacent	 to	 uL14m	was	 found	 to	 be	mitochondrial	 assembly	 of	
ribosomal	large	subunit	1	(MALSU1)	a	member	of	the	RsfS	family	of	proteins	known	










of	 mitoribosome	 assembly.	 It	 is	 thought	 that	 they	 may	 link	 fatty	 acid	 and	 iron-





mt-LSU.	MALSU1	 on	 its	 own	would	 be	 insufficient	 to	 fulfil	 this	 function,	 owing	 to	
deletions	of	 the	mt-SSU	compared	to	 the	bacterial	ribosome,	 including	 loss	of	h14.	
Therefore,	 additional	 proteins	 have	 joined	 the	 module.	 The	 module	 would	 cause	




paper	 into	our	maps.	MALSU1,	L0R8F8	and	mt-ACP	all	 fit	our	density	well	 (Figure	
44).	On	examination	of	the	intersubunit	interface	class	4	is	most	consistent	with	the	






has	 not	 partaken	 in	 any	 rounds	 of	 translation	 and	 therefore	 co-translational	
insertion	 it	 is	 not	 entirely	 unexpected	 that	 OXA1L	 was	 not	 visualised.	 However,	
western	blotting	analysis	did	show	evidence	of	OXA1L	in	the	subunit	peak.		Possible	
explanations	 for	 this	 include	 the	mt-LSU	 assembly	 intermediate	 being	 tethered	 to	


















To	 try	 to	 improve	 upon	 the	 stalling	 of	 actively	 translating	mitoribosomes	we	 also	
utilised	the	antibiotic	viomycin	and	GDPNP	with	the	aim	of	specifically	trapping	the	
GTPase	mt-EF-G.	 The	 aim	was	 to	 try	 and	 explore	 another	method	by	which	 a	mt-
tRNA	could	be	stably	trapped	in	the	P-site.	We	also	attempted	to	actively	stimulate	
mitoribosome	translation	in	the	mitochondria	before	stalling.	This	was	attempted	by	







mitochondrial	 lysis	 and	 grid	 preparations.	 	 Our	 previous	 western	 blotting	 results	
had	 shown	 OXA1L	 and	 the	 mitoribosome	 to	 be	 co-migrating	 after	 the	 sucrose	
gradient	step	but	as	we	are	unable	to	work	out	the	stoichiometry	there	may	be	some	
dissociation	 during	 this	 step	 that	 we	 were	 unable	 to	 quantify.	 Therefore,	
mitochondria	were	 lysed	and	after	 the	 initial	 centrifugation	step	 to	 remove	debris	
the	 mitoribosomes	 were	 pelleted	 through	 a	 sucrose	 cushion.	 At	 this	 stage	 the	
resuspended	mitoribosome	 samples	were	used	 for	 grid	 preparation.	An	 aliquot	 of	
the	sample	was	further	run	on	a	10-50%	sucrose	gradient	and	subjected	to	western	
blotting	 with	 antibodies	 against	 OXA1L	 and	 mS27.	 Our	 western	 blotting	 results	
showed	migration	of	OXA1L	with	the	ribosomal	protein	across	 fractions	2-11	with	











10-50%	 sucrose	 gradient	 and	 11	 equal	 fractions	 collected.	 Red	 bands	





















46.	 After	 motion	 and	 CTF	 correction	 2081	 micrographs	 were	 retained.	 259,082	
particles	 were	 picked	 initially	 but	 after	 a	 2.5X	 downscaled	 2D	 classification	 only	
46,134	 particles	were	 retained	 (Figure	 47).	 Due	 to	 ice	 contamination	 on	 the	 grid	
acquired	 as	 a	 consequence	 of	 unforeseen	 fluctuations	 in	 the	 microscope	




factor	 site.	On	 examination	of	 the	polypeptide	 exit	 channel	 there	was	 also	density	
present	for	a	nascent	chain.	In	order	to	obtain	better	density	for	the	factor,	a	FCwSS	
was	 performed	 on	 the	 mitoribosomal	 factor	 site.	 This	 revealed	 2	 classes	 with	
density	 in	 the	 factor	 site,	 class	 1	 and	 class	 5,	which	 resolved	 to	 7.6	 Å	 and	 10.1	 Å	
respectively.	 Neither	 of	 these	 classes	 however	 have	 a	 concurrent	 P-site	 mt-tRNA.	
FCwSS	on	the	expected	translocon	site	was	also	performed	on	the	1st	3D	refinement	
but	OXA1L	was	not	identified.	Thus,	this	purification	has	provided	us	with	another	
purification	 strategy	 in	 which	 to	 trap	 a	 P-site	 mt-tRNA	 with	 a	 nascent	 chain.	 In	
addition	we	have	seen	density	in	the	factor	binding	site	that	may	represent	mt-EF-G	




migrating	 with	 mitoribosomes.	 The	 omission	 of	 a	 sucrose	 gradient	 step	 with	
resultant	decrease	 in	handling	 time	did	not	appear	 to	make	a	difference	 in	OXA1L	









Figure	 48	 –	 Purification	 3.	 1st	 3D	 classification	 class	 3	 -	 6.6	 Å	 unsharpened	








Figure	 49	 –	 Purification	 3.	 (A)	 FCwSS	 class	 1	 front	 view.	 7.6	 Å	 unsharpened	





Following	on	 from	 the	 above	purifications	we	wanted	 to	 try	 out	 a	 third	 antibiotic	
tigecycline	 on	 its	 ability	 to	 stall	 actively	 translating	 ribosome.	 	 0.5mM	 tigecycline	
with	 the	 non-hydrolysable	 GTP	 analogue	 GDPCP	 (5'-guanosyl-methylene-
triphosphate	 was	 used	 in	 the	 lysis	 buffer.	 The	 traditional	 method	 of	 obtaining	
mitochondria	was	used.	Full	details	on	sample	preparation	are	found	in	the	methods	









peak	 1	 from	 previous	 experiments	 has	 been	 found	 to	 be	 mostly	 large	 subunit	
confirmed	by	data	processing.	We	decided	to	collect	on	the	monosome	peak	2.	We	
collected	 on	 the	 sample	 that	 was	 blotted	 for	 6.5	 seconds.	 As	 previously,	 this	 was	
collected	 using	 linear	 mode	 at	 a	 magnification	 of	 75,000	 on	 the	 FEI	 Titan	 Krios,	





Figure	 50	 -	 Purification	 4.	 15-30%	 sucrose	 gradient	 fractions.	 Peak	 1	 is	










blotting.	 Red	 bands	 represent	 anti-mS27	 signal.	 (A)	 Green	 bands	 represent	













After	 motion	 and	 CTF	 correction	 6219	 micrographs	 were	 retained.	 After	 2D	
classification	 after	 2.5X	 downscaling	 321,475	 particles	 were	 kept.	 The	 first	 3D	
refinement	reached	a	resolution	of	5.3	Å.	On	this	refinement	FCwSS	was	performed	





alignment	 was	 performed	 separating	 the	 data	 into	 8	 classes.	 3	 dominant	 classes	
were	identified.	Class	1	contained	60,535	particles	which	had	strong	density	for	the	
mt-LSU	and	refined	to	9.1	Å.	Further	3D	classification	on	class	1	identified	a	class	of	
mt–LSU	 late	 assembly	 intermediates	 with	 29,050	 particles,	 as	 seen	 in	 previous	
preparations.	The	first	3D	classification	on	the	1st	refinement	also	revealed	classes	3	
and	7	with	61,821	and	166,486	particles	respectively.	The	3D	refinements	of	these	









refined	 to	 5.3	 Å.	 This	 class	 6	 has	 density	 in	 the	 factor	 site	 and	 the	 A-site	 but	 no	
density	for	a	P-site	mt-tRNA.	The	same	FCwSS	of	class	7	revealed	class	3	with	43,122	
particles	that	has	density	in	the	factor	site	extending	into	the	A-site	but	again	had	no	
P-site	mt-tRNA.	This	 class	 refined	 to	 4.3	Å.	 Thus,	 from	 these	 rounds	 of	 FCwSS	we	











Class	3	 from	FCwSS	of	 the	 factor	site	mask	 from	class	7	of	 the	1st	3D	classification	










site	 mt-tRNA	 concurrently	 with	 a	 possible	 nascent	 chain	 and	 with	 an	 unknown	
factor	 in	 the	 factor	 site,	 at	 a	 resolution	 that	 could	be	 improved	upon	with	 further	





ribosomal	 factor	 site	 mask	 from	 class	 7	 of	 the	 1st	 3D	 classification.	 4.3	 Å	








Figure	 55	 –	 (A)	 Class	 5	 (6.5	 Å	 unsharpened	 map)	 and	 (B)	 class	 7	 (7.2	 Å	
unsharpened	map)	 from	FCwSS	of	 the	 exit	 site	 from	 class	 3	 of	 the	 initial	 3D	











and	 non-hydrolysable	 GTP	 analogues	 aimed	 at	 stalling	 the	 ribosome	 in	 active	
translation.	Our	methods	thus	far	have	appeared	to	achieve	stalling	by	visualisation	
of	 good	 P-site	 mt-tRNA	 density	 and	 by	 trapping	 of	 a	 presumed	 GTPase	 in	 the	
mitoribosomal	 factor	 site,	but	have	not	yet	yielded	any	density	 for	 the	 translocon.	
Thus,	 alternative	 methods	 have	 been	 explored	 with	 the	 aim	 of	 increasing	 the	
strength	of	the	stalling	to	promote	translocon	association.	A	cell	line	was	developed	
in	 the	 Minczuk	 lab	 that	 has	 demonstrated	 increased	 mitoribosomal	 stalling	 at	
specific	 mRNA	 codons	 (218).	 The	 poly(A)-specific	 exoribonuclease,	
phosphodiesterase	12	(PDE12)	has	been	found	to	be	important	for	the	regulation	of	
3’	polyadenylation	of	mt-rRNA	and	mt-tRNA	by	removal	of	the	poly(A)	in	a	3’	to	5’	
direction	 (218).	 The	 PDE12-/-	 cell	 line	 demonstrated	 aberrant	 adenylation	 of	 16S	
mt-rRNA	 although	 not	 affecting	 mitoribosomal	 assembly.	 In	 addition,	 aberrant	
polyadenylation	of	mt-tRNA	was	found	to	interfere	with	mt-tRNA	aminoacylation,	in	
particular	of	 the	 lysine	 specific	mt-tRNA	 .	Thus,	 lack	of	mature	 aminoacylated	mt-











We	 therefore	 explored	 the	 PDE12-/-	 cell	 line	 as	 a	 possible	 alternative	 for	
mitoribosome	 stalling.	 	 The	 PDE12-/-	 cell	 line	 was	 cultured	 and	 mitochondria	
extracted	 as	 per	 previously.	 The	 conditions	 used	 to	 solubilise	 the	 mitochondria	
involved	1.5%	β-DDM,	0.15mg/mL	TOCL	and	0.5mM	GDPCP.	The	GDPCP	was	added	
to	 further	 aid	 stalling	 of	 GTPases	 involved	 in	 translational	 elongation.	 	 Additional	
changes	 to	 the	 preparation	 detailed	 in	 the	methods	 section	 included	 the	 15-30%	
sucrose	 gradient	 step	 being	 run	 over	 1.5	 hours	 on	 a	 smaller	 scale	 instead	 of	 this	
being	an	overnight	step,	and	concentration	of	the	mitoribosomes	by	buffer	exchange	
instead	of	pelleting.	The	shortened	time	from	lysis	of	the	mitochondria	to	obtaining	
mitoribosomes	 and	 buffer	 exchange	 step	 were	 trialled	 as	 a	 way	 of	 minimising	
disruption	to	the	mitoribosomes	and	potentially	its	translocon.	The	15-30%	sucrose	
gradient	was	separated	into	15	equal	fractions	and	mitoribosome	absorption	at	A260	
was	 measured.	 Figure	 58	 shows	 the	 A260	 absorbance	 for	 the	 different	 fractions.	
Fractions	 10-14	 with	 an	 A260/A280	 ratio	 of	 above	 1.5	 were	 pooled	 together	 and	
concentrated	 with	 additional	 buffer	 exchange	 to	 lower	 the	 final	 β-DDM	
concentration	 to	 0.05%	 and	 obtain	 an	 A260	 of	 5	 and	 applied	 to	 grids	 as	 per	
previously.	 In	 order	 to	 maximise	 sample	 preparation	 for	 grid	 making,	 smaller	
aliquoted	 fractions	were	not	 taken	 to	 run	on	a	protein	gel	 for	western	blotting	on	
this	occasion.	Instead	an	aliquot	of	the	final	concentrated	sample	was	run	on	a	10-
50%	 sucrose	 gradient	 to	 look	 for	 co-migration	 of	 the	 anti-OXA1L	 and	 anti-mS27	
signal	as	in	previous	experiments.	This	is	shown	in	Figure	59	(A).	Unfortunately	the	
quality	 of	 the	western	 blot	was	 poor,	 but	 it	 is	 still	 faintly	 visible	 that	 there	 is	 co-
migration	in	lanes	4,	5	and	6.	The	preparation	was	therefore	repeated	with	identical	
conditions.	 Figure	 59	 (B)	 shows	 the	 15-30%	 sucrose	 gradient	 fractions	 and	 (C)	














10-15%	 sucrose	 gradient.	 (B)	 Repeat	 of	 purification	 5.	 15-30%	 sucrose	


























1728	 micrographs	 were	 retained.	 After	 2.5X	 downscaling	 and	 2D	 classification,	
126,288	particles	were	remaining.	The	initial	3D	refinement	achieved	a	resolution	of	
6.5	Å.	The	initial	3D	classification	revealed	3	distinct	classes.	Class	1	was	an	mt-LSU	
class.	 Classes	 4	 and	 5	 were	 monosome	 classes.	 Class	 1	 had	 15,323	 particles	 and	
resolved	 to	9.2	Å.	There	was	 clear	density	 at	 the	mitoribosomal	 exit	 site	 although	

















was	 clear	 density	 at	 the	 exit	 tunnel	 likely	 representing	 OXA1L	 as	 labelled.	 Also	




P-site	 mt-tRNA	 and	 patchy	 density	 at	 the	 polypeptide	 exit	 site.	 However,	 after	

















A	 further	 cryo-EM	 data	 set	 was	 collected	 on	 the	 same	 purification	 to	 see	 if	 the	
resolution	of	the	density	at	the	exit	tunnel	could	be	improved.	The	collection	details	
are	the	same	as	the	previous	collection	(Table	7).	The	RELION	classification	scheme	
is	 outlined	 in	Figure	64.	 From	 this	 second	data	 collection	4900	micrographs	were	
obtained.	 After	 downscaling	 2.5X	 and	 2D	 classification	 351,128	 particles	 were	




classification	 revealed	 class	 8	 representing	 the	 mt-LSU	 class	 with	 density	 at	 the	
translocon	site	as	previously	seen	(Figure	65	(A,	B)).	This	class	consisted	of	41,117	
particles.	However,	although	this	mt-LSU	class	was	seen	 in	the	previous	collection,	




mt-tRNA	occupying	 the	P/P	mt-tRNA	 space	 in	 the	mitoribosome.	However,	 in	 this	
map	the	mt-tRNA	(yellow)	 fits	 the	density	 in	this	orientation	 in	the	acceptor	stem,	
but	the	anticodon	stem	loop	is	deviated	towards	the	E-site.	In	Figure	66	a	mt-tRNA	
(green)	 has	 been	modelled	 into	 this	 density	 in	 the	 orientation	 that	 fits	 this	 map.	
When	we	looked	at	the	polypeptide	exit	site	we	were	able	to	see	density	suggestive	
of	 a	 nascent	 chain,	 which	 would	 be	 plausible	 given	 the	 position	 of	 the	 mt-tRNA.		
Additionally,	there	is	density	coming	from	the	L1	stalk	towards	this	mt-tRNA	density	
that	 may	 represent	 an	 E-site	 mt-tRNA	 with	 the	 anticodon	 stem	 loops	 of	 the	 two	











map)	 from	 initial	 3D	 classification	 showing	 a	 hint	 of	 density	 for	 OXA1L.	 (B)	
Different	view	of	same	class	to	show	density	for	the	MALSU1-L0R8F8-mt-ACP	
module.	 PDB	 5AJ4	 docked	 in	 to	 include	 position	 of	 P-site	mt-tRNA	 (50).	 (C)	















position	 with	 the	 nascent	 chain	 having	 been	 released,	 waiting	 for	 subsequent	
mitoribosome	 splitting	 through	 the	 coordinated	 effort	 of	 mt-RRF1	 and	mt-EF-G2.	
However,	in	this	map,	splitting	of	the	mitoribosome	appears	to	have	occurred	prior	
to	 nascent	 chain	 cleavage	 allowing	 for	 a	 P-site	 mt-tRNA	 to	 remain	 in	 situ	 with	
apparent	 stabilisation	 either	 from	 the	 E-site	 mt-tRNA	 or	 an	 as	 yet	 unidentified	
factor.	 In	addition,	 the	MALSU1-L0R8F8-mt-ACP	module,	 thought	to	be	part	of	 late	






map	 is	 suggestive	of	 the	possibility	 that	mitoribosome	recycling	 can	 take	place	on	
the	mitochondrial	 inner	membrane	 when	 stalled.	 In	 this	 situation,	 lack	 of	 PDE12	
possibly	together	with	the	used	of	GDPCP,	appears	to	have	caused	stalling,	and	it	is	
likely	 that	 the	 presence	 of	 the	mt-tRNA	 and	 nascent	 chain	 have	 strengthened	 the	
interaction	 of	 the	 mitoribosome	 with	 OXA1L.	 However,	 other	 changes	 in	 the	
preparation	 such	 as	 a	 shorter	 sucrose	 gradient	 step	 with	 buffer	 exchange	
centrifugation	is	likely	to	have	also	played	a	role.		
	
After	 the	 initial	 3D	 classification,	 classes	2	 and	4	 emerged	which	were	monosome	
classes	 that	 had	 a	 small	 hint	 of	 density	 at	 the	 polypeptide	 exit	 site.	 However,	
following	FCwSS	at	 the	exit	 site	 followed	by	a	2nd	 round	of	3D	classification,	 there	




revealed	 3	 different	 classes	 with	 density	 at	 the	 polypeptide	 exit	 site	 (Figure	 67).	
Class	4	was	 the	most	promising	 for	OXA1L	density	and	had	3,366	particles	with	a	
down	scaled	resolution	of	12.8	Å.	Class	2	also	had	density	in	the	polypeptide	exit	site	
that	might	 represent	 OXA1L.	 Class	 8	 had	 the	most	 number	 of	 particles	 at	 30,926,	
however	the	OXA1L	density	was	the	weakest	in	this	class.	Further	3D	classification	




although	 exit	 tunnel	 density	 on	 the	 mt-LSU	 was	 a	 small	 proportion	 of	 our	 total	
particles,	 convincing	 density	 suggestive	 of	 OXA1L	 at	 the	 polypeptide	 exit	 site	
represented	a	significant	break	through	in	this	project.	However,	density	for	OXA1L	
could	 still	only	be	 seen	on	 the	mt-LSU.	Thus	our	efforts	 continued	 to	 focus	on	not	
only	trying	to	improve	the	density	of	mt-LSU	-	OXA1L	through	collecting	more	data	
but	 also	 to	 try	 and	1)	 improve	 the	density	by	 trialling	different	detergents	 and	2)	











Purification	5	was	 repeated	as	previously	 to	obtain	mitoribosome,	but	 in	 the	 final	
buffer	 exchange/concentration	 step	 β-DDM	 was	 exchanged	 with	 0.05%	 β-
DDM/0.005%	 CHS	 or	 0.05%	 digitonin	 for	 peak	 2.	 Both	 the	 ionisable	 anionic	
detergent	 cholesteryl	 hemisuccinate	 (CHS)	 and	 the	 non-ionic	 digitonin,	 are	
detergents	widely	 used	 in	 the	membrane	 biology	 field.	 Blends	 of	 CHS	 and	β-DDM	
have	been	used	for	the	stabilisation	of	membrane	proteins	due	to	the	ability	of	CHS	
to	mimic	 cholesterol.	 The	 15-30%	 sucrose	 gradient	 for	 this	 purification	 produced	
















Fractions	8-11	 (peak	1)	were	pooled	and	buffer	 exchanged	 in	0.05%	β-DDM	
buffer.	Fractions	13-15	(peak	2)	were	pooled	and	divided	into	two	and	buffer	
exchanged	with	either	0.05%	β-DDM/0.005%	CHS	or	0.05%	digitonin.	Pooled	












We	 decided	 to	 collect	 cryo-EM	 data	 initially	 from	 the	 peak	 2	 samples.	 Cryo-EM	
collection	on	the	sample	buffered	exchanged	with	digitonin	was	collected	 in	 linear	
mode	 on	 the	 300kV	 FEI	 Titan	 Krios,	 Falcon	 III	 detector	 at	 a	 pixel	 size	 of	 1.04	 Å	






2.5X	 downscaled.	 The	 initial	 3D	 refinement	 achieved	 a	 resolution	 of	 5.4	 Å.	 3D	
classification	revealed	3	clear	monosome	classes.	Unfortunately	 two	of	 the	classes,	
class	 2	 and	 class	 5	were	 in	 fact	 cytosolic	 ribosomes	which	 had	 contaminated	 our	
preparation	 (Figure	 71).	We	 do	 see	 cytosolic	 contamination	 of	 our	mitochondrial	
ribosome	preparations	occasionally.	This	is	likely	to	be	resultant	of	contamination	of	
mitochondrial	 harvest	 with	 rough	 endoplasmic	 reticulum.	 Usually	 this	 is	 easily	
separated	at	 the	15-30%	sucrose	gradient	stage	but	 in	 this	case	 the	 fractions	with	






From	 the	 1st	 3D	 classification	 class	 4	 was	 revealed	 that	 showed	 promise	 for	 a	




OXA1L	 in	 the	 monosome.	 We	 now	 had	 a	 sample	 in	 which	 the	 mitochondrial		





in	 all	 of	 the	 samples	 as	 it	 has	 been	 seen	 in	 one	 of	 the	 samples.	 Therefore	 data	
collection	 on	 each	 of	 these	 samples	 would	 act	 as	 a	 trial	 of	 different	 detergent	
conditions.	A	one	day	cryo-EM	data	collection	was	done	on	the	β-DDM/CHS	sample	
using	 the	 same	 microscope	 conditions	 and	 pixel	 size	 as	 above.	 However,	 after	
processing	through	to	the	1st	round	of	3D	classification	it	was	apparent	that	most	of	






















Å	unsharpened	map	 (A)	Front	 view	showing	 the	Psite	mt-tRNA	 in	 green	and	









motion	 and	 CTF	 correction	 and	 419,657	 particles	 picked	 initially	 and	 extracted	
downscaled	 2.5X	 (Figure	 74).	 After	 2D	 classification,	 180,939	 particles	 were	
retained	and	3D	refinement	reached	a	resolution	of	5.2	Å.	There	were	two	classes	of	
interest	 after	 3D	 classification,	 class	 3	 and	 class	 6.	 Class	 3	 containing	 28,965	
particles,	 represented	 the	monosome,	 and	 class	 6	 containing	 19,304	 particles,	 the	
mt-LSU.	Both	 classes	had	 signs	of	 density	 at	 the	mitoribosomal	 exit	 site.	 Their	 3D	
refinements	went	to	resolutions	of	6.8	Å	and	7.6	Å	respectively.	FCwSS	on	the	exit	
site	 was	 performed	 with	 both	 of	 these	 classes.	 From	 FCwSS	 of	 class	 3,	 class	 4	
containing	2,650	particles	was	obtained	that	refined	to	15.7	Å	(Figure	75).	Although	
containing	 relatively	 few	 particles,	 the	 density	 at	 the	 exit	 site	 for	 this	 class	 was	
convincing	for	a	translocon	like	structure	with	a	~100%	occupancy	of	this	class	(the	
exit	 site	 density	 showing	 up	 at	 a	 low	 threshold).	 Of	 the	 total	monosome	 particles	
from	 the	1st	 3D	 classification	 this	 represented	5%.	From	FCwSS	of	 class	6,	 class	2	
was	obtained	that	showed	promise.	Class	2	had	only	1,677	particles	and	refined	to	
18.4	 Å	 but	 again	 this	 largely	 mt-LSU	 class	 showed	 ~100%	 occupancy	 of	 the	
translocon	density.	This	mt-LSU	class	was	still	contaminated	with	monosome	classes	
as	 evident	 in	 Figure	 76	 by	 the	 patchy	 mt-SSU	 density,	 but	 it	 is	 clear	 that	 the	
predominant	 particle	 is	 the	mt-LSU.	 Curiously	 this	 is	 the	 LSU	particle	without	 the	
MALSU1-L0R8F8-mt-ACP	 module	 that	 was	 previously	 seen.	 Therefore,	 this	 may	
represent	another	instance	in	which	OXA1L	can	be	associated	with	the	LSU	possibly	
without	 being	 in	 active	 translation.	 	 From	 the	 initial	 3D	 classification	 class	 4	 and	
class	6	were	both	mt-LSU	and	together	contained	45,907	particles.	Therefore,	as	a	
percentage	 of	 the	 total	 mt-LSU	 classes,	 3.5%	 of	 mt-LSU	 particles	 contained	 the	
translocon	density.			
	
Due	 to	 the	 low	 number	 of	 particles	 this	 data	 set	 was	 not	 taken	 any	 further	 with	
regards	to	re-extraction	and	continued	processing.	 	To	conclude,	from	this	data	set	
we	 have	 been	 able	 to	 classify	 the	 particles	 to	 obtaining	 a	 high	 occupancy	 of	





not	 able	 to	be	 classified	due	 to	 low	particle	numbers.	Our	plan	moving	 forward	 is	





































OXA1	 (OXA1L	 and	 OXA1p	 in	 humans	 and	 yeast	 respectively)	 is	 the	 inner	
mitochondrial	membrane	 translocase	 that	 is	 instrumental	 in	 insertion	 of	 proteins	
translated	 by	 both	mitochondrial	 and	 cytosolic	 ribosomes.	 From	 our	 experiments	
thus	far	we	believe	we	have	made	significant	incremental	steps	towards	the	aim	of	
obtaining	 a	 single	 particle	 cryo-EM	 structure	 of	 the	 human	 mitoribosome-OXA1L	
complex.	 We	 have	 found	 a	 number	 of	 ways	 to	 stall	 an	 actively	 translating	
mitoribosomes	 using	 a	 variety	 of	 antibiotics.	 However	 OXA1L	 remained	 elusive	
under	these	conditions.	The	use	of	PDE12	-/-	cells	however	revealed	a	density	at	the	
exit	tunnel	site	likely	to	be	OXA1L	when	using	either	of	the	two	detergents	β-DDM	or	
digitonin.	 β-DDM	 is	 the	 detergent	 that	 was	 used	 in	 the	 antibiotic	 stalled	
purifications,	so	 the	assumption	 is	 that	 if	OXA1L	had	remained	bound	under	these	
conditions	β-DDM	would	have	been	a	suitable	detergent.	Therefore,	it	is	likely,	that	
although	 the	mitoribosomes	were	 stalled	 in	 an	 actively	 translating	 state,	 this	 stall	
may	not	have	been	robust	enough	to	trap	the	translocon.	Although,	we	also	have	to	
take	 into	account	the	changes	to	the	 latter	stages	of	sample	preparation	to	 include	
the	 shortened	 time	 of	 the	 sucrose	 gradient	 and	 the	 buffer	 exchange	 step.	 The	
detergent	 conditions	 we	 have	 used	 however	 appeared	 to	 be	 optimal	 for	 the	
purification	of	 the	ER	membrane	bound	Sec61	 translocase.	This	may	be	a	positive	




location,	 size	and	contact	points.	What	we	can	 learn	 from	our	maps	of	OXA1L	and	
the	mitoribosome	thus	far	is	the	probable	contact	sites	being	uL24m	and	mL45.	Our	
current	resolution	is	too	low	to	infer	any	further	details,	but	with	higher	resolution	
of	 the	 currently	 trapped	 structures	 we	 should	 be	 able	 to	 trace	 the	 path	 of	 the	
nascent	 chain	 through	 the	 polypeptide	 tunnel	 and	 elucidate	 its	 engagement	 with	
OXA1L.	 Owing	 to	 inherent	 flexibility,	 it	 may	 be	 difficult	 to	 obtain	 high	 resolution	
information	 for	 the	complete	OXA1L,	but	areas	 that	 contact	 the	mitoribosome	will	
likely	be	of	a	higher	resolution	as	already	seen	in	our	 local	resolution	map	(Figure	




solubilised	 samples.	 We	 aim	 to	 collect	 data	 on	 both	 the	 mt-LSU	 and	 monosome	
peaks	 in	 the	PDE12-/-	 sample,	with	 the	end	goal	of	 combining	 the	data	 to	achieve	
higher	resolution.	This	may	pose	a	difficult	challenge	due	 to	 the	 low	abundance	of	
the	mitoribosome	particles	with	OXA1L.	However,	it	is	likely	that	due	to	the	current	
sizes	of	the	data	sets,	particles	are	being	missed	and	discarded	at	the	classification	
stage	 that	would	otherwise	have	been	 retained	 if	 the	 classification	was	done	on	 a	
larger	 starting	 population.	 There	 may	 be	 a	 population	 of	 particles	 with	 the	
translocon	 in	 slightly	 different	 orientations	 that	 are	 not	 able	 to	 be	 classified	




It	 is	 evident	 from	 our	 western	 blot	 results	 and	 the	 subsequently	 seen	maps	 that	
OXA1L-mitoribosome	binding	 is	 likely	present	 in	our	samples	even	 if	 the	apparent	
occupancy	 by	 cryo-EM	 is	 low.	 However,	 we	 have	 been	 unable	 to	 quantify	 the	
stoichiometry	without	purified	OXA1L.	In	the	PDE12-/-	data	sets,	the	mitoribosomal	
particles	 that	 do	 not	 have	 OXA1L	 still	 have	 a	 P/P	 mt-tRNA	 indicating	 active	
translation.	The	issues	may	be	that	OXA1L	is	dislodged	during	sample	handling	and	
grid	 preparation,	 or	 the	 nascent	 chain	 being	 translated	 by	 that	 particular	
mitoribosome	does	not	have	a	strong	enough	interaction	with	OXA1L	to	encourage	
interaction	 with	 the	 mitoribosome.	 However,	 we	 have	 also	 seen	 in	 our	 data	 set	
binding	 of	 OXA1L	 to	 a	 presumed	 inactive	 mt-LSU	 subunit.	 Additionally	 as	 only	 a	
proportion	of	mitoribosomes	are	attached	to	the	membrane,	as	seen	by	cryo-ET,	this	
decreases	the	chance	of	purifying	a	mitoribosome	attached	to	the	inner	membrane	














Human	 mitochondria	 was	 obtained	 from	 HEK293S	 TetF	 GnTI	 or	 PDE12(-/-)	
HEK293	cells.	PDE12	-/-	HEK293	cells	were	kindly	gifted	by	Dr	Michal	Minczuk	and	
Dr	Sarah	Pearce	 (218).	HEK293S	TetF	GnTI	were	gifted	and	 initially	grown	by	Pat	
Edwards.	 HEK293S	 TetF	 GnTI	 cells	 were	 grown	 in	 freestyle	 media	 (Gibco,	 Life	
technologies)	with	5%	 fetal	 calf	 serum	 (Gibco,	 Life	 technologies)	 at	37°C	with	5%	
carbon	 dioxide,	 in	 10L	Wave	 bioreactors	 (GE	 Heathcare)	 to	 ~	 2-3	 x	 106/ml.	 The	
PDE12-/-	 HEK293	 cells	 were	 initially	 grown	 adherently	 in	 Dulbecco’s	 Modified	










sample	 was	 transferred	 to	 the	 chamber.	 ~230	 mL	 SM4	 buffer	 (281mM	 sucrose,	
844mM	 mannitol	 in	 MIB	 buffer;	 1/3	 of	 the	 final	 volume	 of	 resuspended	 cells,	
yielding	a	final	concentration	of	70	mM	sucrose	and	210	mM	mannitol)	was	added	to	













Dounce	 homogenisation	 5	 times.	 The	 sample	 was	 then	 layered	 onto	 a	 sucrose	
gradient	(60%,	32%,	32%,	15%)	and	run	on	the	Beckman	Coulter	SW28	Ti	rotor	at	





vacuum	 in	 a	 CentriVap	 Concentrator	 (Labconco).	 The	 dry	 lipid	 sample	 was	 then	






2-3	 volumes	 of	 lysis	 buffer	 (25	 mM	 HEPES-KOH	 pH7.4,	 100	 mM	 KCl,	 25	 mM	
Mg(OAc)2,	1.5%	β-DDM	(D310,	Anatrace),	0.15	mg/ml	TOCL,	1	tablet/50ml	PI,	2	mM	
DTT)	 was	 added	 to	 the	 crude	 mitochondria	 and	 homogenized	 5	 times	 using	 a	
Dounce	homogenizer.	In	all	purifications,	antibiotics	and/or	GDPxP	was	added	to	the	
lysis	buffer	and	the	subsequent	sucrose	cushions,	15-30%	sucrose	gradients	and	the	
final	 buffer.	 The	 sample	 was	 stirred	 for	 30	minutes	 at	 room	 temperature.	 It	 was	
subsequently	 centrifuged	 at	 30,000	 x	 g	 at	 4	 °C	 for	 20	 minutes	 to	 remove	 the	
insoluble	 material.	 The	 supernatant	 was	 collected	 and	 layered	 onto	 a	 sucrose	
cushion	 (1	M	 sucrose,	 20	mM	Hepes-KOH	pH	7.4,	 100	mM	KCl,	 20	mM	Mg(OAc)2,	




0.3%	 β-DDM(D310),	 0.03mg/ml	 TOCL,	 2mM	 DTT)	 to	 obtain	 an	 absorption	 of	
mitoribosomes	at	A260	>5.	In	all	the	other	preparations	the	resuspended	pellet	was	






were	 collected	 using	 the	 Biocomp	 gradient	 station	 with	 the	 Bio-rad	 Econo	 UV	







with	mitoribosome	 translation	 buffer	 (100mM	KCl,	 5mM	Mg(OAc)2,	 0.1mM	amino	
acid	 mix,	 0.02mM	 methionine,	 1mg/ml	 BSA).	 Following	 this,	 mitoribosome	





A	 sucrose	 gradient	 of	 10-50%	 sucrose	 in	 PS	 buffer	 (50mM	 Hepes-KOH	 pH	 7.4,	
100mM	 KOAc,	 2mM	 Mg(OAc)2)	 was	 used	 to	 separate	 protein	 and	 ribosomal	
fractions.	A	Beckman	Coulter	TLS-55	 rota	was	used	with	adapters	and	 the	 sample	
centrifuged	 for	 20	 minutes	 at	 55,000	 RPM.	 20ul	 of	 sample	 was	 extracted	





gels	 (Invitrogen)	 and	 transfer	 to	 Immobilon®-FL	 membranes	 (Merck).	 The	
membrane	 was	 incubated	 with	 the	 primary	 antibodies	 rabbit	 anti-mS27	 (1/750,	
Abcam)	 and	 mouse	 anti-OXA1L	 (1/1000,	 Abcam).	 After	 incubation	 with	 Alexa	








Mitochondria	 were	 harvested	 using	 the	 traditional	 methods	 above	 from	 10L	 of	
PDE12	-/-	HEK293	cells	at	a	concentration	of	~0.5	x	106	cells/ml.	2	volumes	of	lysis	
buffer	(25mM	Hepes-KOH	pH7.4,	100mM	KCl,	25mM Mg(OAc)2,	1.5%	β-DDM(D310),	
0.15mg/ml	 TOCL,	 0.5mM	 GDPCP,	 1	 tablet/50ml	 PI,	 2mM	 DTT)	 was	 added	 to	 the	
crude	 mitochondria	 and	 homogenised	 5	 times	 using	 a	 Dounce	 homogeniser.	 The	
solution	was	stirred	for	20	minutes	at	4°C,	followed	by	centrifugation	at	30,000	x	g	
4°C	 for	 30	 minutes.	 The	 supernatant	 was	 collected	 and	 loaded	 onto	 a	 sucrose	
cushion	(1M	sucrose,	20mM	Hepes-KOH,	pH	7.4,	100mM	KCl,	20mM	Mg(OAc)2,	0.6%	
β-DDM(D310),	 0.06mg/ml	 TOCL,	 0.1mM	GDPCP,	 2mM	DTT)	 resulting	 in	 a	 sample	
cushion	 ratio	 of	 2.5:1	 and	 centrifuged	 at	 231,550	 x	 g	 	 for	 60	minutes	 at	 4°C.	 The	
pellet	 was	 then	 resuspended	 in	 resuspension	 buffer	 (20mM	 Hepes-KOH,	 pH7.4,	
100mM	KCl,	5mM Mg(OAc)2,	0.3%	β-DDM(D310),	0.03mg/ml	TOCL,	0.25mM	GDPCP,	
2mM	 DTT).	 The	 sample	 was	 then	 loaded	 onto	 a	 15-30%	 sucrose	 gradient	 and	
centrifuged	in	the	Beckman	Coulter	TLS-55	rota	at	213,626	x	g	for	90	minutes	at	4°C.	
After	 fractionation	 of	 the	 gradient,	 the	 optical	 density	 at	 A260	 was	 determined	 by	
nanodrop	and	the	fractions	were	pooled	together	according	to	the	peaks	obtained.	
The	pooled	fractions	were	diluted	with	5-10	volumes	of	final	buffer	(20mM	Hepes-
KOH,	 pH7.4,	 100mM	KCl,	 5mM	Mg(OAc)2,	 0.05%	β-DDM(D310),	 0.03mg/ml	 TOCL,	
0.25mM	GDPCP,	2mM	DTT),	slightly	rotated,	then	put	through	a	30,000	concentrator	
spun	at	1500	x	g	at	4°C.	The	buffer	was	exchanged	to	minimize	the	concentration	of	
sucrose.	The	samples	were	adjusted	 to	an	A260	of	4-5.	 In	some	of	 the	preparations	
















Magnification	 75,000	 75,000	 75,000	 75,000	 75,000	 75,000	
Pixel	size	(Å)	 1.06	 1.06	 1.06	 1.06	 1.04	 1.04	
Defocus	 range	
(-µm)	
1.2-3.0	 1.1-3.2	 1.2-3.0	 1.1-3.2	 1.1-3.2	 1.1-3.2	
Voltage	(kV)	 300	 300	 300	 300	 300	 300	
Exposure	(s)	 1.79	 1	 1.79	 1	 1	 1	
Frames	 71	 39	 71	 39	 39	 39	







3µl	 aliquots	 of	 samples	were	 applied	 to	 30	 second	 glow-discharged	 holey	 carbon	
grids	 (Quantifoil	 R2/2)	 coated	with	 home-made	 continuous	 carbon	 (~50	Å	 thick)	




mode	 on	 an	 FEI	 Titan	 Krios	 300kV	 electron	 microscope	 using	 the	 FEI	 Falcon	 III	
detector	and	EPU.	The	data	collections	were	done	according	to	Table	7.	
 Image	processing	and	figures	3.5.9






Since	 embarking	 on	 my	 PhD	 there	 have	 been	 further	 single	 particle	 cryo-EM	
breakthroughs	 of	 mitochondrial	 ribosomes	 to	 include	 my	 own	 project	 on	 the	
structure	 of	 the	 yeast	mitochondrial	 ribosome	 (135).	 Other	 structures	 include	 the	
human	mt-LSU	late	assembly	intermediate;	the	structure	of	the	Trypanosoma	brucei	
mitoribosome;	human	mitochondrial	initiation	complexes,	the	human	mitoribosome	
in	 complex	 with	 mt-RRF	 and	 a	 recent	 structure	 on	 Trypanosoma	 brucei	mt-SSU	
assembly	 (69,71,158,214,219,220).	 However,	 the	 structural	 study	 of	mitochondrial	
translation	 and	mitoribosome	 assembly	 remains	 a	 young	 field	 compared	 to	 other	






















Selenium	 is	 a	 non-metal	 trace	 element	 that	 is	 an	 essential	 requirement	 for	
selenocysteine	 (Sec)	 synthesis,	 and	 hence	 production	 of	 selenoproteins.	 The	 two	
main	 dietary	 sources	 of	 selenium	 are	 selenocysteine	 and	 selenomethione	 from	
animal	 food	 products,	 and	 selenomethionine	 from	 cereal	 products	 grown	 in	
selenium	rich	soils.	There	are	around	25	selenocysteine	containing	proteins	termed	
selenoproteins.	 These	 selenoproteins	 have	 been	 found	 to	 be	 important	 in	 human	
health	 and	 disease.	 Examples of selenoproteins are enzymes to include glutathione 
peroxidases responsible for the breakdown of hydro and lipid peroxides and thioredoxin 
reductases catalysing thioredoxin regeneration. Known functions of selenoproteins 
include, the protection of membranes, proteins and nucleic acid from cumulative 
oxidative damage, as well as roles in male fertility and thyroid hormone homeostasis. 
Oxidative damage has been linked with cancers, diabetes, Alzheimer’s and Parkinson’s 
disease. Health	 implications	 can	 be	 resultant	 of	 dietary	 selenium	 deficiency,	
mutations	 in	 selenoproteins	 and	 also	 aberrations	 in	 the	 pathway	 of	 selenoprotein	
synthesis.	 Disease	 such	 as	 Keshan’s	 disease,	 Kashin-Beck	 disease	 and	
myxedematous	cretinism	are	caused	by	severe	selenium	deficiency	(221). Mutations 
in selenoproteins and enzymes are linked to disorders of the endocrine, nervous, 
muscular, cardiovascular and immune systems (222,223). The importance of 






recoding	 of	 UGA.	 In	 eukaryotes	 canonical	 termination	 of	 protein	 synthesis	 occurs	




nucleotides,	 UAA,	 UAG	 and	 UGA,	 encoding	 a	 stop	 codon.	 When	 any	 of	 the	 stop	
codons	are	present	 in	 the	A-site	of	 a	 translating	 ribosome,	 they	are	 recognized	by	
the	release	factor	eRF1	that	binds	the	ribosomal	A-site	and	mediates	the	release	of	







ATPase	ABCE1	 is	also	 recruited	 to	 the	 ribosome	and	 together	with	eRF1	catalyses	
ribosome	 splitting	 and	 recycling.	 The	 structure	 of	 this	 was	 trapped	 by	 in	 vitro	
translation	 reactions	 in	 rabbit	 reticulocyte	 lysate	 exploiting	 the	 highly	 conserved	
GGQ	 motif	 and	 substituting	 this	 with	 AAQ	 (eRF1(AAQ))	 which	 inhibits	 peptide	




The	 21st	 amino	 acid	 selenocysteine	 whose	 codon	 is	 UGA	 requires	 a	 specialised	
system	 for	 its	 polypeptide	 incorporation.	 Incorporation	 of	 selenocysteine	 into	





specific	 elongation	 factors	 (228-230).	 Features	 identified	 in	 some	 selenoprotein	
mRNAs	are	 I)	a	conserved	AUGA	at	 the	5’,	and	a	GA	at	 the	3’	of	 the	stem	bases,	as	
well	 as,	 II)	 a	 conserved	 AAR	 motif	 in	 the	 stem	 loop.	 In	 addition,	 in	 a	 subset	 of	
selenoprotein	 mRNAs	 there	 is	 also	 a	 selenocysteine	 codon	 redefinition	 element	
(SRE)	 down	 stream	 of	 the	 UGA	 further	modulating	 selenocysteine	 insertion.	 	 The	
SECIS	element	is	bound	by	the	SECIS	binding	protein	2	(SECISBP2).	Consequently	a	






on	 an	 expansion	 segment	 of	 the	 28S	 rRNA	 (234).	 SECISBP2	 therefore	 steers	 the	
above	 complex	 into	 the	 proximity	 of	 the	 UGA	 stop	 codon,	which	 is	 recognised	 by	
Sec-tRNA[Ser]Sec	(Figure	77).	GTP	hydrolysis	of	EEFSEC	allows	accommodation	of	Sec-
tRNA[Ser]Sec	 into	 the	 ribosomal	 A-site.	 Regulators	 of	 the	 SECISBP2-SECIS	 binding	
interaction	 include	 the	 ribosomal	 protein	 L30	 which	 has	 been	 shown	 to	 interact	
with	 the	 SECIS	 element	 in	 a	 position	 which	 would	 clash	 with	 SECISBP2	 binding	
(235).	 Magnesium	 has	 also	 been	 found	 to	 play	 an	 important	 role	 in	 SECISBP2	
binding	 to	 the	 SECIS	 element.	 In	 conditions	 of	 high	 magnesium,	 the	 ability	 of	




tRNA[Ser]Sec	 placement	 in	 the	 ribosomal	 A-site	 (235).	 In	 addition,	 nucleolin	 and	
eukaryotic	translation	initiation	factor	4A3	(EIF4A3)	has	also	been	found	to	regulate	
this	 system	 (236,237).	Nucleolin	probably	via	 its	 ability	 to	bind	 the	SECIS	element	
(236).	
	
Most	 selenoproteins	 contain	 only	 one	 selenocysteine	 to	 be	 inserted.	 However	 an	
exception	 is	 the	protein	selenoprotein	P.	 Its	mRNA	comprises	10	UGA’s	coding	 for	
selenocysteine	 and	 contains	 two	 SECIS	 elements	 in	 the	 3’UTR	 (238).	 With	 this	









Figure	 77	 –	 Adapted	 image	 courtesy	 of	 Professor	 Krishna	 Chatterjee	 (IMS-
MRL)	(239).	Graphical	representation	of	selenocysteine	incorporation	into	the	
growing	polypeptide	by	the	delivery	of	Sec-tRNA[Ser]Sec	to	the	A-site	UGA	on	the	





pathway	 to	 obtaining	 the	 aminoacylated	 Sec-tRNA[Ser]Sec	 involves	 the	 initial	
tRNA[Ser]Sec	 being	 aminoacylated	 with	 a	 serine	 by	 seryl-tRNA	 synthetase	 (SARS)	
(240).	O-phosphoseryl-tRNA	kinase	(PSTK)	converts	 the	serine	 to	a	phosphoserine	
forming	 O-phosphoseryl-tRNA[Ser]Sec.	 O-phosphoseryl-tRNA:Sec	 tRNA	 synthase	
(SEPSECS)	 uses	 selenophosphate	 to	 convert	 O-phosphoseryl-tRNA[Ser]Sec	 finally	 to	
Sec-tRNA[Ser]Sec	 or	 mcm5U/Sec-tRNASec, which is	 partially	 methylated	 by	 an	
unidentified	Um34	methylase	(240).	The	required	selenophosphate	for	the	last	step	
of	 the	 biogenesis	 is	 synthesised	 by	 selenophosphate	 synthetase	 2	 (SEPHS2)	 from	
selenide	and	ATP	(240).	An	intermediate	complex	is	subsequently	formed	containing	




The	 importance	 of	 regulation	 at	 every	 step	 of	 Sec-tRNA[Ser]Sec	 formation	 and	
selenocysteine	 incorporation	 into	 proteins	 is	 highlighted	 by	 the	 clinical	
manifestations	 of	 perturbations	 (Figure	 78).	 A	 tRNA[Ser]Sec	mutation	 has	 been	





muscle	 weakness,	 fatigue	 and	 abdominal	 symptoms	 (239).	 SEPSECS	 defects	 have	
been	 found	 to	 cause	 progressive	 cerebellocerebral	 atrophy	 (241).	 A	 range	 of	
mutations	have	been	 identified	 in	SECISBP2	families	causing	a	complex	phenotype	
to	include	male	infertility,	muscular	dystrophy	and	photosensitivity	and	progressive	
dilatation	 of	 the	 ascending	 aorta	 due	 to	 cystic	 medial	 degeneration	 (242).	 In	
addition,	 observations	 in	 peripheral	 blood	 include	 impaired	 T-lymphocyte	
proliferation	and	mononuclear	cell	cytokine	secretion	(242).	This	diversity	reflects	
the	 involvement	 of	 selenoproteins	 in	 different	 tissues.	 	 Lack	 of	 antioxidant	
selenoenzymes	glutathione	peroxidases	(GPxs)	and	thioredoxin	reductases	(TrxRs)	
results	 in	 increases	 reactive	 oxygen	 species	 (ROS).	 Selenoprotein	 N	 (SEPN1)	
deficiency	 results	 in	 myopic	 features	 and	 selenoprotein	 deiodinase	 deficiency	
culminates	 in	 thyroid	 dysfunction	 (243).	 	 Mutations	 have	 also	 been	 found	 in	 the	











Much	 of	 what	 we	 know	 structurally	 about	 the	 final	 incorporation	 step	 of	
selenocysteine	 into	 polypeptides	 is	 from	 prokaryotes.	 However	 the	 systems	 have	
some	 key	 differences.	 In	 prokaryotes	 the	 function	 of	 EEFSEC	 and	 SECISBP2	 is	
encompassed	 into	 a	 GTPase	 called	 SelB.	 In	 2016	 Fischer	 et	 al	 published	 cryo-EM	
structures	 of	 six	 intermediates	 on	 the	 pathway	 of	 UGA	 recoding	 in	 E.	 coli	 to	
selenocysteine	to	include	codon	reading	of	Sec-tRNASec	with	SelB	bound(245).	In	the	
mammalian	systems	there	are	crystal	structures	of	human	selenocysteine	tRNA	and	






The	 aim	 of	 this	 project	was	 to	 obtain	 the	 structure	 and	 conformation	 of	 different	
states	 during	 selenocysteine	 incorporation	 on	 the	 eukaryotic	 ribosome	 and	 thus	
reveal	 the	 underlying	mechanism	 of	 selenoprotein	 translations.	 By	 single	 particle	
cryo-EM	we	aimed	to	image	trapped	Sec-tRNA[Ser]Sec	in	the	process	of	recoding	a	UGA	
bound	 to	 EEFSEC	 and	 SECISBP2	 bound	 to	 the	 SECIS	 element.	 Additional	
intermediates	along	this	pathway	may	include	SECIS	binding	of	L30	and	adoption	of	
an	alternative	conformation	of	L30	to	 the	canonical	ribosomal	state.	Knowledge	of	
the	 structure	 will	 enable	 us	 to	 gain	 more	 mechanistic	 insights	 into	 this	 unique	
situation	 of	 translation	 elongation.	 We	 will	 also	 be	 able	 to	 gain	 a	 better	




The	 strategy	 used	 by	 other	 groups	 to	 obtain	 the	 bacterial	 complex	was	 to	 form	 a	





affinity	 purified	 using	 a	 FLAG-tag	 on	 the	 nascent	 chain	 encoded	 for	 on	 a	
programmed	mRNA	 (248).	 This	 strategy	 together	with	 the	 use	 of	 eRF1(AAQ)	was	
used	 in	 a	 collaboration	 by	 the	 Hegde	 and	 Ramakrishnan	 lab	 to	 elucidate	 the	
mechanism	 of	 termination	 in	 mammals	 on	 all	 three	 of	 the	 stop	 codons	 (85).	 We	
hypothesised	 that	 a	 similar	 strategy	 could	 be	 used	 to	 trap	 the	 selenocysteine	




UGA	 stop	 codon	 down	 stream	 of	 this,	 with	 a	 SECIS	 element	 further	 downstream	





the	UGA	stop	 codon	of	 the	mRNA	primed	 in	 the	 ribosomal	A-site.	 Following	FLAG	
affinity	purification	of	 this	 ribosome	nascent	 chain	 complex,	purified	EEFSEC,	 Sec-
tRNA[Ser]Sec,	 SECISBP2	 and	 GDPPCP	 a	 non-hydrolysable	 GTP	 analogue	 would	 be	









PreScission	 protease	 at	 the	 N-terminus	 by	 Dr	 Erik	 Schoenmakers	 (IMS-MRL,	
Chatterjee	 group)	 using	 the	 method	 developed	 by	 Gibson	 (249).	 A	 His-tag	 was	
subsequently	added	at	 the	C-terminus	using	round	the	horn	mutagenesis.	 	EEFSEC	
was	 Gibson	 cloned	 into	 the	 same	 two	 vectors	 as	 for	 SECISBP2.	 EEFSEC	 isoform	1	
was	used	which	is	596	amino	acids	in	length.	Purification	of	EEFSEC	and	SECISBP2	























and	 the	 PHGPX	 gene	 to	 include	 the	 SECIS	 element.	 (A)	 Human	 PHGPX.	 (B)	




glutamine	upstream	of	 the	TGA	was	mutated	 to	a	valine	 to	 increase	nascent	chain	
stability	within	 the	 ribosome,	while	 the	 other	 retained	 the	 glutamine	 (250).	 In	 all	
constructs	the	TGA	was	followed	by	the	gene	sequence	to	include	the	SECIS	element.	
However,	 stop	 codons	 in	 the	 non	 coding	 region	 down	 stream	 of	 the	 TGA	 were	
mutated	to	alanine’s	to	minimise	interference	with	eRF1(AAQ)	binding	to	the	STOP	
codon	of	interest	in	3	of	the	constructs.	The	mRNA	geneblocks	were	Gibson	cloned	
into	 a	 pSP64-3X	 FLAG-beta-VHP-3Lcommon.	 	 Following	 this,	 the	 desired	 DNA	
fragment	was	obtained	by	PCR	and	 in	vitro	 transcribed	using	 the	SP6	promoter	 to	
obtain	the	mRNA.		
	
To	 obtain	 the	 aminoacylated	 Sec-tRNA[Ser]Sec,	 total	 tRNA	 from	 fresh	 pigs	 liver	 or	
testis	was	obtained	from	fresh	products.	Once	total	tRNA	was	purified	we	used	FLAG	
tagged	 EEFSEC	 to	 affinity	 purify	 Sec-tRNA[Ser]Sec	 in	 the	 presence	 of	 GTP,	 and	
subsequently	purified	the	Sec-tRNA[Ser]Sec	bound	to	the	EEFSEC.	To	liberate	the	Sec-
tRNA[Ser]Sec	 a	 phenol	 extraction	 and	 ethanol	 precipitation	 was	 performed.	 We	





cDNA	 which	 was	 subsequently	 sent	 for	 sequencing.	 Sequencing	 results	 yielded	
tRNA[Ser]Sec	 however	 this	 does	 not	 give	 us	 an	 indication	 of	 the	whether	 or	 not	 the	
tRNA	was	aminoacylated.		
	
The	 function	 of	 the	 purified	 SECISBP2	 and	 EEFSEC	 was	 tested	 by	 Dr	 Erik	
Schoenmakers	 using	 a	 luciferase	 luminescence	 measuring	 assay	 (251).	 Increased	
relative	 light	 units	 measured	 in	 the	 assay	 correlated	 with	 increased	 rates	 of	
translation.	Thus,	 the	 translation	 rates	were	determined	 in	 the	presence	of	 a	UAA	
control	 and	 UGA	 mRNA	 with	 increasing	 amounts	 of	 EEFSEC	 and	 SECISBP2.	 The	
results	 showed	 that	 with	 increasing	 concentrations	 of	 SECISBP2	 translation	 rates	
increased	 accordingly	 (Figure	80).	 This	was	not	 the	 case	with	 addition	 of	 EEFSEC	
where	the	rates	did	not	appear	to	increase.	These	results	are	consistent	with	rabbit	














in	vitro	 translation	 experiment	was	 set	 up	 using	 S35	methionine	with	 and	without	
eRF1(AAQ).	 The	 results	 of	 the	 crude	 in	 vitro	 translation	 experiment	 showed	 that	
without	eRF1(AAQ)	the	polypeptide	was	largely	detected	at	~17	kDa	(as	predicted	
by	the	molecular	weight	of	the	full	released	nascent	chain)	and	that	with	addition	of	
eRF1(AAQ)	 the	 radioactive	 band	 was	 largely	 detected	 at	 ~37	 kDa	 suggesting	 the	
trapped	 nascent	 chain	 tRNA	 complex	 (Figure	 82	 (A)).	 This	 showed,	 that	 without	
eRF1(AAQ),	 there	 was	 limited	 read	 through	 and	 the	 transcript	 terminated	 at	 the	
UGA	 stop	 codon.	 However,	 termination	 at	 this	 stop	 codon	 would	 also	 result	 in	
ribosome	 dissociation.	 In	 the	 presence	 of	 eRF1(AAQ)	 there	 was	 the	 same	
termination	 at	 the	 stop	 codon	 but	 in	 addition	 the	 polypeptide	 was	 likely	 still	
attached	 to	 the	 ribosome	as	evidenced	by	 the	polypeptide	 chain	being	detected	 in	
complex	with	the	tRNA	at	~37	kDa.	To	further	test	this,	the	crude	samples	were	run	
on	 a	 10-50%	 sucrose	 gradient	 and	 11	 equal	 fractions	 taken.	 Aliquots	 of	 these	
fractions	were	 run	 on	 a	 protein	 gel	 and	 the	 S35	methionine	 radioactivity	 detected	
(Figure	 81	 B-D).	 	 The	 results	 showed	 that	 without	 eRF1(AAQ),	 for	 all	 the	 mRNA	
transcripts,	 the	majority	 of	 the	 polypeptide	was	 in	 the	 free	 fractions	 in	 lanes	 1-4.	
There	was	also	some	evidence	of	stalling	on	the	ribosome	too	as	evidenced	by	the	
higher	~37	kDa	band	being	present	in	the	ribosome	fractions,	approximately	lanes	
6-9.	 With	 eRF1(AAQ),	 for	 all	 the	 transcripts,	 there	 was	 an	 increase	 in	 the	
polypeptide	 chain	 in	 fractions	 6-9	 representing	 ribosomes	 with	 tRNA	 bound	
polypeptides.		
	
Thus,	 the	mRNA	 transcripts	have	been	 shown	 to	have	 the	 ability	 to	 translate,	 and	
increased	stalling	can	be	achieved	at	the	UGA	using	eRF1(AAQ).	So	with	this	and	the	



















salt	 0.5M	 sucrose	 cushion	 to	 pellet	 the	 ribosomes.	 The	 pelleted	 ribosomes	 were	
resuspended	in	RNC	buffer	(5.1.6.10)	and	mixed	with	anti-FLAG	M2	beads	for	1	hour	
at	 4°C	 to	 allow	 the	 FLAG	 motif	 on	 the	 nascent	 chain	 to	 bind	 to	 the	 beads.	 After	
sequential	washes	the	ribosome	nascent	chain	complex	was	eluted	from	the	beads	
using	3X	FLAG	peptide	and	pelleted.	For	resuspension	1360nM	Sec-tRNASec,	500nM	




buffer	 to	 then	 pellet	 to	 reach	 an	 A260	of	 6.	 Grids	 were	made	 as	 described	 section	
5.1.6.11	 and	 the	 data	was	 collected	 on	 the	 300	 kV	 FEI	 Titan	 Krios	 on	 a	 Falcon	 II	
detector.		
	
Though	 initially	 planned,	 the	 final	 sample	 was	 not	 tested	 by	 10-50%	 sucrose	
gradient	centrifugation	with	subsequent	western	blotting	(to	assess	for	co-migration	
with	ribosomes)	as	the	amount	of	obtained	sample	proved	to	be	limiting.	In	future	














picked.	 The	 particles	 were	 then	 extracted	 with	 a	 2.5	 fold	 downscale	 and	 after	
subsequent	 2D	 classification	 66,705	 particles	 were	 retained.	 The	 initial	 3D	
refinement	 achieved	 a	 resolution	 of	 8.4	 Å.	 Focussed	 classification	 with	 signal	
subtraction	was	performed	on	the	ribosomal	factor	site	to	determine	whether	there	
was	a	subclass	of	particles	that	contained	a	factor	that	was	being	averaged	out	in	the	
complete	 refinement.	After	 several	 rounds	of	 focussed	 classification	one	 class	was	
found	 (class	3	 –	3883	particles)	 that	 contained	density	 in	 the	 factor	 site.	After	3D	
refinement	 this	 yielded	 a	 map	 at	 a	 downscaled	 resolution	 of	 17.4	 Å	 (Figure	 84).	
However	 contrary	 to	 the	 prediction	 of	 an	 actively	 translating	 insertion	 complex	
there	was	no	tRNA	in	the	ribosomal	P-site.	However,	 the	presence	of	other	classes	
































The	 luciferase	 assays	 have	 confirmed	 that	 the	 SECISBP2	 protein	 purified	 is	
functional	 and	 able	 to	 regulate	 selenocysteine	 incorporation	 into	 the	 growing	
polypeptide.	The	purified	EEFSEC	could	not	be	verified	as	functional	in	this	assay	as	
EEFSEC	 is	 not	 in	 limiting	 amounts	 in	 rabbit	 reticulocyte	 lysate.	 To	 address	 this	
problem	we	are	in	the	process	of	setting	up	a	wheat	germ	based	in	vitro	translation	
system,	 which	 in	 the	 wild	 type	 does	 not	 contain	 selenocysteine-incorporating	




transcription.	 However,	 this	 does	 not	 tell	 us	 if	 the	 tRNA	 is	 aminoacylated	 and	
functional.	 Additionally	 our	 initial	 yield	 of	 purified	 Sec-tRNA[Ser]Sec	 was	 small.	 In	
order	to	 increase	the	yield	of	Sec-tRNA[Ser]Sec	we	also	obtained	total	 tRNA	from	pig	
testis	 known	 to	 be	 a	 rich	 source	 of	 Sec-tRNA[Ser]Sec.	 The	 Sec-tRNA[Ser]Sec	 obtained	
from	this	method	has	not	yet	been	used	in	experiments.		
	
Currently	 the	 EEFSEC	 is	 stalled	 by	 the	 non-hydrolysable	 GDPCP	 during	 complex	
formation.	 Additional	 ideas	 to	 enhance	 both	 stalling	 and	 promote	 complex	
formation	have	not	 yet	 been	 explored	 experimentally.	Additional	 strategies	would	
include	the	addition	of	spermidine,	and	didemnin	B	elongation	inhibitor,	to	support	
complex	 formation	 (253,254).	 Spermidine	 is	 a	 polyamine	 known	 to	 have	 positive	
effects	on	translational	efficiency	and	fidelity	(255).	Didemnin	B	has	been	found	to	







Furthermore,	 it	 has	 been	 found	 that	 magnesium	 plays	 an	 important	 role	 in	
selenocysteine	 incorporation	 owing	 to	 its	 ability	 to	 regulate	 RNA	 secondary	
structure	(256).	Thus,	we	aim	to	optimize	magnesium	levels	in	the	sample	buffers.		
	
Although	 SECISBP2	 and	 EEFSEC	 have	 been	 found	 to	 be	 the	 only	 necessary	
components	for	selenocysteine	incorporation	via	Sec-tRNA[Ser]Sec,	it	may	well	be	that	
there	are	other	 factors	 affecting	 the	efficiency	of	 the	process	 that	may	be	vital	 for	
trapping	 the	 structure	 (251).	 One	 idea	 discussed	 is	 to	 produce	 rabbit	 reticulocyte	
lysate	devoid	of	eRF1	and	add	this	lysate	at	the	complex	formation	stage.	Removal	of	
eRF1	would	ensure	that	there	is	no	competition	with	EEFSEC-	Sec-tRNA[Ser]Sec	for	A-












threonine	 48,	 aspartate	 92	 and	 histidine	 96	 are	 important	 for	 GTP	hydrolysis	 but	
mutation	 does	 not	 effect	 the	 structure	 of	 EEFSEC	 or	 its	 ability	 to	 bind	 GTP/GDP	
(247).	On	addition	of	the	mutant	EEFSEC	to	the	in	vitro	translation	reaction	it	would	
compete	with	wild	 type	 eRF1.	The	 aim	would	be	 to	 add	an	 excess	of	EEFSEC	 that	
would	 bind	 endogenous	 or	 supplemented	 Sec-tRNASec.	 Then,	 after	 in	 vitro	
translation,	the	ribosome	nascent	chain	complex	would	be	enriched	for	by	a	15-30%	






















































Reverse	 5’-	 GAA	 TTC	 GTA	 ATC	 ATG	 GTC	 ATA	
GCT	G	-3’	




















Cycle	step	 Temp	(°C)	 Time		 N.o	 of	
cycles	
Initial	denaturation	 98	 30s	 1	
Denaturation	 98	 10s	 1	
Annealing	 55	 30s	 1	
Extension	 72	 variable	 30	
Final	extension	 72	 10m	 1	





reaction	and	 incubated	 for	37°C	 for	90	minutes.	The	 size	of	 the	product	was	 then	
verified	 using	 agarose	 gel	 electrophoresis.	 100mls	 of	 0.5x	 TBE	 was	 heated	 for	 2	
minutes	 in	 the	 microwave	 with	 1g	 agarose	 to	 produce	 a	 1%	 agarose	 gel.	 This	
mixture	 was	 cooled	 to	 room	 temperature	 and	 10ul	 of	 GelRed	 nucleic	 acid	 stain	
10,000X	 (Biotium	 41002)	 was	 added.	 The	 mixture	 was	 poured	 into	 an	 Owl™	
EasyCast™	B1	Mini	Gel	Electrophoresis	to	cast	the	gel.	The	samples	were	mixed	with	
loading	dye	and	 together	with	 the	DNA	 ladder	 loaded	onto	 the	cast	gel	and	run	at	
150V	(Pharmacia	Biotech	EPS3500	XL)	for	50	minutes	at	room	temperature	in	0.5X	
TBE.	 The	 PCR	 product	 was	 purified	 using	 QIAquick®	 PCR	 Purification	 Kit.	 The	
eluted	 products	 were	 quantified	 using	 UV	 absorption.	 For	 Gibson	 cloning	 3-20X	
molar	excess	of	insert	PCR	was	added	to	150ng	of	vector	PCR.	2X	Gibson	assembly	
master	mix	 E2611-NEB	was	 added	 to	 the	 same	 volume	 of	 the	 above	mixture	 and	
incubated	at	50°C	for	15	minutes	in	a	water	bath.	A	proportion	of	the	mixture	was	













EEFSEC	 plasmids	 respectively.	 The	 products	were	 run	 on	 a	 1%	 agarose	 DNA	 gel.	
Promising	clones	were	sent	off	for	sanger	sequencing	with	GATC	biotech	using	GATC	
T7	 as	 a	 forward	primer,	 PET	RP	 as	 the	 reverse	 primer	 and	 an	 additional	 forward	
primer	 to	 sequence	 the	 central	 part	 of	 SECISBP2	 (SECISBP2	 central-GATC-
fwdprimer-2168818).	
	
For	 round	 the	 horn	mutagenesis	 (RTH)	 ligation	 100ng	 concentration	 of	 RTH	 PCR	
was	added	to	1X	T4	DNA	ligase	buffer	and	200U	of	T4	DNA	ligase	and	the	reaction	
allowed	 to	 proceed	 for	 1	 hour	 at	 room	 temperature.	 The	 whole	 reaction	 was	
transformed	in	100µl	of	DH5α	cells	and	continued	on	as	above.		
	




the	 vector	 according	 to	 the	 scheme	 above.	 Plating	was	 onto	 ampicillin	 plates	 and	
inoculation	into	LB	supplemented	with	1X	ampicillin.	Once	cloned	the	plasmid	was	
subjected	 to	DNA	 restriction	digest	using	NCO1	HF	and	 run	on	a	DNA	gel	 and	 the	






















sequence	 5’	 to	 VASQ-
TGA	 deleted.	 TAG	 in	 3’	
end	 deleted	 if	 not	 part	
of	 the	 SECIS	 element.	
Part	 of	 the	 3’UTR	 and	





















sequences	 5’	 to	 VASQ-
TGA	deleted.	 Poly	A	 tail	
deleted	 as	 well	 as	 a	



















sequences	 5’	 to	 VASQ	
deleted.	 Q	 changed	 to	
VAL	 to	 increase	
stability.	 	 Otherwise	 all	










with	 an	 extension	 time	 of	 2	 minutes.	 The	 PCR	 products	 were	 used	 in	 in	 vitro	
transcription	 reactions.	 Aliquots	 of	 10X	 SP6	 buffer	 (40mM	 Hepes-KOH	 pH	 7.4,	
60mM	 MgCl2,	 20mM	 spermidine,	 100mM	 DTT)	 were	 prepared.	 The	 T1	 mixture	
(1.32X	 of	 10X	 SP6	 buffer,	 0.66mM	 ATP-NaOH,	 0.66mM	 CTP-NaOH,	 0.13mM	 GTP-
NaOH,	 0.66mM	 UTP-NaOH,	 0.66mM	 7-methyldiguanosine	 triphosphate)	 was	 also	
prepared	 and	 flash	 frozen	 in	 liquid	 nitrogen	 and	 stored	 at	 -80°C.	 In	 vitro	
transcription	reactions	were	set	up	accordingly	for	a	10µl	reaction	(7.6µl	T1	mix,	2µl	















OD600	~	1	with	0.2mM	 IPTG	 (isopropyl	β-d-1-thiogalactopyranoside)	 for	16	hrs	at	














hour	 in	 the	 cold	 room	 to	 remove	 the	 PreScission	 protease.	 The	 protein	 was	
concentrated	using	a	30K	concentrator	in	PreScission	buffer	and	run	on	a	protein	gel	
(Figure	 87).	 The	 measured	 concentration	 using	 Nanodrop 2000 spectrophotometer 
















FLAG	resin	(2x300ul)	 for	2	hours	at	4C.	The	beads	were	 then	spun	at	1000g	 for	5	










~1	 by	 adding	 0.5mM	 IPTG	 for	 1.5	 hour	 at	 30°C.	 The	 cells	 were	 pelleted	 and	
resuspended	 in	50mls	of	 lysis	buffer	 (buffer	B	 (50mM	Tris	pH8,	150mM	NaCl,	5%	
glycerol,	 2mM	DTT)	+	1%	Triton	X-100,	PI,	 1mM	PMSF).	Cells	were	 then	 lysed	by	
sonication	at	60%	amplitude	 for	5	minutes	 (5	sec	on/10	sec	off	 cycle).	Cell	debris	
was	 removed	by	 centrifugation	38,000	x	 g	 for	30	minutes.	The	 lysate	was	 filtered	
through	Mira	cloth	and	a	45µM	filter.	The	filtered	lysate	was	then	loaded	onto	a	pre-
equilibrated	 in	 buffer	 B	 Strep	 trap	 HP	 5ml	 column	 (2ml/min)	 and	 washed	 with	
buffer	B,	buffer	X	(50mM	Tris-HCl,	pH8,	1M	NaCl,	5%	glycerol,	2mM	DTT)	and	buffer	
B	 again.	 The	 protein	 was	 eluted	 with	 elution	 buffer	 (buffer	 B	 +	 2.5mM	 D-
desthiobiotin).	The	eluted	protein	was	concentrated	 to	2ml	and	 treated	with	32µg	
PreScission	 protease	 overnight.	 The	 concentration	 of	 the	 protein	 by	 A280	 was	
2.87µg/µl.	The	cleaved	protein	was	diluted	in	20ml	of	Ni-A	buffer	(50mM	Tris-HCl,	
pH	 8,	 500mM	 NaCl,	 50mM	 imidazole,	 5%	 glycerol,	 5mM	 β-mercaptoethanol)	 and	





NaCl,	 500mM	 imidazole,	 5%	glycerol,	β-mercaptoethanol).	 The	 eluted	protein	was	
concentrated	and	buffer	exchanged	in	a	0.5ml	30	MWCO	Amicon	concentrator	into	




This purification was done in collaboration with Dr Sebastian Kraatz (LMB-MRC, 
Ramakrishnan group). 1.8kg	of	 fresh	pigs	 liver	was	obtained	 from	a	 local	butcher’s.	
The	 liver	was	cut	 into	small	pieces	 in	 the	4°C	room	and	homogenized	 in	a	Waring	
blender	 using	 2L	 ice-cold	 homogenisation	 buffer	 in	 deionised	water	 (20mM	 Tris-












mixed	 and	 incubated	 overnight	 at	 -20°C.	 The	 next	 morning	 the	 mixture	 was	




400mL	 homogenisation	 buffer	 at	 room	 temperature.	 The	 crude	 tRNA	was	 loaded	
onto	 the	 column,	 allowing	 the	 tRNA	 to	 bind	 to	 the	 resin,	 and	 the	 flow	 through	
discarded.	The	column	was	washed	with	>200ml	of	homogenisation	buffer	until	the	






20%	ethanol	 at	 4°C	 after	 regeneration.	 Two	 volumes	 of	 ethanol	was	 added	 to	 the	
eluate	and	kept	at	-20°C	overnight.	The	tRNA	was	then	pelleted	at	12,000	x	g	at	4°C	
for	25	minutes,	the	pellet	was	washed	with	70%	ethanol,	air	dried	and	resuspended	













immobilized	 FLAG-EEFSEC.	 Washes	 with	 RNC+G	 buffer	 were	 repeated.	 The	 Sec-
tRNA[Ser]Sec-FLAG-EEFSEC	 complex	 was	 eluted	 with	 100µg/ml	 3X	 FLAG	 peptide	
incubated	 for	 30	 minutes	 at	 4°C	 in	 the	 cold	 room.	 The	 eluate	 was	 collected	 by	
tabletop	 centrifugation	 at	 maximum	 speed.	 To	 obtain	 Sec-tRNA[Ser]Sec	 a	 phenol	













F500	 rotor.	 The	 supernatant	 was	 transferred	 to	 phenol	 resistant	 tubes.	 	 The	
supernatant	 and	 reagents	 were	 added	 in	 the	 following	 ratio	 5:3:2:5,	
supernatant:water:5X	 buffer	 T	 (50mM	 NaOAc,	 3.25mM	 NaCl,	 50mM	 MgCl2,	 5mM	
EDTA,	 pH4):phenol.	 The	mixture	was	 inverted	 and	 centrifuged	 at	 4000	 x	 g	 for	 10	
minutes	at	4°C.	The	aqueous	 layer	containing	total	RNA	was	transferred	to	a	clean	
tube	and	an	equal	volume	of	phenol	added,	vortexed	and	centrifuged	as	above	for	10	








before	 for	 pig	 liver	 Sec-tRNA[Ser]Sec.	 To	 FLAG-EEFSEC	 immobilized	 on	 anti-FLAG	
beads	in	a	gravity	flow	column,	starting	from	6L	of	cells,	45mg	of	total	pig	testis	RNA	
(13.44mg/ml)	 was	 added.	 10X	 TB	 buffer	 (20mM	 Tris-HCl,	 pH	 7.5,	 100mM	 KCl,	
2.5mM	MgCl2,	2mM	DTT,	0.5mM	GTP)	and	water	to	reach	a	concentration	of	1X	TB	
buffer	and	 incubated	at	4°C	 for	30	minutes.	The	column	was	washed	5	 times	with	
cold	1X	TB	buffer.	The	FLAG-EEFSEC-	Sec-tRNA[Ser]Sec	complex	was	then	eluted	with	






























A	 2ml	 in	 vitro	 translation	 reaction	 in	 rabbit	 reticulocyte	 lysate	 was	 set	 up	 in	 the	
presence	 of	 0.5µM	 eRF1(AAQ)	 for	 25	 minutes	 at	 32°C.	 The	 in	 vitro	 translation	
reaction	contained	1/20	in	vitro	transcription	reaction,	1/2	CT2	mix	and	0.5	μCi/μL	
S35-methionine	 (Perkin	 Elmer	 EasyTag).	 The	 CT2	 mix	 contained	 nuclease-treated	
crude	rabbit	reticulocyte	(Green	Hectares),	20	mM	Hepes-KOH,	pH	7.4,	10	mM	KOH,	
40μg/mL	 creatine	 kinase	 (Roche),	 20μg/mL	 pig	 liver	 tRNA,	 12mM	 creatine	
phosphate	(Roche),	1mM	ATP	(Roche),	1mM	GTP	(Roche),	50mM	KOAc,	2mM	MgCl2,	
1mM	glutathione,	0.3mM	spermidine,	and	40μM	of	individual	amino	acids	except	for	
methionine	 (Sigma).	 After	 25	minutes	 the	 reaction	was	 adjusted	 to	 750mM	KOAc	
and	 15mM	 Mg(OAc)2	 and	 incubated	 at	 room	 temperature	 for	 5	 minutes.	 The	
reaction	was	then	centrifuged	on	a	0.5M	sucrose	cushion	(50mM	Hepes-KOH,	pH7.4,	
750mM	KOAc,	 15mM	Mg(OAc)2,	 1mM	DTT)	 at	 100,000	 RPM	 for	 1	 hour	 at	 4°C	 in	
TLA100.3	rotor	(Beckman	Coulter).	The	ribosome	pellet	was	resuspended	in	500ul	
RNC	buffer	 (50mM	Hepes-KOH,	 pH7.4,	 100mM	KOAc,	 5mM	Mg(OAc)2,	 1mM	DTT)	
and	incubated	with	100ul	(packed	volume)	of	anti-FLAG	M2	beads.		The	beads	were	
washed	 sequentially	 with	 3ml	 50mM	 Hepes-KOH,	 pH	 7.4,	 100mM	 KOAc,	 5mM	
Mg(OAc)2,	 0.1%	 triton	 X-100,	 1mM	 DTT;	 3mls	 50mM	Hepes-KOH	 ,pH7.4,	 250mM	





3X	 FLAG	 peptide	 (Sigma)	 in	 RNC	 buffer	 incubating	 at	 room	 temperature	 for	 25	
minutes.	 A	 further	 200µl	 of	 RNC	 buffer	 was	 added	 to	 the	 combined	 eluates	 and	
centrifuged	at	100,000	RPM	for	20	minutes	in	the	TLA	120.1	(Beckman	Coulter).	The	





3µl	 sample	 were	 applied	 to	 continuous	 carbon	 coated	 (~50	 Å)	 copper	 Quantifoil	
R2/2	grids.	Grids	were	blotted	 for	4.5	 seconds	 after	 a	30	 second	wait	 using	 a	 -15	





equipped	with	 a	back-thinned	FEI	Falcon	 III	 detector	 at	 a	magnification	of	75,000	
and	 pixel	 size	 of	 1.06	 Å.	 71	 frames	 and	 fractions	 were	 collected	 per	 1.79	 sec	
exposure.		5	images	were	collected	per	hole	with	defocus	values	ranged	from	-1.4	to	
-3.2.	 Subsequent	 image	 processing	 was	 done	 using	 RELION	 and	 map	 figures	
generated	in	Chimera	(121,167).	
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